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Suvorexant (Belsomra®), a novel dual orexin receptor antagonist for the treatment 
of insomnia, was recently introduced to the pharmaceutical market in 2015. Insomnia 
affects up to one-third of the American population, which could make suvorexant a popular 
option for treating these patients. However, due to its recent introduction to the market, 
few methods have been developed for the detection of suvorexant and limited case reports 
have been published that examine suvorexant in forensic toxicology casework. Since a 
limited number of studies exist detailing the analysis of suvorexant, little is known 
regarding its role in human performance toxicology and postmortem investigations. This 
study aimed to further the understanding related to its analytical detection, the 
identification of metabolites, and the drug’s physicochemical properties. In broader terms, 
the potential for drug-mediated interferences using liquid chromatography-mass 
spectrometry (LC-MS) is also addressed.  
Methods for the detection of suvorexant in blood at forensically relevant 
concentrations were developed and validated using liquid chromatography-
quadrupole/time-of-flight-mass spectrometry (LC-Q/TOF-MS) and liquid chromatography 
tandem mass spectrometry (LC-MS/MS). Ion suppression and matrix effects using 
electrospray (ESI) techniques were evaluated and strategies for mitigating interferences in 
quantitative targeted assays were assessed. The importance of using stable isotope labeled 
internal standards (SIL-IS) was highlighted using a statistical comparative approach with 
a structurally similar analog. Suvorexant was quantitated in forensic case specimens and 
 
v 
its lipophilicity was determined experimentally and theoretically to evaluate its potential 
to undergo postmortem redistribution (PMR). In the absence of commercially available 
metabolite standards, major metabolites for suvorexant were produced in vitro using 
recombinant cytochrome P450 enzyme systems and were subsequently identified in 
authentic case specimens.  
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Insomnia is a prevalent medical condition that affects approximately one-third of 
the adult population (1, 2). Of Americans suffering from the condition, one-half reported 
having at least one symptom of insomnia per night and one-third reported having insomnia 
every night (3). The consequences of insomnia that affect daytime activities have included 
irritability, inability to concentrate, low energy levels, absence from work, and poor job 
performance. In addition, insomnia can increase risk for traffic-related accidents and can 
lead to other health problems (3). Direct and indirect costs related to insomnia are estimated 
to exceed $100 billion per year in the United States, and the US market for insomnia 
medications had already been projected to exceed $5 billion by the year 2010 (3). Persons 
with underlying medical conditions such as gastrointestinal problems, hypertension, 
pulmonary diseases, or urinary problems may experience higher levels of insomnia than 
the general population (1). Individuals suffering from insomnia are significantly more 
likely to suffer from depression and anxiety, and sleep disorders are part of diagnostic 
criteria for a number of psychiatric disorders including bipolar disorder, post-traumatic 
stress disorder, and major depressive disorder (1). It may also serve as a risk factor for 
substance abuse and an overall diminished quality of life (4). Primary insomnia sufferers 
may have difficulties in initiating or maintaining sleep, experience premature awakening, 
or may find that their sleep is non-restorative (5, 6). Treating insomnia has become a 
concern of socioeconomic interest as well as improving the quality of life of those 
individuals who experience its symptoms.   
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Finding safe treatments for insomnia that improve sleep while avoiding 
dependence, next-day impairment, and rebound insomnia has been an ongoing and 
challenging task (3). Typically, the aim of insomnia medications is to promote sleep, 
maintain sleep architecture, and to avoid association with residual side effects (7). The 
ideal insomnia drug is dependent on many pharmacokinetic and pharmacodynamic 
parameters, receptor binding, potency, and mechanism of action (7). Timing of receptor 
activity is key with the treatment of insomnia, as a rapid central nervous system penetration 
is desired to increase sleep-onset efficacy, and the receptor occupancy must be sufficiently 
high to maintain sleep; however, the compound occupancy at the receptor must drop before 
the desired time of wakening (7). For example, a compound that is effective at low receptor 
occupancies may promote sleep onset more efficiently, but the likelihood of residual effects 
is greater, while a compound with high occupancy threshold for sleep-promoting effects 
may have less inherit risk for carry-over effects (7).  
Several therapeutics have been developed that have aimed to achieve the desired 
effects while minimizing side effects, but the perfect insomnia drug still eludes 
pharmaceutical companies. Traditional treatments for insomnia have included histamine 
receptor agonists, γ-aminobutyric acid (GABA) receptor agonists, and melatonin receptor 
agonists (6, 8, 9). Most widely prescribed are central nervous system depressants that 
directly act on GABA which is an inhibitory neurotransmitter. Sedative hypnotics have 
typically included drugs such as barbiturates, benzodiazepines, and non-benzodiazepines 
that modulate the activity of GABA-A receptors (9). Barbiturates were used for the 
treatment of insomnia beginning in the early 1900s, but led to abuse, physical dependence, 
withdrawal, and overdoses in large part due to respiratory depression. Treatments then 
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shifted to benzodiazepines in search of a barbiturate alternative (10). Benzodiazepines have 
been commonly used as GABA modulators since their development in the early 1960s, but 
are associated with dependence risks, impaired memory, and daytime sleepiness (3). Some 
benzodiazepines that have been used in the treatment of insomnia are estazolam, 
flurazepam, lorazepam, quazepam, temazepam, and triazolam (11). Non-benzodiazepine 
GABA modulators have been developed more recently, including the “Z-drugs” (zolpidem, 
zopiclone/eszopiclone and zaleplon), but there are safety concerns with these sedative 
hypnotics as well (3). Both benzodiazepine and non-benzodiazepine GABA-A receptor 
modulators have an increased risk for side effects such as next-morning sedation and 
cognitive residual effects, which is in part due to the long half-lives of some of these 
treatment options (7). Moreover, these GABA-A modulators likely are associated with 
residual activity during the wake period due to their low receptor occupancy threshold for 
efficacy in vivo (~27%) (7). A melatonin receptor agonist for the treatment of insomnia is 
ramelteon which is novel in its approach, but also poses concerns for safety and efficacy 
(3). Sedating and tricyclic antidepressants have also been prescribed for insomnia 
treatment, such as doxepin, amitriptyline, mirtazapine, and trazadone which was the most 
commonly prescribed insomnia medication in 2002 (6, 11). Anticonvulsants such as 
gabapentin and pregabalin have been used, as well as antipsychotics like olanzapine and 
quetiapine (6). The most recent approach to insomnia treatment has been the modulation 
of the orexin signaling system. Since reduction in the function of the orexin signaling 
system leads to a decrease in wakefulness, antagonists of the orexin system have become 
a promising approach to treating insomnia as well as other disorders that interrupt the 
circadian rhythm, such as jet lag or shift work (3, 12). 
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Orexin Receptor Antagonism 
Orexin (hypocretin) neuropeptides A and B were only recently discovered in 1998, 
which paved the way for orexin receptor 1 and 2 (OX1R and OX2R) characterization and 
drug development for orexin receptor antagonism (3, 5, 12). Both OX1R and OX2R are G-
protein coupled receptors (9, 13). Orexin A binding affinity to OX1R is greater than that of 
orexin B, but binding affinity to OX2R is equal for both orexin A and B (3, 14). The peptide 
orexin is produced in the perifornical area/latero-posterior hypothalamus by about 50,000-
80,000 neurons in humans. From the lateral hypothalamus, the projections reach areas of 
the neuraxis to include the tuberomammillary nucleus (TMN), laterodorsal tegmental 
nucleus (LTD), paraventricular thalamic nucleus (PVT), and arcuate nucleus of the 
hypothalamus (5, 14, 15). Less dense projections are present in the amygdala, 
hippocampus, and colliculi (5). The production of orexin can result in reduced activity of 
parts of the brain that promote sleep, thereby increasing wakefulness. It is hypothesized 
that orexin plays a large role in the sleep to wake cycle, and release of the neuropeptide 
typically follows the circadian rhythm (1, 10, 12, 16). Orexin neurons primarily fire during 
waking and activate wake state-favoring centers such as the locus coeruleus and dorsal 
raphe, and firing stops when sleep begins (5, 12, 14, 17). Shortly after this discovery, 
defects in the orexin system at the peptide level in dogs were related to 
narcolepsy/cataplexy, and it was found that orexin producing cells were largely absent in 
the lateral hypothalamus (5). Orexin was found to be a predominating mediator of arousal 
after increased arousal was observed following exogenous administration of orexin-A to 
animal models with narcolepsy (10). Narcolepsy is a condition characterized by instability 
of the wake cycle which results in symptoms such as excessive daytime sleepiness and 
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daytime hypersomnia (12, 18). The role of orexin peptides in narcolepsy was first described 
in animal models which helped to establish the link between the disorder and orexin 
dysfunction (15, 18, 19). After discovery that mutation in the orexin 2 receptor in dogs was 
very similar to that of humans, it was suggested that the loss of signaling that is mediated 
by this receptor could be responsible for narcoleptic phenotypes in humans as well, and the 
disorder is more prevalent in familial clusters (18). Narcoleptic patients are at a three-times 
higher risk to be involved in motor vehicle accidents due to lack of alertness and dozing 
off (18). Narcolepsy has also been associated with sleep fragmentation, premature 
awakenings, vivid dreams, hypnagogic hallucinations, and sleep paralysis during nocturnal 
sleep (18). Patients can suffer with narcolepsy with or without cataplexy, which is a sudden 
episode of muscle weakness during consciousness that is usually triggered by a strong 
emotional stimulus (5, 18). About 0.05% of the population is affected by narcolepsy with 
cataplexy (5). The lack of orexin producing neurons in the lateral hypothalamus has been 
documented in postmortem studies of individuals suffering from narcolepsy, and patients 
with the condition have been reported to have the absence or very low levels of orexin in 
the cerebrospinal fluid (5, 15). The discovery of the relationship between orexin signaling 
and narcolepsy has given scientists a new way to try to mitigate the effects of insomnia, by 
mimicking the effects of narcolepsy seen due to orexin deficiency. The therapeutic 
potential of selective or dual orexin receptor antagonists has been investigated in an attempt 
to target both receptors in the function of the sleep/wake cycle but without causing 
cataplexy. 
As such, a new class of medications called dual orexin receptor antagonists 
(DORAs) has proved a promising alternative approach to treating insomnia since they have 
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no effect on GABA activity (7). It has been reported that many orexin receptors are 
glutaminergic, but they are not GABAnergic (5). DORAs inhibit orexin neuropeptides and 
their wake-promoting activities, as opposed to promoting sleep itself (7). Higher 
percentages of receptor occupancy are required for their efficacy and to block the effects 
of the orexin peptide ligands (7). Many pharmacodynamic factors are responsible for the 
effects of insomnia medications in addition to plasma half-lives, such as the mechanism of 
action which can dictate a drug’s receptor occupancy levels in order to be effective. As 
such, the need for high effective receptor occupancy in the use of DORAs can allow them 
to promote sleep at lower doses (12). These DORAs are suspected to have less “hangover” 
effects than benzodiazepines and Z-drugs because they do not suppress rapid eye 
movement (REM) sleep and do not affect memory as GABA-A modulators might (5). 
Studies on the mechanisms of orexin receptor antagonists have shown that response to 
arousal stimuli is preserved with the use of these agents, in contrast to zolpidem and 
eszopiclone which impair ability to arouse to salient stimuli (10, 12). Arousability is 
necessary for normal psychological responses during sleep, and it seems that DORAs can 
preserve the arousal threshold, while the threshold is increased with GABA-enhancing 
drugs (12). Since OX2R seems to have more implications in sleep/wake regulation than 
OX1R, the possibility of using single orexin receptor antagonists (SORAs) is being 
explored (12). The pharmacokinetics and receptor-binding kinetics of DORAs make them 
promising candidates in restricting their effects to the resting phase (7). Critical 
requirements of any DORA in development are that they should have a rapid onset of 
action, a duration of action lasting no more than 8 hours, a short-half life, and they should 
avoid accumulation at the receptor site (5, 15, 20). Some advantages in the early stages of 
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development in the first DORAs are the absence of anterograde amnesia that is commonly 
seen with other narcoleptics and perhaps a lower abuse potential (5). 
The use of DORAs has also been explored to characterize their potential use in 
treating depression, anxiety, pain conditions, and neurogenerative disorders such as 
Alzheimer’s disease (10, 12, 20). It has also been noted that since sleep and migraines are 
interconnected, that the regulation of sleep through the use of DORAs might provide a 
novel approach to migraine prevention (12). These compounds may also provide an 
alternative to hypnotics given to patients experiencing lack of sleep due to post-operative 
pain, and can reduce the occurrence of post-operative delirium as a result (12). Orexin 
modulation may also have a role in regulating rewarding and reinforcing properties of 
drugs of abuse, and preliminary research has shown that DORAs can reliably reduce 
cocaine’s rewarding properties in clinical trials (17). It has been suggested that orexin 
transmission to and within the ventral tegmental area (VTA) in the brain is highly 
implicated in the reinforcing effects of cocaine and morphine (12, 13). Studies are ongoing 
to assess the diminishing effects of drug-induced mesolimbic dopamine transmission from 
the VTA following blockade of orexin transmission (17). Orexin receptor targeting may 
provide a new approach to treating opioid use disorder as well (13). Research has shown 
that the lateral hypothalamus plays a large role in drug-seeking and reward behavior, and 
that orexin may be responsible for linking the lateral hypothalamus and mesolimbic 
pathway in the processing of reward/reinforcement (13). 
There have only been a handful of DORAs developed to date and only one is 
currently on the market. Almorexant was the first DORA that was characterized in clinical 
trials for the treatment of insomnia by Actelion Pharmaceuticals in Switzerland. It made it 
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to phase II clinical studies, however it did not meet registration stages of approval (5). It 
was shown that almorexant was associated with infrequent transient increases in liver 
enzymes, which were found to be unrelated to the orexin system (12, 20). GlaxoSmithKline 
(GSK) also developed a DORA known as SB-649868 (or GW-649868) but like 
almorexant, it failed prior to phase III clinical trials and is no longer in development (5, 
12). Suvorexant was the first DORA to reach the registration stage with the FDA, and 
subsequently became commercially available (5, 8). It is also the first new-class insomnia 
medication to be introduced to the market since ramelteon (Rozerem®) was approved for 
use in 2005 (11). Filorexant was a subsequent drug similar to suvorexant in its receptor 
binding and was being developed by Merck & Co., but is no longer listed in the production 
pipeline (5). Filorexant had a shorter half-life than suvorexant, but it was found to have 
increased next-day somnolence in a dose-dependent manner (12, 20). Lemborexant 
(E2006) is the newest proposed DORA which is currently in phase III clinical trials, but 
initial reports show that it provides greater efficacy at even lower doses and may minimize 
next-day somnolence (10, 12, 21). Seltorexant (JNJ-42847922) is the only SORA in 
development and in early clinical stages thus far (10, 12). Other SORAs previously 
explored were MK-1064 and MK-3697 (10). These DORAs and SORAs are depicted in 
Figure 1.1. From the reports, almorexant, suvorexant, filorexant, and SB-649868 have 
narcoleptic effects that reduce awakenings, lessen the time to sleep onset, and increase total 
sleep time (5). Suvorexant is the first drug in its class that has been prescribed to patients 





Figure 1.1.  Chemical structures of DORAs (almorexant, SB-649868, filorexant, suvorexant, and 





Suvorexant (MK 4305) is a DORA currently available on the market in the United 
States and Japan (9, 12, 22, 23). It is manufactured by Merck & Co. and is marketed under 
the trade name Belsomra®. The chemical name for suvorexant is [(7R) -(4-(5-chloro-1,3-
benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl] [5-methyl-2-(2H-1,2,3-triazol-2-yl) 
phenyl] methanone (24, 25). The suvorexant molecular formula is C23H23ClN6O2 with a 
molecular weight of 450.932 g/mol (4, 25). Suvorexant synthesis has been described by a 
few authors, but Cox et al. described the synthesis of suvorexant from a core diazepane 
ring, in which they noted that the diazepane core is key for the drug’s potency (Figure 1.2) 
(3, 26-28). The chlorobenzoxazole has demonstrated improved metabolic stability, 
favorable target potency, and brain penetration over other DORA alternatives that preceded 











Figure 1.2. The structure of suvorexant depicting its core diazepane functionality responsible for 




Suvorexant was first approved for use in the United States in 2014 by the FDA and 
it is currently placed under Schedule IV of the Controlled Substances Act (CSA) (24,29). 
It is classified as a sedative hypnotic due to these drugs having the common 
pharmacological property of sedative activity (9). Although sedative hypnotics have been 
used in the treatment of insomnia, these drugs are associated with an inherent risk for 
physical dependence and withdrawal, and some animal studies have shown a resulting self-
administration indicating the possibility for physical dependence (9). Suvorexant improves 
sleep onset and maintenance and is believed to have less side effects and more favorable 
tolerability than other therapeutic options (4, 30). The main benefit that was identified 
during clinical studies is the low potential for addiction or dependence with suvorexant (4, 
31). FDA evaluation of the drug found that sleep induction is dose-dependent and that 
suvorexant may be unsafe at the higher concentrations originally proposed by Merck (30-
40 mg) and that doses should be limited to 10-15 mg (1, 5, 8, 32, 33). At higher doses there 
were reports of sleep paralysis and narcolepsy-like events (6). It has also been noted that 
suvorexant, like other sedative hypnotics, should be avoided in patients with severe hepatic 
impairment (4). While insomnia and mood disorders often have a high comorbidity, 
patients with depression or psychiatric disorders have been excluded from suvorexant 
clinical trials. As such, there is a possibility of worsening depression or suicidal ideation 
in these populations with the use of suvorexant, although post-marketing surveys have 
indicated that the safety profile matches that of the product’s labelling (10, 12, 31). 
Suvorexant is contraindicated in patients with narcolepsy, since symptoms due to orexin 




During trials, onset of sleep occurred more rapidly in individuals who received the 
40-mg dose, which occurred between 56- and 68-minutes following administration (4). 
Suvorexant has the potential to produce next-day drowsiness which can interfere with daily 
activities, and the effect is more pronounced at doses >40-mg and increase as the dose 
increases (4, 8). The original proposed dose of suvorexant was 40-mg but 
recommendations were made to reduce the daily recommended dose to 10-mg after these 
safety concerns were made (4, 8). Increases in suvorexant dosage are only suggested for 
patients who display tolerability to the lower dose with no side effects (4). Unlike GABA-
modulating agents which are only recommended for short term or intermittent use, 
suvorexant can be used long-term and on a daily basis with no risk of physical dependence 
(4, 34). The abrupt cessation of suvorexant administration has not been associated with 
withdrawal or rebound insomnia at the available prescribed doses (1, 4, 11, 34). Suvorexant 
is prescribed to adults 18 years and older (4). The safety profile of suvorexant indicates 
that the treatment be used for individuals under the age of 65, although the >65 age group 
is most likely to seek treatment for sleep impairment (4). Individuals over the age of 65 
were more sensitive to the adverse side effects of suvorexant in clinical trials, including a 
significant impairment of balance (4).  
A one-year controlled safety and efficacy study of the use of suvorexant to treat 
insomnia was described by Michelson et al. The study demonstrated that suvorexant was 
well tolerated by insomnia patients, both male and female, and elderly and non-elderly 
across various populations (35). The most reported adverse effect was somnolence, which 
aligns with other studies (8, 35, 36). Suvorexant studies were performed to determine if 
administration negatively affected patients with chronic obstructive pulmonary disease 
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(COPD) (36). There is a concern for patients suffering with COPD or other respiratory 
disorders, such as obstructive sleep apnea, since comorbidity with insomnia is about 17% 
in these individuals (36, 37). As such, there is an associated risk of further respiratory 
depression in these patients that are prescribed GABA-modulating sedative hypnotics for 
the treatment of insomnia (36). It is thought that orexin may have a role in respiratory 
function since there are orexin neurons that project through the brain to some respiratory 
centers (37). There is limited literature on this theory and studies were performed to 
determine the relationship between orexin receptor antagonism and respiratory impairment 
(37). Uemura et al. studied the effects of suvorexant on respiratory function during sleep 
on healthy male and female subjects and determined there were no adverse effects in 
healthy subjects, then suggested performing studies with population groups with COPD or 
obstructive sleep apnea (37). A study by Sun et al. demonstrated that subjects with COPD 
or obstructive sleep apnea that were given twice the maximum FDA-approved dose (40-
mg) were generally able to tolerate suvorexant with no meaningful effects of respiration 
(36, 38). Although suvorexant should be taken with caution in these patients, it seems to 
be more well-tolerated in subjects with compromised respiratory function than traditional 
benzodiazepine options (36, 38).  
Suvorexant slowly equilibrates at OX1R and OX2R receptors but has a high 
selectivity for both (5, 9). Suvorexant binds to these receptors over 6000x more selectively 
than to over 170 other receptors and enzymes that were studied (24). In both orexin 
receptors, suvorexant binding occurs at the orthosteric location (10). Suvorexant promotes 
sleep by blocking the binding of orexin A and B neuropeptides and is reversible with no 
other known neurochemical interactions (4, 34). In preclinical studies it was determined 
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that 65-80% orexin receptor occupancy is required to promote sleep (11). The human 
plasma suvorexant concentration measured to correspond to 65% OX2R occupancy is 0.33 
µM, free and bound, which is the minimum percentage associated with predicted sleep-
promoting efficacy at this receptor (7). Mean suvorexant plasma concentrations fell below 
this occupancy 8 hours following 10-mg and 20-mg doses which indicates that the sleep-
promoting effects of suvorexant should not persist into waking hours at these doses (7). In 
addition, with a half-life ranging from 9-13 hours, the effects of suvorexant are expected 
to be maintained throughout the entire sleep period, reducing the number of awakenings 
associated with insomnia (7). 
The recommended dose for suvorexant is 10-mg and it is to be taken once nightly 
within 30 minutes of going to sleep, but not within 7 hours of the anticipated time of 
wakening (8, 24). Although the lowest possible dosage should be used, if the 10-mg dose 
is well-tolerated but not effective, the dosage can be increased to a daily maximum of 20-
mg (12, 24). Patients who are prescribed the higher 20-mg dose are advised against next-
day activities, such as driving, where alertness may be compromised (8, 24, 39). The 
median time to maximum plasma concentrations (Tmax) is 2 hours (range 30 min to 6 hours) 
under fasting conditions, while administration following a meal high in fat can delay Tmax 
by as much as 1.5 hours (12, 24, 25, 32, 34). For a faster onset of sleep, meals before 
administration should be avoided (25). Steady state equilibrium can be reached within 3 
days of daily administration of suvorexant and the mean bioavailability following a 10-mg 
oral dose is 82% (12, 24, 25, 32). The mean half-life of suvorexant is 12 hours (34). 
Suvorexant concentrations increase with female sex and obesity, but kinetics are not 
affected by age or race (8, 25, 34). The drug is 99.5% protein-bound to plasma proteins 
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and binds to both human serum albumin and α-1-acid glycoprotein (24, 25). The drug does 
not appear to readily distribute into red blood cells (24, 25). Suvorexant metabolism is the 
primary route of elimination for the drug, with cytochrome P450 (CYP) 3A being reported 
as the primary contributor, with minor contribution from CYP 2C19 (25, 32). Suvorexant 
and its hydroxylated metabolite, having no expected pharmacological activity, are the 
major species in circulation (25). Patients who are prescribed suvorexant should not take 
other medications which are associated with CYP450 3A enzyme systems and should avoid 
grapefruit juice as it could reduce metabolism of the drug (4, 34). Potent CYP 3A inhibitors 
can cause suvorexant to exceed therapeutic thresholds as plasma concentrations are 
increased, whereas CYP 3A inducers can decrease suvorexant plasma concentrations (4, 
25). Suvorexant itself is a mild CYP 3A inhibitor but is not expected to cause significant 
inhibition of CYP 1A2, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2C19, or CYP 2D6 (4, 24). 
If patients are taking moderate CYP 3A4 inhibitors (i.e. diltiazem or ketoconazole), the 
suvorexant dose should be reduced to 5-mg daily (8, 12, 24, 25). Suvorexant is not 
recommended in combination with strong CYP 3A inhibitors (24, 25). Suvorexant 
administration with oral contraceptives or warfarin is not expected to cause inhibition of 
these compounds (8, 24). Alcohol and suvorexant do appear to have additive effects, 
particularly on psychomotor performance, and administration of suvorexant with other 
central nervous system (CNS) depressant drugs is not recommended due to potential 
additive effects (24). The use of suvorexant with other insomnia medications is also not 
recommended (24, 25). 
Adverse events have been reported in studies following higher doses of suvorexant. 
Following 40-mg and 80-mg doses, the most common patient-reported adverse events were 
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abnormal dreams, somnolence, headache, dizziness, upper respiratory tract infection, and 
urinary tract infection (11, 16). Other events reported have included instances of sleep 
paralysis and visual hallucinations, as well as unusual nighttime activities and suicidal 
ideation in doses exceeding 20-mg (8, 15, 16). Side effects may also include dry mouth 
and fatigue (34). It has been noted that the side effects of suvorexant seem to be dose-
related (16). However, there were some initial concerns by the FDA in the development of 
suvorexant regarding next-day somnolence, inability to decide against driving while still 
under its effects, sleep walking, vivid dreaming, and other abnormal activities (5). The risk 
for impacts on driving performance and other activities that require mental alertness can 
be increased if suvorexant is taken with less than a full night of sleep, at higher than the 
recommended dosage, or if taken in combination with other CNS depressants (24, 25). 
Patients who have a history of drug abuse, use suvorexant in combination with other drugs 
or alcohol, or who use suvorexant for a prolonged period of time are more likely to abuse 
suvorexant (25). Suvorexant abuse can lead to increased risks of impaired reaction times 
while driving skills and somnolence (25). However, there is no evidence of physical 
dependence on suvorexant following prolonged use (25). 
Vermereen et al. performed two driving studies following use of suvorexant, one 
in healthy non-elderly volunteers and one in healthy elderly volunteers (40). The first study 
examined volunteers aged 23-64 and evaluated next-morning driving performance after 
single, repeated doses of 20- and 40-mg of suvorexant or placebo over 8 days. Driving 
performance was assessed using standard deviation of lateral position (SDLP) in a 
standardized on-the-road driving test for those administered suvorexant versus placebo. 
Zopiclone was used as a control for days 1 and 8 and placebo was given in between. A 
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word learning test and body sway were also implemented. Five driving tests were 
prematurely stopped by four females due to drowsiness. While there were no clinically 
relevant findings for the study, it was noted that measurable impairment occurred compared 
to placebo, but less than those observed for alcohol blood concentrations of 0.05 g/dL. The 
premature stoppage of the study by the individuals who reported excessive drowsiness may 
indicate that some individuals may experience next-day impairment that hinders driving 
(40). A similar study was performed in 24 elderly volunteers aged 65-80 years administered 
15-30 mg doses of suvorexant or placebo in the same fashion. The results were comparable 
to the study in healthy younger volunteers, but it was advised that individuals taking 
suvorexant avoid next-day activities such as driving due to inter-individual variability and 
the small sample size of the study (41). 
The use of suvorexant in combination with alcohol was also studied to determine 
additive or synergistic effects of co-administration, and to further assess safety and 
tolerability (23). Pharmacokinetics and psychomotor performance were assessed for 
healthy subjects who had been administered a 40-mg oral dose of suvorexant with and 
without alcohol. There were no indications that suvorexant and alcohol had 
pharmacokinetic interactions, and the most common adverse effects observed after co-
administration were dizziness, nausea, somnolence, and headache. Suvorexant 
administered alone and with alcohol was well-tolerated, but minor decreases in oxygen 
saturation were observed in subjects given both substances, suggesting that the respiratory 
depression effects were attributed to alcohol (23). Although pharmacokinetic parameters 
were not affected by alcohol administration, suvorexant in combination with alcohol had 
negative effects on psychomotor performance. These effects included additive negative 
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effects on sustained attention/vigilance, reaction time, working memory, and postural 
stability, which exceeds those observed with alcohol alone. The conclusion of the study 
was that suvorexant should not be taken in combination with alcohol, much like other 
insomnia medications (23).   
It has been noted that the effects on insomnia are quite modest at the low doses 
available, but at the higher doses where greater effects can be seen the adverse effects also 
increase (34). In addition, the drug can be expensive which can deter its use over other 
therapeutics (34). With the novelty of the drug, wholesale prices have averaged $315-340 
for 30 tablets and is only available in one oral formulation (8). However, as a novel 
hypnotic, suvorexant is expected to feature in both antemortem and postmortem toxicology 
investigations.  
Detection Methods 
Relatively few analytical methods have been published that describe the analysis 
of suvorexant in biological samples (Table 1.1). Gas chromatography-mass spectrometry 
(GC-MS) and liquid chromatography-mass spectrometry (LC-MS) have been used to 
detect suvorexant in plasma, urine, blood, and tissues. Of the published reports to date, 
there is only one study that examines suvorexant in postmortem casework. This highlights 






Table 1.1. Summary of published analytical methods for the detection of suvorexant.  




Plasma 0.1 ml LLE 13C2H3-suvorexant LC-MS/MS C18 APCI 1 (42) 
Urine 2 ml LLE estazolam-D5 GC-MS DB5-MS EI 10 (43) 
Urine 1 ml LLE estazolam-D5 LC-Q/TOF-MS EC-C18 ESI+ 5 (44) 
Plasma 0.2 ml LLE rivaroxaban LC-MS/MS C18 ESI+ 0.33 (45) 
Plasma 0.1 ml LLE carbamazepine LC-MS/MS C18 ESI+ 0.16 (46) 








diazepam-D5 LC-MS/MS PFP ESI+ 1 (48) 
LLE, liquid-liquid extraction; D-LLE, dispersive LLE; PPT, protein precipitation; Captiva ND, phospholipid removal device.; LC-
MS/MS, liquid chromatography tandem mass spectrometry; GC-MS, gas chromatography-mass spectrometry; LC-Q/TOF-MS, liquid 




The first analytical method describing the detection of suvorexant in human plasma 
was performed by Merck & Co. using liquid chromatography tandem mass spectrometry 
(LC-MS/MS) (42). The method employed a 96-well liquid-liquid extraction (LLE) using 
methyl tert-butyl ether (MTBE) as the extraction solvent. Separation was achieved using a 
Waters Atlantis dC18 column (2.1 x 50 mm x 3 µm) with isocratic elution of 30/70 (v/v 
%) of 10 mM ammonium formate. The isotopically labeled internal standard (13C2H3-
suvorexant) was manufactured in-house and used for the quantification of suvorexant. 
Atmospheric pressure chemical ionization (APCI) was used in positive mode with multiple 
reaction monitoring. The transition monitored for suvorexant was m/z 451 → 186 and the 
transition for the internal standard was 455 → 190. The assay was validated over a linear 
range of 1-1,000 ng/mL with a limit of quantitation (LOQ) of 1 ng/mL in human plasma 
(42). Extraction recovery was only ~50% but the authors note that the use of the stable 
isotope internal standard compensates for variability across plasma matrices. Accuracy 
ranged from 96-105% of the expected concentration and inter- and intraassay precision 
were within 10%. Suvorexant was stable in human plasma held at room temperature for at 
least 6 hours following thaw, and samples stored at -20°C for a period of 25 months were 
found to be stable. This method was then applied to human plasma samples that were 
collected 2 hours following oral administration of the drug at a 10-mg dose to 6 subjects. 
The method was able to detect suvorexant in all plasma samples within the established 
range and was reproducible, demonstrating its applicability to clinically relevant doses of 
suvorexant (42). However, this study has limitations in that it only examined suvorexant 
plasma concentrations from known dosing of healthy subjects in a clinical setting. In 
forensic casework, the prescription dosage may differ from the actual administered dosage, 
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and in postmortem work human plasma is not as commonly analyzed as other biological 
specimens such as whole blood, urine, or tissues. In addition, while this method is robust, 
it only employs one precursor to product ion transition which is not generally acceptable 
for forensic use. A minimum of two ion transitions are required for identification purposes 
so that ion ratios can be compared (49).  
Methods to detect suvorexant in urine were previously developed in our laboratory 
using GC-MS and liquid chromatography-quadrupole/time of flight-mass spectrometry 
(LC-Q/TOF-MS). The first GC-MS method by Carson et al. isolated urine via liquid-liquid 
extraction (LLE) with ether/toluene (50:50) as the organic solvent. At the time of method 
development, solid phase extraction (SPE) using copolymeric ion exchange columns 
indicated that suvorexant eluted in the neutral drug fraction (i.e. organic wash). In the 
absence of a commercially available deuterated analog, estazolam-D5 was used as the 
internal standard (IS) due to its structural similarity to suvorexant. These similarities 
included a chlorine moiety, a triazole, and a 7-memebered azapine/azepane ring (43). 
Method development was initially performed on a traditional DB5-MS column (30 mm x 
0.25 mm) with a film thickness of 0.25 µm, but suvorexant eluted at nearly 30 minutes due 
to its high boiling point (669°C). Development was then continued using a DB-5MS 
column (30 mm x 0.25 mm) with a reduced film thickness of 0.1 µm, which decreased the 
elution time to 11.7 minutes. Quantitation of suvorexant and estazolam-D5 was performed 
on an Agilent 5975C Mass Selective Detector in selected ion monitoring (SIM) mode with 
electron impact (EI) ionization at 70 eV. The ions monitored for suvorexant were m/z 
450.2, 186.1 and 104.1, with 186.1 being the quantitation ion. The ions selected for 
estazolam-D5 were m/z 299.1, 264.1, and 219.1, with 299.1 being the quantitation ion. The 
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method was validated in accordance with the Scientific Working Group for Forensic 
Toxicology (SWGTOX) Standard Practices for Method Validation in Forensic Toxicology 
(50). Analytical recovery for the method averaged 106% with LOD and LOQ of 10 ng/mL. 
The linear range was 10-1,000 ng/mL with accuracy ranging from 98-101%. Intra- and 
inter-assay precision were within 20% and there were no interferences detected from fifty 
common drugs or matrix. Carryover following injection of 1,000 ng/mL standard was 
mitigated with the use of 12 pre- and post-injection methanol needle washes. Processed 
stability was evaluated, and it was found that the internal standard was not stable past 48 
hours on the room temperature autosampler, lending that samples stored longer than 24 
hours at this temperature should not be analyzed. This method highlighted the limitations 
with GC-MS analysis for suvorexant, in that retention times using traditional screening 
parameters and columns could cause the drug to go undetected in a typical acquisition 
window. Mitigation of these problems include the reduction of the column thickness and 
the use of a SIM method to increase analytical sensitivity (43).  
A second urine method validated in accordance with SWGTOX recommendations 
for forensic use was developed by Sullinger et al. with LC-Q/TOF-MS (44). Like the 
method by Carson et al, this method employed estazolam-D5 as the IS in the absence of a 
stable isotope suvorexant standard and used LLE with ether/toluene (50:50) (43, 44). 
Analytes were separate on an Agilent 1290 Infinity binary LC system with a Poroshell 120 
EC-C18 column and EC-C18 guard column. Gradient elution of 0.1% formic acid in water 
(A) and 0.1% formic acid in acetonitrile (B) was performed to achieve the desired 
chromatographic profile, and detection of suvorexant and IS ions was achieved with an 
Agilent 6530 Accurate-Mass Q/TOF operated in positive electrospray ionization (ESI) 
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mode. The product ion transitions monitored for suvorexant were m/z 451.1644 → 
186.0664 (quantifier ion) and 451.1644→ 104.0493 (qualifier ion) at a collision energy of 
50 eV. The transitions monitored for estazolam-D5 were m/z 300.1059→ 272.0875 
(quantifier) and 300.1059→ 210.1076 (qualifier) at a collision energy of 30 eV. The 
method was validation over a range of 5-250 ng/mL in urine using a quadratic weighted 
(1/x) calibration model. The LOD and LOQ were 0.5 ng/mL and 5 ng/mL, respectively, 
with intra- and inter-assay precision <8%. The bias ranged from -2 to 4% and no carryover 
was detected. No interferences were reported from the internal standard, matrix, or other 
common drugs (50 analytes evaluated). This method provided an easily adapted LLE that 
labs can apply to their existing protocols using newer LC-Q/TOF-MS technology for 
toxicological analysis (44). 
An increasing number of methods for suvorexant are being developed for use with 
LC-MS techniques. The analysis of suvorexant in urine has also been described by Iqbal 
et al. using a unique dispersive liquid-liquid micro-extraction and LC-MS/MS (47). 
Suvorexant was isolated from urine using a simplified dispersive liquid-liquid micro-
extraction followed by ultrasound assisted back extraction of solidified organic droplets 
(DLLME-SFO-UABE), with acetonitrile and 1-undecanol as the dispersive and extraction 
solvents, respectively. LC-MS/MS was used in positive electrospray ionization mode and 
using multiple reaction monitoring. The suvorexant transitions used were m/z 451.12 → 
104.01 and m/z 451.12 → 186.04. The internal standard, carbamazepine, had one transition 
of m/z 237.06 → 194.1. Separation was achieved using a Waters Acquity UPLCCSH™ 
C18 column and isocratic elution of 15 mM ammonium acetate: acetonitrile: formic acid 
(15:85:0.1%; v/v/v). This method too was validated according to SWGTOX 
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recommendations over a range of 0.27-1000 ng/mL in urine using a linear weighted (1/x2) 
calibration model (50). The LOD was 0.1 ng/mL and the LOQ was 0.27 ng/mL with 
precision and bias within acceptable ranges. The method was free from carryover and ion 
suppression was negligible. Stability of suvorexant in urine was described at different 
storage temperatures and was found to be stable up to 24 hours at room temperature, for 
up to one month at -80°C, and for 24 hours in the autosampler in which the temperature 
was not specified. Suvorexant was stable after three freeze-thaw cycles according to the 
authors (47). While this method demonstrated improved sensitivity over the previous 
methods for urine, the use of an internal standard that is not isotopically labeled could pose 
problems during analysis of samples in which carbamazepine is also present, as it is also a 
commonly encountered drug in forensic toxicology. In addition, SPE, LLE, and protein 
precipitation (PPT) are commonly used in forensic laboratories, but the use of DLLME-
SFO-UABE might be limited. 
This research group has also published methods for the detection of suvorexant in 
plasma using LC-MS/MS (45, 46). In one method, suvorexant was isolated from rat plasma 
using LLE with diethyl ether as the organic extraction solvent. The internal standard used 
was rivaroxaban, and detection was performed using LC-MS/MS in positive ESI mode 
with multiple reaction monitoring. The transitions for suvorexant were m/z 451.12 → 
104.01 and m/z 451.12 → 186.04 and the transition for rivaroxaban was m/z 436.10 → 
144.93. Separation was achieved on a Waters Acquity BEH™ C18 column with an 
isocratic elution consisting of acetonitrile and 15 mM ammonium acetate (85:15, v/v%). 
The method was validated with SWGTOX guidelines and provided a linear (1/X2) 
concentration range of 0.33-200 ng/mL in rat plasma (50). The LOD was 0.1 ng/mL and 
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the method met all other standards regarding precision, bias, carryover, matrix effects, and 
interferences. This study also included dilution integrity experiments in which suvorexant 
met acceptability criteria following dilution (2x and 4x) of positive samples with blank 
plasma (45). The authors describe a separate assay for the detection of suvorexant in 
fortified human plasma (46). Suvorexant and the internal standard, carbamazepine, were 
isolated using LLE with MTBE as the extraction solvent. The Waters Acquity BEH™ C18 
column was used with isocratic elution of 10 mM ammonium acetate/acetonitrile/formic 
acid (15:85:0.1%; v/v/v) for the separation of suvorexant and carbamazepine. LC-MS/MS 
was used in positive ESI mode, and the transitions for suvorexant and carbamazepine were 
the same as in the previous report for urine (47). Using a weighted (1/X2) linear model, the 
calibration range was 0.16-250 ng/mL in plasma with an LOQ of 0.08 ng/mL. The method 
met acceptability for bias, precision, carryover, matrix effects, and interference from 11 
other drugs (46). While these methods are sensitive and selective for the detection of 
suvorexant in plasma, this matrix is not commonly used in postmortem forensic casework 
unless comparing antemortem and postmortem concentrations, and specimens such as 
blood or tissues could be more informative in a death investigation. 
There has only been one analytical method for the detection of suvorexant in urine, 
blood, and tissues that has been used on authentic case specimens in the literature to date. 
In 2018, Waters et al. described the detection of suvorexant in three forensic autopsy cases 
using GC-MS/MS and LC-MS/MS, providing the first report of suvorexant distribution in 
the body following death (48). In this study, samples were first screened for suvorexant by 
GC-MS/MS. Like in previous studies, the authors acknowledge that using traditional GC-
MS conditions resulted in the elution of suvorexant at 23.7 minutes which could cause it 
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to go undetected during data acquisition (43, 48). The late elution of suvorexant, due to its 
high boiling point, was mitigated in this study using tandem GC columns. With tandem 
columns, the total run time was reduced to 9.16 minutes with a suvorexant retention time 
of 5.25 minutes. Following positive identification with GC-MS/MS, fluids and tissues were 
prepared for LC-MS/MS quantitation using diazepam-D5 as the internal standard. Urine 
and blood samples were subjected to protein precipitation with acetonitrile. Tissues were 
prepared by homogenization and protein precipitation of the resulting fluid. Supernatants 
of all precipitated samples were subsequently subjected to Agilent Captiva ND Lipids 
cartridges for clean-up. Separation of analytes was achieved using a Hypersil GOLD PFP 
column and gradient elution of 0.1% formic acid in water (A) and 0.2% formic acid in 
acetonitrile (B). The LC-MS/MS source was operated in positive ESI mode with 
suvorexant transitions of m/z 451 → 186 and m/z 451 → 104 being used, as well as 
diazepam-D5 transition m/z 290 → 198. The method was validated according to SWGTOX 
and used to analyze postmortem case specimens. The LOD and LOQ for both blood and 
urine were 0.5 ng/mL and 1 ng/mL, respectively. The calibration range was from 0.5-500 
ng/mL using a linear model. Precision, bias, and matrix effects fell within acceptable 
ranges, and there was no carryover or interferences from 20 common analytes observed. 
Stability of QC samples following storage at 4°C for 6-24 hours demonstrated 92-99% 
accuracy (48).   
Suvorexant in Toxicology Casework 
Suvorexant casework has not been adequately described in the literature and few 
reports have been made available to indicate its prevalence in forensic cases. Therefore, 
little is known of its role in human performance toxicology or in forensic investigation. No 
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studies are available concerning antemortem suvorexant concentrations outside of the 
clinical setting, and the only study to date detailing the analysis of suvorexant in 
postmortem specimens was published in 2018 by Waters et al. (48). The method detected 
suvorexant in three forensic autopsy cases using LC-MS/MS. 
The first of the three cases involved a female in her forties that was found deceased 
on the beach. It was determined the cause of death was drowning and she had been 
prescribed depression medications along with suvorexant for the treatment of insomnia. 
Other drugs found during toxicology were 7-aminoclonazepam, flunitrazepam, olanzapine, 
and quetiapine. Suvorexant was present in right heart blood (455 ng/mL), left heart blood 
(491 ng/mL), left femoral blood (421 ng/mL), liver (201 ng/mL), kidney (280 ng/mL), 
spleen (36 ng/mL), pancreas (55 ng/mL), lung (122 ng/mL), muscle (93 ng/mL), and fat 
(359 ng/mL). Police records had indicated that the decedent had been prescribed the 20-
mg dose of suvorexant to take once nightly for insomnia. Previous clinical studies on 
suvorexant administered to 5 healthy men in a 50-mg oral dose indicated average peak 
plasma concentrations of 392 ng/mL (30). Blood concentrations, which accounted for most 
of the suvorexant detected in this case, were well above expected peak plasma 
concentrations. 
The second case involved a male decedent found lying prone in a bedroom with no 
remarkable injuries. At autopsy a bluish-green substance was found in the oral cavity, 
esophagus, and stomach contents indicating that the substance Rohypnol® may have 
consumed. The man had been prescribed Rohypnol® as well as a 20-mg nightly dose of 
suvorexant. Other significant findings were the presence of 15 additional drugs at the time 
of autopsy, with elevated levels of promethazine, nifedipine, chlorpromazine, and zotepine 
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present. Suvorexant was detected in right heart blood (15 ng/mL), left heart blood (17 
ng/mL), left femoral blood (11 ng/mL), urine (<1 ng/mL), liver (6 ng/mL), kidney (4 
ng/mL), spleen (<1 ng/mL), pancreas (1 ng/mL), lung (40 ng/mL), muscle (<1 ng/mL), and 
fat (5 ng/mL). The concentrations of suvorexant were less than those reported in clinical 
findings for plasma. Due to the presence of several drugs, some at toxic levels, the cause 
of death was determined to be combined drug intoxication. 
The third case was another male decedent in his 80s who had reportedly become 
blind due to diabetes 10 years prior. The man was reported to be found hanging from the 
neck, and autopsy showed furrows in the neck with subcutaneous bleeding, and a fractured 
thyroid cartilage. The manner and cause of death were suicide by hanging. In addition to 
diabetes, the man suffered from anxiety and was prescribed 20-mg suvorexant tablets, 
triazolam, and other medications that were not described. Ethanol was found in the blood 
at a concentration of 0.02 mg/mL and other drugs found in the cardiac blood were 
bisoprolol, N-desalkylflurazepam, and triazolam. Suvorexant was found in right heart 
blood (138 ng/mL), left femoral blood (155 ng/mL), urine (10 ng/mL), liver (158 ng/mL), 
kidney (232 ng/mL), spleen (31 ng/mL), pancreas (24 ng/mL), lung (41 ng/mL), muscle 
(30 ng/mL), and fat (278 ng/mL) (48). 
The authors acknowledge that the distribution of suvorexant varied significantly 
between the three cases. While the first case had the highest suvorexant concentration in 
blood, the second and third cases exhibited the highest concentrations in lung and fat 
respectively. Postmortem redistribution (PMR) could not be identified due to the lack of a 
significant pattern but is often used to help interpret postmortem concentrations of a drug. 
In the three cases, the central/peripheral (C/P) blood ratios ranged from 0.89-1.36 which 
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suggests that suvorexant did not have an obvious tendency to redistribute into central blood 
during the postmortem interval (48). Although this is the first case report to be published 
detailing the analysis of parent drug in forensic specimens, no studies have been published 
to date detailing the analysis of suvorexant metabolites in forensic casework. 
Metabolism  
In vitro Approaches to Metabolism 
Understanding the metabolism of a therapeutic or drug is essential, so that adverse 
drug reactions may be predicted during the preclinical stages of its development. 
Preclinical development of compounds usually involves investigation of pharmacological 
properties and heavily examines metabolism of these compounds. When drugs are 
metabolized in the body, production of active metabolites can potentially cause toxic 
effects, so a thorough evaluation of biotransformation is necessary using in vivo and in 
vitro methodologies in animal models (51). Metabolic characteristics that are usually 
studied include the drug’s metabolic stability, metabolic route, which enzyme systems are 
responsible for drug metabolism, and how these systems are inhibited for identifying 
potential drug-drug interactions (51). 
The two stages of metabolism involve phase I, where nonpolar species are 
converted to a polar species, which can subsequently be conjugated with a glucuronic acid, 
sulfate, glycine, methyl, or acetyl group in phase II metabolism. These biotransformations 
primarily take place in the liver which also houses many cytochrome P450 (CYP) enzymes 
that are responsible for various metabolic reactions. The CYPs primarily responsible for 
drug metabolism are CYP 3A4, 2C19, 2D6, 2C9, and 1A2, while others exist that 
contribute to metabolism to a lesser extent (51, 52). CYP 3A4, which is present in the liver 
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in high concentrations, is one of the most important isoforms involved in human drug 
metabolism. It is involved in the metabolism of the majority of drugs covering a wide range 
of uses, which is problematic from the standpoint of drug-drug interactions and interactions 
arising from an individual’s diet which can also affect drug interactions (i.e. grapefruit 
juice) (52). However, it is common for a drug to be subjected to more than one metabolic 
pathway, and identifying these pathways is important if adverse interactions are to be 
avoided. 
Many in vitro experimental approaches have been developed for estimating in vivo 
human drug metabolism by using systems derived from human liver. These have included 
microsomes, supersomes, S9 fractions, and human hepatocytes, among others (51). Each 
of these systems can help identify major metabolic pathways for a compound, but all have 
their own advantages and vary in the information they provide. Human liver microsomes 
(HLMs) are useful in identifying metabolites and predicting drug clearance and are the 
most popular in vitro model in part due to being one of the most characterized models (51). 
HLM reactions are typically used first to evaluate metabolism formation rates using 
enzyme kinetic analysis. HLMs contain many drug-metabolizing species such as 
cytochrome P450s (CYPs), flavin monooxygenases, and UDP glucuronyl transferases 
which require NADPH regenerating systems, exogenous cofactors, to measure oxidase 
activity in producing phase I metabolites. Phase II metabolites can also be studied by the 
addition of uridine-5’-diphospho-α-D-glucuronic acid (UDPGA) cofactors. Metabolite 
identification is typically performed by incubation with HLMs followed by high resolution 
mass spectrometry (HRMS) techniques which allow for structural elucidation with 
increased mass accuracy. While useful for predicting likely metabolism, HLMs are 
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disadvantageous in that their high concentration of CYPs makes it difficult to translate 
quantitative values to in vivo human metabolism where enzymes are present in lesser 
amounts (51). 
To complement HLMs, supersomes are often used to investigate 
biotransformations in vitro. This approach uses insect cells that would usually be devoid 
of endogenous CYP or uridine 5’-diphospho-glucuronsyltransferase (UGT) activity but 
contain human CYP- or UGT-expressing hepatocyte endoplasmic reticulum vesicles and 
baculo virus. The advantage of using supersomes, or bactosomes, is that single CYP 
isoform contribution can be identified which is important for contraindication of drugs by 
their expected drug-drug interactions as well as influence of polymorphisms on metabolism 
(51). Like studies with HLMs, addition of cofactors such as NADPH-regenerating systems 
are needed for activity (51). Recombinant enzyme systems such as these have the added 
advantage of ease of preparation versus HLMs which are more difficult to obtain (53). S9 
fractions are another method that has been used for describing metabolic systems, although 
not as commonly used as human liver microsomes or supersomes. S9 fractions consist of 
microsomal and cytosolic fractions from the liver and require NADPH for activity of CYP 
enzymes. Advantages of using this method are that both phase I and phase II metabolites 
can be generated, but the lower activity of these fractions compared to the two previously 
described methods can allow for some metabolites to go undetected (51). Another popular 
way to study phase I and phase II metabolism in vitro is using human hepatocytes which 
have good correlations for in vitro-in vivo studies. Human hepatocytes have been used to 
study metabolic stability, drug-drug interaction potentials, and metabolic profiling. These 
hepatocytes are generally reflective of heterogeneity of human liver expression of CYPs 
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and when cryopreserved, enzyme activity can be retained for phase I and phase II reactions 
(51).   
While useful for the purposes of predicting likely metabolism, there are some 
intrinsic differences that can arise between in vitro and in vivo data due to the nature of 
these modeling experiments. One reason may be that metabolism can take place in areas 
of the body other than the liver, while most of these approaches focus on liver-derived 
mechanisms, so metabolism can be underestimated. For instance, orally administered drugs 
will have a higher concentration in the gut, which is rich in CYP 3A4, particularly in the 
small intestine. High-clearance drugs are more susceptible to these types of 
underestimations. In addition, high concentrations of drug used in in vitro metabolic studies 
that exceed the anticipated therapeutic range of the compound can influence its metabolic 
behavior due to saturation of the enzymatic system (53). One of the biggest disadvantages 
of most of the in vitro methods discussed is the discrepancies arising from inter-individual 
variability, or genetic polymorphisms, in enzymatic activity. An example of an enzyme 
system with a high degree of polymorphism is that of CYP 2D6 in which the three 
phenotypes are slow-metabolizers, rapid-metabolizers, and ultrarapid-metabolizers, which 
can affect toxicity of drugs on individuals. CYP 2C19 is also known for its polymorphism. 
Most CYP isoforms are known to have some degree of genetic polymorphism associated 
with them, but inter-individual variability may also be affected by enzyme induction or 
inhibition, diet, age, chronic smoking, and overall health of the individual (52). This can 
be overcome in part by using pooled HLMs and hepatocytes, but is still an important 
consideration when conducting in vitro assays (51-53). 
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Currently, HRMS and nuclear magnetic resonance (NMR) assays are the most 
powerful tools in metabolomic studies, as they can identify individual metabolite profiles 
using both in vivo and in vitro approaches. Methods that use mass spectrometry are 
becoming increasingly used over NMR techniques due to their high sensitivity and wider 
availability of instruments. While they do not have the precise structural identification 
capabilities of NMR, HRMS techniques can be used to perform structural elucidation by 
using accurate mass and MS/MS fragmentation patterns (54, 55). To help with the 
identification of individual metabolites in vivo, radio-tracing or radiolabeling has been 
utilized. In this approach, subjects are administered a radiolabeled dose of the compound 
and elimination is monitored based on the radioactive dose recovered and analytes can be 
deduced in this manner. This requires synthesis of a radiolabeled compound which can 
often be expensive and requires a facility capable of housing radioactive compounds (54). 
Conversely, drug metabolites can be monitored using treatment and placebo groups, and 
identifying metabolites based on mass spectral differences between the treatment group 
(which will contain metabolites) and the control group which should contain no metabolite. 
Differences can be assessed by peak recognition, ion identification, and analysis of ion 
abundance, either performed manually or by a data matrix which can incorporate centroid 
profiles, isotope patterns, and mass filtering for very large data sets (54, 56). It is due to 
these capabilities that LC-MS techniques are becoming more widely used in metabolite 
identification and description during metabolomic studies. 
Suvorexant Metabolism 
The metabolism of suvorexant in vivo and in vitro has only been described in one 
report. In this report, the metabolism and elimination of suvorexant was characterized in 
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healthy subjects that were administered [14C]-suvorexant and unlabeled suvorexant. 
Metabolism of suvorexant was also investigated using a number of in vitro techniques to 
identify enzymes responsible in the biotransformation of the drug (22). 
A clinical study with the administration of radiolabeled suvorexant was performed 
on males 18-45 years of age who were healthy and non-smoking. A single 50-mg oral dose 
of [14C]-suvorexant was administered to subjects following an overnight fast. Over a 28-
day period, samples of urine, blood, and feces were collected. Plasma samples were also 
collected pre-dose and up to a period of 504 hours following dosing. Radioactivity of the 
plasma samples was performed using liquid scintillation counting (LSC) and suvorexant 
concentrations were determined using LC-MS/MS over a range of 1-1000 ng/mL. 
Following the 50-mg dose, study of human plasma showed that followed the radioactive 
dose, suvorexant had a mean Cmax of 1.6 µM (720.32 ng/mL), a Tmax of 1.5 h, and a terminal 
t1/2 of 12.3 h. Results indicated that 12-35% of plasma radioactivity was contributed from 
unchanged suvorexant. Excretion of radiolabeled suvorexant was determined to be 
primarily fecal elimination (66%) followed by urine (23%) (22). 
Metabolism was assessed by overall recovery of [14C]-suvorexant in urine, feces, 
and plasma measured by LSC. Metabolite profiles were obtained using HRMS with offline 
radiometric identification and quantitative analysis was performed based on the % 
radioactivity compared to the initial dose. Proposed metabolites were based on structural 
changes to the key fragment ions used in suvorexant identification (m/z 451.1644 and m/z 
186.0662). Metabolites M4, M9, and M10a were identified and compared to standards 
(manufactured by Merck & Co.) for confirmation (Figure 1.3). Of the other metabolites 
identified, structural elucidation and confirmation was performed for four species (M7a, 
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M8, M16, and M17) using high resolution solution NMR analysis. Metabolites were 
confirmed using both NMR and MS/MS after production using Codexis® BM3 
Cytochrome P450 variants. Results showed that these four metabolites are characterized 
by hydroxylation of the chlorobenzoxazole, with M7 and M17 having an additional 








Figure 1.3. Chemical structures of notable hydroxylated metabolites of suvorexant (M9, M4, and 








Figure 1.4. Chemical structures of additional hydroxylated metabolites of suvorexant (M7, M8, 
and M17) identified by HRMS structural elucidation and NMR. 
 
The carboxylated metabolite of suvorexant, M4, and the corresponding glucuronide 
of that metabolite, M19, were found to the be the primary urinary metabolites (4.1% and 
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5.3% of the total dose, respectively). The glucuronidated metabolites M3, M12, and M11 
were detected in urine at 3.8%, 2.7%, and 1% radioactivity of the original dose. No 
radioactively labeled parent suvorexant was detected in urine. For feces, the primary 
species was M4 (18%) followed by M18 (10.6%). The hydroxylated M9 metabolite, and 
the M10a metabolite produced from hydroxylation of the methyldiazepan, were also 
present in feces at 9% each. Other minor metabolites were detected in feces to include 
M6b/c, 7a, and 13a/b/c, but minimal parent drug was present. The plasma concentrations 
measured reflected the highest amount of suvorexant (30.1%) and its hydroxylated 
metabolite (36.5%). Plasma also contained M12 (glucuronidated M10a) at 12.2% and 
showed minor contributions from metabolites M4, M7a, M8, M10a, and M17 (22). 
Following identification of potential metabolites, plasma samples from a multiple 
rising dose study were analyzed for the presence of unlabeled suvorexant and its 
metabolites. Forty healthy males aged 18-45 participated in a controlled, double-blind, 
randomized multiple dose study in which subjects were either given a suvorexant oral dose 
of 10, 20, 40, 80, or 100 mg, or were administered a placebo. Plasma was collected pre-
dose and up to 72 hours post-dose. Subjects were allowed a 120-day washout period before 
being administered a matching dose (or placebo) for a 14-day period. Plasma samples were 
collected pre-dose and up to 96-hours post-dose. Plasma samples were analyzed by HRMS. 
It was found that results from this study were in good agreement with those from the 
radiolabeled suvorexant administration study. In addition to the parent drugs and M9 being 
the most predominant species present, it was observed that M17 was more prevalent in this 
study and accounted for 17% of the total dose. Ciu et al. also describe the plasma protein 
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binding of suvorexant metabolites M9 and M17, which are extensively bound to plasma 
proteins as with the parent drug (22). 
To identify the specific enzymes associated with the metabolism of suvorexant, the 
authors performed cytochrome P450 reaction phenotyping and enzyme kinetics studies. 
Immuno-inhibition studies using human liver microsomes (HLMs) and monoclonal 
antibodies (anti-CYP 1A2, 3A4/5, 2C8/18/19, and 2D6). Concurrent monitoring of 
metabolite formation using HRMS and online radiometric detection using a radiochemical 
flow detector was performed using a column splitter. In the presence of anti-CYP 3A4/5, 
the formation of the M8 metabolite was inhibited by 82-100% while M9 formation was 
inhibited 65-80% depending on the suvorexant concentration (2 or 20 µM). Anti-CYP 2C 
resulted in 10-30% metabolite formation inhibition at 20 µM of suvorexant, and anti-CYP 
1A2 and 2D6 had minimal inhibition of metabolite formation. As a result, CYP 3A is the 
main enzyme identified in the oxidative metabolism of suvorexant. Specific substrate 
turnover study with rCYPs only implicated rCYPs 3A4 and 2C19 in kinetic activity (22). 
Suvorexant induction and inhibition was studied in a reversible inhibition study 
using CYPs (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) and HLM activity for those CYPs. 
Data showed that there was some suvorexant inhibition activity for CYP 2C19 and 3A4, 
with weak inhibition of the remaining enzymes studied. Inhibition of CYP 3A4 activity in 
HLMs by suvorexant was determined to be time dependent. Hepatocyte induction was 
studied using human hepatocytes across a range of suvorexant concentrations (0.1 µM and 
20 µM), and mRNA levels and enzyme activity of CYP 3A4, 1A2, and 2B6 were assessed. 
Overall, CYP 3A4, 2B6, and 1A2 mRNA increases were observed incubations at all 
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suvorexant concentrations. Decreasing enzyme activity with increasing suvorexant 
concentrations could be explained by time-dependent inhibition (22). 
In summary, the report demonstrated that suvorexant’s oxidative metabolites and 
glucuronidated analogs were the major components found in human urine and feces, while 
unchanged suvorexant and its hydroxylated M9 metabolite were predominant in human 
plasma. Data shows that metabolites account for a large portion of the circulating material 
following oral dosing of suvorexant, and it seems to be well absorbed (>90%) and 
extensively metabolized. The metabolites described in vitro and in vivo are not expected 
to contribute to pharmacological activity in humans and the pharmacological effects 
observed are due to the parent compound alone. Moreover, suvorexant shows low systemic 
clearance and low first-pass metabolism. The elimination of suvorexant is primarily 
facilitated by CYP 3A-mediated metabolism and at recommended doses it has low 
potential for inhibition or induction of major CYPs (22). 
Postmortem Redistribution  
Postmortem redistribution (PMR) is a significant concern in forensic toxicology 
casework. Postmortem redistribution is known as the movement of drugs in tissues, organs, 
and fluids following death (57). Changes that occur after death can cause increases or 
decreases in drug concentrations which can affect interpretation of drug concentrations 
(58). Not only are these changes highly variable, but they are also time and site dependent 
which requires that special attention to where a specimen was sampled from following 
death (58, 59). In addition, the postmortem stability of a compound is highly dependent on 
its physicochemical properties. As such, it is difficult to estimate the antemortem 
concentration for a drug, particularly when postmortem redistribution is significant. 
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Physicochemical properties of drugs that can greatly affect postmortem 
redistribution are its size and charge, pKa, apparent volume of distribution, protein binding, 
partition coefficients, and residual enzyme activity. Environmental factors may include 
temperature, pH, blood movement between body cavities, repositioning of the body, and 
bacterial activity (57, 58). Site dependence is an important consideration for collection and 
interpretation of samples, as drug distribution can differ between sites (i.e. higher drug 
levels in central blood over peripheral blood). The difference in concentration between 
central and peripheral sites is known as the central/peripheral (C/P) ratio. Peripheral blood 
is much less susceptible to the effects of postmortem redistribution and is a more reliable 
forensic specimen. C/P ratios can be informative about the distribution of drug at the time 
of death, however they can change depending on the time between death and postmortem 
examination (57, 60). Comparison of antemortem and postmortem concentrations can 
provide information on the redistribution of drugs, however antemortem concentrations are 
often not available for comparison. 
Other changes that occur after death can occur due to decompositional changes 
which can affect drug concentrations. After death, blood and plasma do not easily separate 
due to hemolysis, so interpretation of blood plasma ratios is usually not possible. This 
causes difficulties from the standpoint of interpreting clinical therapeutic concentrations 
which are generally reported for plasma, and most drugs have differential binding to blood 
and plasma fractions (58, 61). After death, the body becomes increasingly more acidic 
which can cause drugs to redistribute with the increased permeability of membranes (58, 
61). Drugs with high volumes of distribution (>3 L/kg), weak basicity, and lipid solubility 
are more likely to redistribute after death (58, 59, 62). While the volume of distribution is 
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known for suvorexant (0.5-0.9 L/kg) and the pKa is reported to be 1.5, there is limited 
literature regarding its PMR and lipophilicity (63). In addition, only the report by Waters 
et al. described suvorexant in postmortem specimens in a series of just three cases (48). 
There was no apparent pattern of PMR in this study but understanding additional 
physicochemical properties of suvorexant can help predict its behavior before and after 
death. 
Lipophilicity 
The lipophilicity of a compound is often used in preclinical drug discovery or 
development to estimate its likely absorption, distribution, and elimination within the body. 
Membrane permeability of drugs is highly dependent on its solubility and lipophilicity to 
reach receptor targets. During drug development a drug must be able to be absorbed and 
distributed, which is influenced by its ability to undergo passive diffusion (64). Compounds 
must be sufficiently lipophilic to traverse membranes, but not so lipophilic that they 
become trapped within the membrane. Partition and distribution coefficients (P and D, 
respectively) are often used to measure this property, typically expressed as a logarithm 
(Log P, Log D). Log P refers to the distribution of the unionized compound while Log D 
is the descriptor for ionizable compounds in a two-phase system (65). When lipophilicity 
is expressed in this manner it can be the most informative in the application to the 
absorption, distribution, metabolism, and excretion (ADME) profile of a compound (64). 
Log P values have been both theoretically and experimentally evaluated for a number of 
compounds. 
To measure Log P experimentally, the most common approach is determining its 
partitioning between two immiscible phases, most frequently octanol and water. This is 
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typically performed using the classical shake-flask method in which a known amount of 
analyte is mixed between these two immiscible phases and then partitioning, expressed as 
Log P, is the resulting ratio of species present in each phase (octanol/water) following 
thorough equilibration. This method has traditionally been the most accurate for 
determining Log P values ranging from -3 to 4, but it does have its disadvantages. These 
methods may require large solvent volumes, sufficient analyte concentrations for 
determination of highly lipophilic compounds in the aqueous phase (parts per billion 
range), and inaccuracies that can be suffered from limited solubility of compounds and 
adsorption to glass walls (64, 66). For highly lipophilic compounds it is also important to 
consider that these compounds tend to also have low aqueous solubility which can also 
result in inaccurate determination of partitioning. In such cases, a co-solvent such as 
DMSO can be used to increase the solubility of the standard solution. Alternatively, the 
sample can be dissolved in octanol, and then the amount of drug in the aqueous phase is 
increased by directly equilibrating with aqueous phase without dilution. After offline 
separation of phases, common analytical techniques can be used to measure the 
concentration of analyte in organic and aqueous phases. Analysis time can be reduced by 
only determining the concentration of analyte in one phase and obtaining the concentration 
of the other phase by difference from the starting concentration- considering no absorption 
of analyte to glass occurred (64).   
More recently, a popular way to measure partition coefficients is by use of online 
LC separation procedures, which provide greater speed and simplicity over traditional 
methods (66). UV spectroscopy and LC can be used to measure concentration of analyte 
in both organic and aqueous phases. One advantage of LC is the reduction in analyte 
44 
 
concentration required for accurate determination and the elimination of impurities by 
chromatographic separation (64, 67). Andres et al. (2015) described a method in which 
equilibration between the phases and analysis of the sample were performed in sample 
chromatographic vials, but went on to describe the difficulty of LC measurement of 
concentration in both organic and aqueous phases due to the high viscosity of octanol 
which can dirty the analytical column. In addition, the low volatility of octanol can prevent 
it from being used as a solvent in mass spectrometry (MS) detection (64). Another proposed 
method involves measuring an aqueous standard solution prior to equilibration with 
octanol, then measuring the aqueous phase again following equilibration. Partition 
coefficients can be calculated by comparing the peak areas of the standard solution and the 
aqueous phase. Other experimental approaches to determining lipophilicity have been thin-
layer chromatography, electroseparation techniques, and electroanalytical methods (68, 
69). 
Log P values can be determined theoretically which can help estimate lipophilicity 
of compounds that would otherwise be difficult to measure and when experimental 
techniques are not available (68, 70). Computational techniques have been developed 
utilizing a variety of algorithms. Computational programs have included IAlogP, ClogP, 
CSLogP, LogPKowwin, xlogP, MILOGP, Hyperchem 7.0, ALogPS, and ACD Labs/Log 
P (71, 72).  Additive atomic contribution methods that take into account “correction 
factors” such as intermolecular interactions are achieved with ClogP, xlogP, Log Kowwin, 
MILOGP, HyperChem 7.0, ACD Labs/Log P. Programs that use electrotopological 
characteristics and E-state indices to predict Log P include ALogPS, IALogP, and CSLogP 
(71, 72). Methods that use additive constitutive fragment determinations, such as ACD 
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Labs/Log P and Log KowWin, operate by summing all of the atoms and fragments of a 
molecule with their relative contributions, and then adjusting the overall hydrophobicity 
by incorporating a correction factor. The correction factor serves to take into account other 
interactions that occur within the molecule that can affect lipophilicity. For Log KowWin, 
the correct factor examines steric interactions between hydroxy and carbonyl substituent 
groups as well as the linear equation constant (71, 72). For ACD Labs/Log P, follows a 
similar process and also examines possible tautomerization of compounds and 
contributions from carbons not belonging to a functional group based on hybridization state 
(73, 74). On the other hands, programs that use electrotopological characteristics may give 
better predictions for partitioning of compounds. ALogPS is one of these programs which 
predicts Log P values by considering both electronic and topological characteristics of 
molecules, and subsequently assigning E-state values to atoms based on those 
characteristics and its neighboring atoms (72). 
Ultimately, lipophilicity can affect partitioning into tissues and organs and can be 
an additional predictor for postmortem redistribution. The lipophilicity of suvorexant is 
unknown and experimental determinations for its partition coefficients have not been 
made, further highlighting the gap in knowledge that needs to be filled regarding its 
physicochemical properties. 
Matrix Effects & Ion Suppression 
Matrix effects are an important consideration when used LC-based techniques. 
High performance liquid chromatography (HPLC) techniques have been paired with 
several modes of ionization such as electrospray (ESI), atmospheric pressure chemical 
(APCI), and atmospheric pressure photoionization (APPI). HPLC-based methods are 
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becoming the preferred technique for analyzing pharmaceuticals and have applications 
across a wide variety of disciplines, including forensic toxicology. Mass selective detection 
in combination with hydrophobic separation make LC-MS techniques powerful analytical 
tools, and ESI-based LC methods have become the benchmark for identifying drugs and 
their metabolites in biological specimens (75). It is believed that the high selectivity of LC-
MS/MS in combination with successive mass filtration reduce the elimination of co-
extractive and co-eluting interferences, which in turn has led to analysis that features 
minimal specimen preparation and shorter chromatographic retention (75-77). However, it 
is become well known that LC-based methods are susceptible to interferences, such as 
matrix effects, that can lead to ion suppression and reduced ionization for target analytes. 
Analytical data in the forensic toxicology setting must be correctly interpreted and free 
from these interferences to ensure underestimations and false interpretations are not made 
(78). 
Matrix effects occur when endogenous species altering the ionization efficiency. 
The increase in efficiency of ionization is referred to as ion enhancement, while the 
decrease in ionization efficiency is known as ion suppression (75, 78, 79). The successful 
development of an analytical method is dependent upon a thorough understanding of 
matrix effects, and many methods fail to adequately address the problem of matrix effects 
(75). This is an analytical challenge, as matrix effects can affect accuracy and precision of 
LC-ESI-MS/MS methods and ion suppression can adversely impact the sensitivity of a 
method (i.e. LOQ) (75, 80). Retention time shifts and changes in baseline response can 
also occur, as well as imprecise calibration (81, 82). Retention time shifting in LC-MS/MS 
techniques can be detrimental in methods that employ automation when identifying 
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compounds such as metabolites whose identification is highly dependent on retention time 
matching and accurate mass. This can impact the drug development and pharmacokinetic 
discovery processes (82). 
Matrix effects were first described in detail by Kebarle and Tang in 1993 (75, 83). 
The authors observed a phenomenon in which the responses of organic bases were 
decreased when the presence of other organic bases was increased, which led to the 
hypothesis that coeluting, undetected matrix components were competing with the analyte 
for ionization when using electrospray ionization (75, 83). Electrospray ionization is the 
most commonly used type of ionization source in LC-MS (75). For successful ionization, 
the transfer of analyte from the liquid to the gas phase must occur and the analyte must 
become charged. Singly or multiply charged ions are produced in the electrospray interface 
by creating a fine spray of charged droplets in the presence of a strong electric field and 
heat (75, 84). Droplets are then evaporated, and analyte ions are directed through the mass 
spectrometer for detection. Incomplete evaporation of the droplet can result in non-transfer 
of analyte ions to the source, as conversion to the gas phase was incomplete (83, 84). This 
can occur when the analyte precipitates from the droplet solution. This was further 
demonstrated by King et al. who postulated that matrix effects are a result of nonvolatile 
matrix components and analyte ions compete for charge at the droplet surface, which 
subsequently allows them to be transferred to the gas phase (75, 84). The exact mechanism 
of reduction in release of analyte to the gas phase in the presence of nonvolatile species is 
unclear in these studies, but the authors hypothesize that the prevention of droplets to be 
reduced to smaller droplets could be a possible reason for ion suppression (75, 84). Trufelli 
et al. described the reasons for decreases in ionization efficiency as 1) the competition of 
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analyte and coeluting interference for access to droplet surface charge, 2) reduced droplet 
formation due to increased viscosity and surface tension, 3) formation of precipitating 
particles with non-volatile mobile phases additives, and 4) the formation of ion pairs 
between analyte and interferences or additives (85). Both ion suppression and ion 
enhancement are highly dependent on the matrix as well as the ionization source itself, and 
these effects can also be compound dependent (75, 86). Compounds with high mass and 
increased basicity more likely to cause matrix effects (87). Endogenous interferences can 
result from a plethora of species including lipids, salts, carbohydrates, ionic species, and 
highly polar compounds (88). Addition interferences can arise from metabolites, 
impurities, formulation agents, and degradation products that coelute with the analyte (77, 
86). Polar compounds are more likely to suffer from matrix effects than nonpolar 
compounds, and species such as phospholipids are especially problematic when present in 
high concentrations (81). The removal of nonvolatile species can greatly reduce the 
potential for ion suppression (84). Other sources of matrix effects can include species from 
specimen containers as well as the types preservatives and anticoagulants that are present 
in some of these containers (75). Atmospheric pressure chemical ionization (APCI) 
techniques have been shown to be less susceptible to matrix effects and other interferences 
than ESI techniques (75, 76, 78, 82). One limitation of using APCI is that the analytes must 
be thermally stable for ionization (75). Despite ESI techniques having a higher probability 
for falling victim to these effects, they are still commonly used over APCI due to their 
increased sensitivity (77). 
Matrix effects are generally studied during method development, optimization and 
validation using fortified matrices that often have a homogenous nature. However, this 
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does not account for the fact there may be variability between subjects or specimens. To 
overcome this challenge, it has been proposed that matrix effects should be evaluated in 
pooled matrices that originate from varying sources (75, 76). The two main techniques for 
assessing matrix effects are post-extraction addition and post-column (syringe) infusion 
(75, 76, 78, 79, 86). Post-extraction addition is a technique in which matrix effects are 
quantitatively determined for the analyte of interest. Analyte peak areas are determined for 
neat samples containing no matrix and compared to those of blank matrix samples that are 
fortified with analyte after extraction. The difference in analytical responses are presented 
as a percent difference from the neat standards with no matrix (100% signal) and the 
resulting signal in the presence of matrix. A calculated value of 0% represents no matrix 
effects. In this way, the matrix effect for several different samples can be statistically 
compared. One disadvantage of the post-extraction addition technique is that it only 
provides matrix effect estimation at the retention time of the analyte and thus is considered 
a static technique (75, 78). Conversely, post-column infusion is considered a dynamic 
technique in which analyte in constantly infused into the ion source with an infusion pump 
creating a constant detector signal. Drug-free matrix is simultaneously injected into the 
instrument and is separated using the chromatographic conditions of the method, then 
ionized along with the infused analyte. As such, the matrix effects can be visualized over 
an entire chromatographic run by assessing the changes in analyte response at different 
retention times (75, 78). Using this information, the retention of an analyte can be changed 
to avoid a problematic region in the chromatography. These post-column experiments 
should use an infusion of analyte that is within the analytical range of the method being 
assessed. Post-column infusion can allow for easier visualization of where enhancement or 
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suppression occurs using different extraction protocols, analytical columns, or mobile 
phases (75). Post-column infusion techniques are well-suited during method development 
and optimization, when chromatographic conditions can still be modified if problems arise. 
Quantitative analytical methods should be validated using these methods and should 
demonstrate that the method is free from matrix and metabolite interferences, other 
coeluting compounds, and is free from “cross-talk” effects when analytes may share 
product ions (76). While there are guidelines on the quantitative result of matrix effect 
evaluation (± 25% matrix effects, <15% CV), there are no qualitative guidelines for the 
assessment of these interferences besides the requirement that the change in baseline signal 
must not exceed 25% (50, 78). In best practice, both methods should be employed to gain 
a thorough assessment of matrix effects in analytical methods so that they can be mitigated 
as much as possible. 
While coeluting compounds may cause matrix effects, there are certain measures 
that can be taken in an attempt to reduce these effects. Matrix effects can be affected by 
the extraction technique that is used and the chromatographic separation employed (i.e. 
elution profile, mobile phase, and analytical column) (78, 80, 86). The two approaches that 
are most commonly taken for mitigating matrix effects are to either modify sample 
preparation to reduce the number of interferences or to alter the chromatography to prevent 
coelution of analytes and endogenous species (75). Sample preparation can have a major 
impact on downstream interferences using LC-MS. Three major extraction techniques exist 
in forensic toxicology laboratories which are solid-phase extraction (SPE), liquid-liquid 
extraction (LLE), and protein precipitation. Of the extraction techniques commonly used 
in forensic toxicology and other applications, simple protein precipitation is often 
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considered the most unclean technique, especially compared to LLE or SPE. Using 
multiple sample preparation steps may help rid methods of some matrix interferences (89). 
Cleanliness is not the only factor that must be considered but also chromatographic 
separation when optimizing methods. Flow splitting can also be used to reduce matrix 
effects, as less solvent requires less ionization and may help mitigate ionization efficiency 
effects (75, 86). Another option for mitigating matrix interferences is by use of two-
dimensional chromatography. Most matrix effects occur during the solvent front portion of 
the chromatographic run. In these cases, increasing the retention time of the analytes could 
be one way to reduce matrix effects. However, increases in the total run time resulting from 
the shift in chromatography can hinder high-throughput analysis. The use of “ballistic 
gradient” is another option for separating analytes and the solvent front which uses a rapid 
gradient to quickly elute the unwanted species at the beginning of the run (75, 85). Strongly 
retained endogenous species can remain on the analytical column and slowly elute causing 
ionization drift and increased background noise (81). The implementation of post-
equilibration times or changes in gradient at the end of sample runs must be considered to 
eliminate some of these carryover effects. 
A common approach aside from revisiting sample clean-up and chromatography is 
careful internal standard selection. Matrix effects and other interferences can lead to both 
positive and negative quantitative bias depending on if the interference affects ionization 
of the analyte or the internal standard. The overall analytical response may be monitored 
for an internal standard between a quality control and an extracted sample which can help 
identify decreased or enhanced ionization, but this is not true for samples where an 
analyte’s concentration is unknown. As a result, an interference may go undetected or be 
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invisible to the analyst. The best approach for overcoming this analytical challenge is by 
using stable-isotope labeled internal standards (SIL-IS) (88, 90). These internal standards 
are a structural analog of the analyte of interest in which certain atoms (usually 1H or 12C) 
are replaced with isotopes (i.e. 2H or 13C). The isotopically labeled internal standard will 
maintain structural characteristics and behave almost identically to the analyte during 
various phases of method development (extraction and separation) (79, 91). Since the 
compounds will co-elute, any matrix effect that is observed will affect both the internal 
standard and the analyte and the relative response between them will remain unchanged, 
compensating for the interference (86). SIL-ISs are the gold standard for mitigating 
interferences in LC-MS based methods, but they are often not available for novel 
compounds as they require synthesis and can be quite costly. Higher costs of isotopically 
labeled internal standards may not be feasible for methods containing numerous 
compounds, so multiple analytes may share the same internal standard which cannot 
compensate for matrix effects of all analytes (88, 92). Although their use is ideal, ways to 
mitigate interferences in the absence of these labeled standards should be considered. 
Standard addition is a technique commonly used in laboratories, but its applicability in 
forensic toxicology may be limited. In this technique, a sample is fortified with known 
concentrations of a standard at increasing concentrations to form a calibration curve that 
can be used to extrapolate the unknown analyte concentration (88). For calibrator 
preparation this technique requires larger sample volumes, which are unfortunately often 
not available in forensic casework making this method a less popular option. 
Manipulation of the mass spectrometric conditions may provide some alleviation 
of ion suppression and enhancement. The effects of suppression and enhancement may be 
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altered by switching from positive to negative electrospray ionization if a compound if 
amenable to both (79, 85). The orientation of the ionization source itself can influence the 
amount of suppression observed. It has been shown that linearly oriented sources are more 
prone to ion suppression than those with an orthogonal or Z-spray setup (80, 85, 93). In 
electrospray ionization, a solvent is pneumatically forced through a highly charged metal 
capillary, and the distance between the tip of this capillary (spray head) and the skimmer 
cone can be adjusted. This spray head position along with parameters such as capillary 
voltage can affect spray stability and subsequently the efficiency of ionization of the 
solvent and signal intensity (93). Other parameters that can affect the efficiency of 
ionization include the sheath and drying gas temperatures, as well as gas flow rates (93). 
Gas flow rates have been known to alter instrument response, and flow of nitrogen gas is 
used to protect the sample cone during sample transition from the ESI source and the mass 
analyzer. Although sheath gas (cone gas) flow does not have as pronounced of an effect, 
dramatic changes in ionization efficiency can be observed when the drying gas flow is 
reduced suggesting that desolvation is highly dependent on these conditions. Changing the 
gas temperature and flow rates can potentially reduce ion suppression (93). Similarly, 
decreases in sheath gas temperature can cause greater decreases in ion efficiency the farther 
away the capillary is placed from the aperture, meaning decreased desolvation can cause 
ions to not traverse the entire capillary plane (93). Although steps can be taken to attempt 
interference mitigation by altering these parameters, the special effects of ESI are lesser 
understood than other strategies so are described with less frequency. 
Matrix effects have been described as “the Achilles heel” of LC techniques that use 
ESI (75). LC-MS/MS has become one of the most powerful tools in the pharmaceutical 
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industry due to its selectivity, sensitivity, and general applicability in modern quantitative 
techniques. However, this technique is susceptible to factors that can reduce ionization and 
therefore analytical response. While the underlying factors that decrease ionization 
efficiency may be reproducible between samples, it can ultimately lead to decreased 
sensitivity of methods (75). These issues are of significant concern when multiple analytes 
are being analyzed at once and in rapid LC method where the occurrence of analyte 
coelution is unavoidable. Method may suffer from significant ion suppression when the 
magnitude of interferent concentration well exceeds that of the target analyte. Therefore, 
novel ways to mitigate matrix effects and other co-extractive interferences in forensic 
toxicology casework is of the utmost concern for reliable and robust analysis, particularly 
in cases that utilize multi-analyte procedures in complex matrices. 
Statement of the Problem 
Suvorexant is a novel drug for the treatment of insomnia that has not been widely 
reported in forensic investigations. As a sedative hypnotic, suvorexant is expected to 
feature prominently in toxicology investigations, as with other therapeutics within this 
class such as zolpidem (Ambien®). The limited number of reports might be attributed to 
the scope of current toxicological testing and difficulties associated with its detection using 
routine immunoassay or GC/MS screening. Laboratories will need to consider suvorexant 
as a potentially impairing or toxic substance in both antemortem casework (e.g. impaired 
driving, DFSA) and medicolegal death investigations. Few methods have been published 
that describe suvorexant detection in biological samples. With suvorexant peak plasma 
concentrations expected to be less than 200 ng/mL with the most commonly prescribed 10-
mg dose, sensitive analytical methods are needed for its detection in a variety of specimens 
55 
 
that are encountered in forensic toxicology. Limited research is available detailing 
suvorexant analysis in authentic specimens, but more cases may be reported with the 
increased availability of techniques that labs may easily adapt to their scope of testing.  
No analytical methods were available describing the analysis in suvorexant in 
whole blood using high resolution mass-spectrometry (HRMS) techniques, and we are the 
first to describe a validated method. As a novel substance, the methods that are available 
for suvorexant describe analysis in the absence of a stable isotope internal standard (SILS-
IS) which may pose challenges regarding matrix effects and drug interferences. While the 
previous methods described were free from matrix effects or interferences from a limited 
number of common analytes, developing a method that is impervious to interferences from 
coeluting compounds is nearly impossible in the absence of a SILS-IS. Other gaps in the 
literature for suvorexant are the limited metabolism studies that are available and the lack 
of commercially available metabolites for use in detection and method validation. The 
potential for suvorexant to undergo postmortem redistribution is relatively unknown, as 
only one study has been published that examined suvorexant concentrations in postmortem 
specimens and no remarkable pattern was identified. Many physicochemical properties of 
suvorexant have yet to be investigated or reported which could help aid in the interpretation 
of suvorexant concentrations in antemortem and postmortem casework. 
The research described herein aims to develop analytical methods to improve the 
understanding of suvorexant properties that will aid forensic toxicologists in identifying 
and interpreting concentrations of the drug and its metabolites in forensic casework. The 
first objective of this research was to develop a highly sensitive and specific assay for the 
identification of suvorexant in whole blood using LC-Q/TOF-MS. Next, as LC-MS/MS is 
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also a commonly used platform in forensic toxicology, we describe the validation of an 
analytical method for the detection of suvorexant using LC-MS/MS. Performance of the 
LC-Q/TOF-MS and LC-MS/MS method were compared, specifically in regard to matrix 
effects and other interferences. To help understand the physicochemical properties of 
suvorexant, partition coefficients for the compound were determined both theoretically and 
experimentally over a range of ionic strength and pH to determine its lipophilicity and help 
assess its potential to undergo postmortem redistribution. Suvorexant was then detected in 
a variety of authentic case specimens using the developed and validated LC-Q/TOF-MS 
method to try to help characterize its presence in biofluids of forensic interest, and to 
compare to values obtained during the lipophilicity study. Due to the novelty of the drug, 
and the concern for capacity limited ionization using ESI techniques in LC-MS/MS, 
mitigation strategies for drug-mediated interferences were evaluated to help understand 
ways to overcome these challenges in the forensic laboratory. Finally, suvorexant 
biotransformations in vitro using cytochrome P450 recombinant enzymes were studied in 
order to optimize a method to identify metabolites using LC-Q/TOF-MS. The in vitro 
generated metabolite controls were used to qualitatively identify metabolites in authentic 
case specimens based on retention time matching, structural elucidation, and mass 
accuracy. The research described in this dissertation provides further insight regarding the 
identification, characterization, and metabolism of suvorexant in forensic case samples and 
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Suvorexant is a novel drug for the treatment of insomnia that is marketed under the trade 
name Belsomra®. Unlike other hypnotics, suvorexant is a dual orexin receptor antagonist 
that is believed to have a lower abuse potential compared to other therapeutics. Although 
sedative hypnotics feature prominently in forensic toxicology investigations, there have 
been limited reports that describe the analysis of suvorexant in biological samples. 
Following a 10-mg oral dose, peak concentrations are typically less than 200 ng/mL. A 
highly sensitive assay is required because forensic toxicology laboratories are often 
required to identify a drug several hours after a single dose. A new analytical procedure for 
the quantification of suvorexant in whole blood was developed that will aid in the 
identification of this new drug in forensic toxicology casework. A simple acidic/neutral 
liquid-liquid extraction (LLE) was used to isolate suvorexant from whole blood followed 
by liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry 
analysis using positive electrospray ionization (ESI). The extraction efficiencies of various 
solvents in blood were evaluated in addition to limit of detection, limit of quantitation, 
precision, accuracy and bias, calibration model, matrix effects, interferences, and 
carryover. The recovery of suvorexant was evaluated using four different extraction 
solvents (N-butyl chloride, ether/toluene (1:1), hexane/ethyl acetate (9:1), and methyl tert-
butyl ether (MTBE)). Although no significant differences in analytical recovery were 
observed, N-butyl chloride demonstrated improved reproducibility, efficiency and 
convenience. A weighted (1/x) quadratic calibration model was selected over a range of 2-
200 ng/mL (R2=0.995). Using only 0.5 mL whole blood, limits of detection and 
quantification were 0.5 ng/mL. Intra-assay (n=5) and inter-assay (n=15) precision (% CV) 
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were ≤ 13% and bias ranged from -5 to 2% at concentrations of 5, 50, and 160 ng/mL. 
Matrix effects were 16% (9% CV) and 15% (8% CV) for 20 ng/mL and 100 ng/mL (n=20), 
respectively. No qualitative interferences or carryover were observed; however, a 
quantitative interference with the internal standard, estazolam-D5, could be attributed to 
sertraline when present at a 10-fold higher concentration. In the absence of a commercially 
available deuterated internal standard, the potential for quantitative interferences using LC-
based methods are discussed. 
Keywords:    Suvorexant, LC-Q/TOF-MS, Blood, Forensic toxicology
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QUANTIFICATION OF SUVOREXANT IN BLOOD USING LIQUID 
CHROMATOGRAPHY-QUADRUPOLE/TIME OF FLIGHT (LC-Q/TOF) MASS 
SPECTROMETRY 
Introduction  
Insomnia is a prevalent medical condition that affects approximately one-third of 
the adult population in America and can be described as difficulty falling asleep, staying 
asleep, or experiencing nonrestorative sleep (1,2). Insomnia has been associated with 
depression, anxiety disorders, irritability, inability to concentrate, and a general diminished 
quality of life (2). Most commonly, pharmacological interventions include the use of 
benzodiazepines and other drugs that modulate the gamma-amino butyric acid (GABA) 
receptor. However, these receptor agonist hypnotics can stimulate GABA and may pose 
consequences such as rebound insomnia, next-morning sedation, amnesia, potential for 
abuse, and physical dependence (3).  
Suvorexant, also known as MK-4305, is a novel drug that is used for the treatment 
of insomnia (4). Suvorexant is marketed under the trade name Belsomra® and is 
manufactured by Merck & Co. as a dual orexin receptor antagonist (DORA). In August 
2014, the Food and Drug Administration approved suvorexant and in February of 2015 it 
became commercially available. Currently, suvorexant is listed under Schedule IV of the 
Controlled Substances Act (5). Its mechanism of action is unique from other clinically 
approved hypnotic drugs, because it affects the activity of orexin neurons in the lateral 
hypothalamus, which are thought to play a key role in the regulation of wakefulness (6). 
As a dual orexin receptor antagonist, suvorexant blocks both OX1R and OX2R receptors 
which promote sleep by inhibiting orexin A and B. Thus, suvorexant aids in the transition 
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from wakefulness to sleep, and has no effect on GABA receptors. This drug provides 
alternative treatment options for insomnia, and is reported to have a lower potential for 
addiction compared to existing therapeutics (7). 
Suvorexant should be administered within 30 min of going to sleep, and not<7 h of 
the time of awakening. The recommended oral dose of suvorexant is 10 mg, although doses 
of 15 and 20 mg are also available (3). The drug is primarily metabolized by cytochrome 
P450 CYP3A4 and CYP2C19 enzyme systems. The proposed metabolites of suvorexant 
are the M4 metabolite produced by carboxylation of the parent drug, and the M9 metabolite 
produced by hydroxylation (Figure 1) (8). Suvorexant metabolites are not yet 
commercially available, so their analysis is precluded at the present time. 
 
 
Figure 2.1. Chemical structures of suvorexant and its carboxylated and hydroxylated metabolites, 
M4 and M9, respectively. Estazolam-D5 was selected as the internal standard due to its structural 
similiarities to suvorexant. These include a 7-membered azepane/azepine ring, a heterocyclic 




Suvorexant is reported to be eliminated predominantly as inactive metabolite in 
feces. The drug is extensively protein-bound (99.5%), predominantly to α-1 acid 
glycoprotein and serum albumin (9). The half-life of suvorexant is approximately 12 h and 
steady-state plasma concentrations are reached within three days of daily administration 
(8). Peak plasma concentrations occur approximately two hours after administration on an 
empty stomach, but ingestion of suvorexant following a meal can delay the time to 
maximum concentration (Tmax) by an additional 1.5 h (9). Although race and age do not 
seem to have an impact on peak plasma concentrations (Cmax), they are reported to be 
higher in females by about 9%, and in obese patients by 17%. The oral bioavailability of 
suvorexant is reported to be approximately 82%, with absorption of the drug having an 
inversely proportional relationship to the dose administered, resulting in decreased 
bioavailability as the dose increases (10). Blood plasma ratios have yet to be reported and 
very little is known of its distribution in tissues and fluids of toxicological interest (11). 
Generally, short half-lives and rapid clearance are preferred for hypnotic 
medications. The likelihood of residual effects, drowsiness or decreased alertness increases 
in a dose dependent fashion. These effects have the potential to interfere with daily 
activities (7). The FDA recommends that next-day activities, such as driving, be avoided 
by patients taking the maximum daily dose of 20 mg (4). Sedative hypnotics (such as 
zolpidem) feature prominently in impaired driving and drug-facilitated sexual assault 
investigations. The long half-life of the drug raises concerns that drivers may be impaired 
for extended periods following its use. However, most forensic toxicology laboratories do 
not routinely screen for suvorexant, so very little is understood regarding its prevalence or 
role in human performance toxicology investigations. Moreover, due to its high boiling 
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point (669 °C, 450.9 g/mol), suvorexant is a very late eluting compound using gas 
chromatography/mass spectrometry (GC/MS) techniques, which increases the likelihood 
that the drug might go undetected (12).  
There are relatively few published reports that describe the quantitative analysis of 
suvorexant in biofluids of forensic significance. Merck & Co. published an analytical 
method for the detection of the drug in plasma using liquid-liquid extraction (LLE) and 
liquid chromatography- tandem mass spectrometry (LC-MS/MS) over a concentration 
range of 1–1000 ng/mL. This method utilized an isotopically labeled internal standard 
(suvorexant-13C2H3) that was manufactured in-house by Merck (2). The method was used 
to quantify parent drug in plasma samples as part of the clinical study. However, the 
method was not validated in accordance with generally accepted standards in forensic 
toxicology (13). Additionally, this LC-MS/MS procedure utilized only one transition and 
did not utilize a secondary (qualifying ion), precluding the use of ion ratios for evaluation 
or acceptance purposes. This approach is not forensically defensible, since it is generally 
accepted that a minimum of two ions are required (14). More recently, Iqbal et al. 
developed a method for the determination of suvorexant in plasma using LLE and LC 
MS/MS using rivaroxaban as the internal standard. A linear concentration range of 0.33 
200 ng/mL was used with an LOD of 0.1 ng/mL and LOQ of 0.33 ng/mL (15). Carson et 
al. reported a quantitative assay in urine using LLE and gas chromatography/ mass 
spectrometry (GC/MS). In the absence of a commercially available deuterated internal 
standard, estazolam-D5 was used due to its structural similarity to the compound of 
interest. These include a 7- membered azepine ring, heterocyclic triazole, and a chlorine 
moiety (Figure 2.1). Performance of the assay proposed by Carson et al. was evaluated in 
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accordance with the Scientific Working Group for Toxicology (SWGTOX) Standard 
Practices for Method Validation in Forensic Toxicology (13). The limits of detection and 
quantitation for the assay in urine were determined to be 10 ng/mL (16). 
Similarly, a quadrupole time-of-flight liquid chromatography/mass spectrometry 
(LC-Q/TOF-MS) method in urine was developed and optimized by Sullinger et al. using a 
modified LLE procedure as previously described (12,16). Liquid-liquid extraction was 
previously identified as the preferred extraction technique due to suvorexant's high 
miscibility with organic solvents. The LOD for the method was determined to be 0.5 ng/mL 
and the LOQ was 5 ng/mL. Despite the lack of a deuterium or isotopically labeled internal 
standard for suvorexant, the assay demonstrated excellent precision and accuracy 
throughout the entire calibration range (2–250 ng/mL) (12). 
The purpose of this study was to develop, optimize and validate a method for the 
detection and quantification of suvorexant in whole blood samples using LC-Q/TOF-MS. 
Blood is the most common matrix encountered in both death investigations (postmortem 
toxicology) and human performance toxicology. Since hypnotic drugs feature so 
prominently in both types of casework, and suvorexant is of particular importance from the 
standpoint of impaired driving and drug-facilitated sexual assault, forensic laboratories 
should have analytical methods that are capable of identifying this new drug. 
Suvorexant was isolated from blood using a modified acidic/neutral liquid-liquid 
extraction. This approach should allow laboratories to adapt their existing acidic/neutral 
extraction protocols to identify suvorexant readily. In this study, extraction efficiencies in 
blood were further investigated and the method was validated in terms of limits of 
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detection, quantification, precision, bias, calibration model, matrix effects, interferences, 
carryover, and processed sample stability. 
Materials and Methods 
Chemicals and Reagents 
Suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-
yl][5-methyl-2-(2H-1,2,3,-triazol-2-yl)phenyl]methanone) was purchased from Adooq 
Bioscience as a powder (Irvine, CA). Estazolam-D5 internal standard was purchased from 
Cerilliant Corp. (Round Rock, TX) at a concentration of 100 μg/mL in methanol. Fifty-
three additional interfering drugs were purchased as 1 mg/mL methanolic standards from 
Cerilliant Corp. (Round Rock, TX) as follows: (+)-propoxyphene, 7-aminoclonazepam, 7-
aminoflunitrazepam, acetaminophen, alprazolam, amitriptyline, amobarbital, 
amphetamine, bupropion, butalbital caffeine, carbamazepine, carisoprodol, clonazepam, 
cocaine, codeine, cyclobenzaprine, dextromethorphan, diazepam, fluoxetine, flurazepam, 
gabapentin, hydrocodone, hydromorphone, ketamine, methylenedioxymethamphetamine 
(MDMA), meperidine, meprobamate, methadone, methaqualone, morphine, nordiazepam, 
oxazepam, oxycodone, oxymorphone, pentobarbital, phencyclidine, phenobarbital, 
phenytoin, pseudoephedrine, salicylic acid, secobarbital, sertraline, temazepam, delta-9-
tetrahydrocannabinol (THC), carboxy-THC, tramadol, trazodone, valproic acid, zaleplon, 
zolpidem and zopiclone. 
Acetic acid (glacial) (ACS grade), sodium acetate (ACS grade), and toluene (ACS 
grade) were obtained from Mallinckrodt Chemicals (St. Louis, MO). LC/MS grade 
methanol and ACS grade ether were obtained from J.T. Baker (Center Valley, MA). Formic 
acid (LC/MS grade) and methyl tert-butyl ether (MTBE) were obtained from Sigma-
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Aldrich (St. Louis, MO). N-butyl chloride (99+%, pure) manufactured by Acros Organics 
and LC/MS grade acetonitrile were purchased from Fisher Scientific (Pittsburgh, PA). A 
Millipore Direct-Q ® UV Water Purification System (Billerica, MA) was used for the 
purification of all deionized water. 
Sodium acetate buffer (0.4 M) at pH 3.6 was prepared for routine use in extraction. 
Mobile phase A and B consisted of 0.1% formic acid in deionized water and in acetonitrile, 
respectively. Mobile phase A and B (1:1) were used for the reconstitution of analyte for 
injection into the instrument. Pooled drug-free bovine blood preserved with 1% sodium 
fluoride and 0.2% potassium oxalate was purchased from Quad Five (Ryegate, MT) and 
stored at 4 °C. 
Suvorexant stock solution was prepared at a concentration of 0.1 mg/mL in 
methanol. Working standards were routinely prepared in methanol at concentrations 0.01, 
0.1, 1, and 10 ng/μL. A working standard solution of estazolam-D5 was prepared in 
methanol at 2 ng/μL. 
Instrumentation 
The LC-Q/TOF-MS used was manufactured by Agilent Technologies (Santa Clara, 
CA) and consisted of a 1290 Infinity Binary LC System and a 6530 Accurate-Mass 
Quadrupole Time-of-Flight LC/MS system equipped with electrospray ionization (ESI) 
technology. Gradient elution was performed for the chromatographic separation of the 
compounds using a Poroshell EC-C18 column (2.1×100 mm, 2.7 μm particle size) and a 
Poroshell 120 EC-C18 guard column (2.1×5 mm, 2.7 μm particle size). The column 
temperature was maintained at 35 °C with a flow rate of 0.4 mL/min. The gradient elution 
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profile was 40–80% B (0–3 min), a 1 min hold, a decrease to 40% B (5 min), followed by 
re-equilibration. 
The electrospray (ESI) probe apparatus was operated in positive mode. Ionization 
conditions were fully optimized as follows: 300 °C gas temperature, 13 L/min gas flow, 45 
psi nebulizer pressure, 350 °C sheath gas temperature, and 12 L/min sheath gas flow. The 
mass spectrometer parameters were 3000 V capillary voltage, 2000 V nozzle voltage, and 
150 V fragmentor voltage. The collision energies used were 50 eV for suvorexant and 30 
eV for estazolam-D5. The MS scan rate was 10 spectra/s and the MS/MS scan rate was 5 
spectra/s over a MS scan range of 100–1600 m/z. Using targeted MS/MS data acquisition, 
the two product ion transitions used for suvorexant and estazolam-D5 were m/z 451.1644 
> 186.0664; m/z 451.1644 > 104.0493 and m/z 300.1059 > 272.0875; m/z 300.1059 > 
210.1076, respectively (Figure 2.2). 
 
Figure 2.2. MS/MS spectra of suvorexant (upper) and estazolam-D5 (lower) at the optimum 




Our previously published method for urine was adapted for use with whole blood 
(12). Calibrators and controls were prepared at 0, 2, 5, 10, 50, 100, and 250 ng/mL by 
fortifying 0.5 mL of blood with the appropriate volume of suvorexant working standard in 
10 mL screw-top round bottom glass centrifuge tubes. Internal standard was added to 
achieve a final concentration of 100 ng/mL. Following fortification of the blood, 1 mL 
sodium acetate buffer (pH 3.6, 0.4 M) and 2.5 mL ether/toluene (1:1) were added, 
respectively. The samples were placed on a rotary mixer for 5 min, followed by 
centrifugation at 3000 rpm for 5 min. The organic layer was removed and placed into 
conical glass tubes, which was then evaporated to dryness under nitrogen (50 °C). The 
extracts were then reconstituted with 30 μL of mobile phase A and B (1:1) and 2 μL was 
injected into the LC-Q/TOF-MS. 
Recovery was evaluated using four different extraction solvents as follows: 
ether/toluene (1:1), MTBE, N-butyl chloride, and hexane/ethyl acetate (9:1). In a 10 mL 
round bottom glass centrifuge tube, 0.5 mL of bovine blood was fortified with estazolam-
D5 internal standard to achieve a final concentration of 100 ng/mL. For extracted samples, 
blood was then fortified with 100 ng/mL suvorexant prior to liquid-liquid extraction. To 
each tube 1 mL sodium acetate buffer (pH 3.6, 0.4 M) was added followed by 2.5 mL of 
the appropriate extraction solvent. Samples were placed on the rotary mixer for 5 min then 
centrifuged at 3000 rpm for 5 min. The organic phase was removed and placed into glass 
conical tubes, and non-extracted samples were fortified with suvorexant to reach a final 
concentration of 100 ng/mL. Extracts were evaporated to dryness under nitrogen at 50 °C, 
reconstituted with 30 μL of mobile phase A/B (1:1) and analyzed using LC-Q/ TOF-MS. 
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Samples extracted using methyl tert-butyl ether were not injected due to their visual 
appearance, which was dark in color. Recoveries were calculated by direct comparison of 
the relative peak areas (drug/IS) of extracted and non-extracted samples in quadruplicate. 
Following selection of N-butyl chloride as the extraction solvent, the injection 
volume was optimized (2–10 μL). Using low calibrators (0.5, 1, 2, 5, and 10 ng/mL), peak 
shape, abundance and signal-to-noise (S/N) ratios were evaluated. 
Method Validation 
Assay performance was evaluated in accordance with SWGTOX recommendations 
to include extraction efficiency, limit of detection, limit of quantification, calibration model 
precision, accuracy and bias, carryover, processed sample stability, matrix effects, and 
interferences. 
The limit of detection (LOD) and limit of quantification (LOQ) were determined 
by fortification of three independent sources of blood with suvorexant and internal 
standard. Each of the three blood samples were analyzed in duplicate over three runs at 
each concentration (0.5, 1, 2, 5, and 10 ng/mL). The LOD was determined by selecting the 
lowest concentration to produce a retention time within 2% of the verified standard, ion 
ratios within 20%, and signal-to-noise ratio > 3:1. The LOQ was defined as lowest 
concentration to produce a retention time within 2% of the standard, ion ratios within 20%, 
a signal-to-noise ratio >10:1, and concentration within 20% of the expected concentration. 
Calibration models were evaluated using eight non-zero calibrators in whole blood 
(2, 5, 10, 25, 50, 100, 150, and 200 ng/mL) and 100 ng/mL IS over five days. The 
calibrators were extracted using the previously described method and analyzed using LC-
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Q/TOF-MS. Precision and bias were evaluated at low, medium, and high concentrations 
(5, 50, and 160 ng/mL) in pooled blood in triplicate over five days. 
Carryover was evaluated by injecting drug-free extracts immediately following the 
highest suvorexant calibrator (200 ng/mL) in triplicate. Processed sample stability was 
evaluated using a single positive blood control (100 ng/mL suvorexant and IS). 
Quantitative measurements were made in triplicate following 0, 6, 18, 24, 48, and 60 h of 
storage in the autosampler compartment (4 °C). 
Ion suppression or enhancement was evaluated qualitatively during method 
development using post column infusion. Ten drug-free blood samples from independent 
sources were extracted and injected onto the LC-Q/TOF-MS while suvorexant and internal 
standard were infused directly into the source using a syringe driver (KD Scientific, KDS 
100 Legacy Single Syringe Pump, Hollistion, MA) and T-connector. Matrix effects were 
evaluated quantitatively using the post-extraction addition technique. Ten drug-free 
matrices were extracted in duplicate. Following evaporation, samples were fortified with a 
low and high concentration of suvorexant (20 ng/mL and 100 ng/mL) and internal standard 
(100 ng/mL). Mobile phase was fortified with the same concentrations of suvorexant and 
internal standard. Matrix effects were evaluated by comparing the abundance of drug and 
internal standard in the presence and absence of biological matrix Criteria for acceptability 
were < 25% matrix effect and CV < 15%. 
Interferences from other drugs were determined by fortifying blood samples with 
the fifty-three common drugs listed previously. Drug interferences were evaluated using 
positive and negative controls of suvorexant and IS in the presence of other drugs (potential 
interferents) at a ten-fold and 100-fold higher concentration. 
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Results and Discussion 
Extraction Optimization 
The analytical recovery of suvorexant was evaluated using four different extraction 
solvents (Figure 2.3). Ether/toluene (1:1) had marginally higher recovery (93 ± 12%) but 
required extensive evaporation time due to the high boiling point of toluene. Although 
hexane/ethyl acetate (9:1) produced adequate recovery of suvorexant (82 ± 10%), the 
internal standard abundance was significantly reduced (Figure 2.4) and MTBE was not 
evaluated due to its visual (darkened) appearance. Although N-butyl chloride appeared to 
have slightly lower recovery (77 ± 6%), it showed improved reproducibility (Figure 2.3). 
ANOVA and a two-tailed student t-test were used to evaluate analytical recoveries of N-
butyl chloride and ether/toluene. No significant difference was evident (p=0.12, α=0.05), 
so N-butyl chloride was selected for convenience (faster evaporation) and reduced reagent 
preparation time. Optimum injection volumes were evaluated in terms of absolute peak 
area, peak shape, and signal-to-noise ratio. Although no qualitative differences were 





Figure 2.3. Extraction efficiency of suvorexant from whole blood using ether/toluene (1:1), N-
butyl chloride, and hexane/ethyl acetate (9:1). Data represents the mean ± 1 SD. 
 
 
Figure 2.4. Total Ion Chromatograms (TICs) of the internal standard and suvorexant in blood (100 






The limit of detection (LOD) and limit of quantitation (LOQ) were determined 
empirically by fortification of whole blood with suvorexant over three days. The LOD and 
LOQ were determined to be 0.5 ng/mL. At the LOQ, the mean S/N was 47:1 and accuracy 
was 110%. The mean calculated concentrations, accuracy, precision (%CV) and S/N ratios 
(0.5–10 ng/mL) are summarized in Table 2.1. Examples of chromatographic quality of 
samples at both the LOD and LOQ are depicted with an extracted ion chromatogram in 
Figure 2.5. 












0.5 0.55 ± 0.07 13.3 110% 47:1 
1 0.99 ± 0.10 10.5 99% 74:1 
2 1.92 ± 0.30 15.8 96% 165:1 
5 4.70 ± 0.83 17.6 94% 192:1 




Figure 2.5. Extracted ion chromatograms for the internal standard at 100 ng/mL (upper) and 
suvorexant at the LOQ of 0.5 ng/mL (lower). 
 
Coefficients of determination (R2) were generated for linear, quadratic, weighted 
and non-weighted calibration models. The presence of heteroscedasticity (a change in 
variance across concentration levels) was evaluated using residual plot analysis. 
Systematic bias at high concentrations was observed for linear calibration models, 
regardless of weighting (Figure 2.6). A weighted quadratic model was selected due to 
improved performance at both the low and high end of the calibration. The average R2 




Figure 2.6. Evaluation of calibration models using residual plot analysis. Unweighted (upper) and 
weighted (lower). 
 
Precision and accuracy were assessed by fortification of pooled blood with 
suvorexant at low, medium, and high concentrations (5, 50, and 160 ng/mL) in triplicate 
over five days. Intra-assay precision (n=5) was 10%, 4%, and 5% for low, medium, and 
high concentrations, respectively. Inter-assay precision (n=15) was 13%, 5%, and 8% for 
each concentration, respectively. Accuracy ranged from 95 to 102% for all concentrations. 
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Values fell within the 20% acceptance criteria for intra-assay precision, inter-assay 
precision, and bias (80–120% accuracy) (Table 2.2). 











5 10% 13% 102% 
50 4% 5% 99% 
160 5% 8% 95% 
 
No carryover was observed with the injection of blank matrix following the highest 
suvorexant calibrator (200 ng/mL) (n=3). Processed samples were stable in the autosampler 
compartment for 24 h post-extraction. Accuracy at 0, 6, 18 and 24 h was 94, 95, 84 and 
82% respectively, and precision was 0.1–2.7% (n=3). However, by 48 h quantitative 
accuracy was significantly diminished (66%). 
Ion suppression/enhancement was assessed qualitatively using post-column 
infusion. No qualitative interferences were observed with the injection of ten drug-free 
blood samples and syringe infusion of suvorexant and internal standard (Figure 2.7). In 
addition, matrix effects were determined quantitatively with post-extraction addition using 
a low and high concentration (20 ng/mL and 100 ng/mL). Percent matrix effects were 
calculated at each concentration by comparing analyte peaks of neat standards to matrix 
samples fortified after extraction. The mean matrix effect at 20 ng/mL was 16% with a CV 
of 9% (n=20). At 100 ng/mL the mean matrix effect was 15% with a CV of 8% (n=20).
 
 






Current guidelines require drug interferences to be evaluated qualitatively, not 
quantitatively (13). Drug interferences were evaluated using negative and positive blood 
controls containing suvorexant (0, 10, and 100 ng/mL) and IS (100 ng/mL) in the presence 
of the fifty-three common drugs listed previously (potential interferents) at a tenfold and 
100-fold higher concentration (1000 ng/mL). Interferences were evaluated qualitatively 
and quantitatively. Although no qualitative interferences were observed, a quantitative 
interference was identified. Further investigation revealed that the coelution of sertraline 
with the internal standard was responsible (Figure 2.8). Although the coelution did not 
influence retention time or ion ratios used for qualitative purposes, the decreased ionization 
efficiency in the source (in the presence of excess interferent), resulted in significant bias. 
The hypothesis that this quantitative interference was due to “competition” between the IS 
and sertraline to ionize was further investigated by evaluating the magnitude of the bias 












Sertraline interference was quantitatively evaluated in triplicate with concentrations 
ten-fold lower (1:10), equivalent (1:1), and ten-fold higher (10:1) concentration, relative to 
the internal standard (100 ng/mL). Quantitative concentrations were within the expected 
range when the interferent (sertraline) to IS concentration ratios were 1:10 and 1:1. Bias 
using triplicate measurements were −0.2 ± 11.3% and 8.8 ± 5.6%, respectively. However, 
a significant bias (82.5 ± 11.9%) was observed when sertraline was present at 10-fold 
higher concentration than the IS (Figure 2.9). These results highlight the potential for 
coeluting species to decrease overall ionization efficiency due to capacity-limited source 
ionization. This phenomenon, particularly in fast LC analysis where multiple drugs are 
simultaneously quantified, deserves additional attention. An excess of any coeluting drug 
at a much higher concentration than the target analyte has the potential to produce this 
effect during electrospray ionization. These effects can be somewhat mitigated by avoiding 
fast LC methods with excessively short run times, using minimal specimen, injection 
volume, and selective sample clean-up steps. If commercially available, the use of a 
deuterated suvorexant standard would eliminate this issue. These results highlight the need 
to critically evaluate interferences both qualitatively and quantitatively, particularly if 




Figure 2.9. Potential for systematic bias in electrospray ionization due to coelution. Bias was 
evaluated using sertraline:estazolam-D5 concentration ratios of 1:10, 1:1 and 10:1. Data represents 
the mean ± 1 SD (n=3). 
 
Currently, laboratories are not required to evaluate quantitative interferences (13) 
but this is highly encouraged in LC/MS-based assays. Systematic bias caused by reduced 
ionization efficiency in the electrospray source is not evident from peak shape, ion ratios 
or retention times, all of which may be within acceptable ranges. 
Conclusion 
Sedative hypnotic drugs feature prominently in forensic toxicology investigations, 
but to date there have been no published reports that describe the analysis of suvorexant in 
whole blood using LC-Q/TOF-MS. Forensic toxicology laboratories must have methods 
of analysis available in order to determine its role in human performance and death 


















Sertraline : Estazolam-D5 Concentration
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suvorexant using LC-Q/TOF-MS. A limit of detection of 0.5 ng/mL was achieved using 
only 0.5 mL whole blood. This technique improves upon previously published techniques 
in urine that were capable of detecting suvorexant in urine at 10 ng/mL and 5 ng/mL using 
gas chromatography–mass spectrometry and LC-Q/TOF-MS, respectively. Furthermore, 
this new technique can be readily adapted to existing acidic/neutral liquid-liquid extraction 
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Suvorexant (Belsomra®) is a novel dual orexin receptor antagonist used for the treatment 
of insomnia. The prevalence of suvorexant in forensic samples is relatively unknown, 
which demonstrates the need for robust analytical assays for the detection of this sedative 
hypnotic in forensic toxicology laboratories. In this study, suvorexant was isolated from 
whole blood using a simple acidic/neutral liquid-liquid extraction followed by analysis by 
liquid chromatography tandem mass spectrometry (LC-MS/MS). Matrix effects were 
evaluated qualitatively and quantitatively using various extraction solvents, proprietary 
lipid clean-up devices, and source conditions. The method was validated in terms of limit 
of detection, limit of quantitation, precision, bias, calibration model, carryover, matrix 
effects, and drug interferences. Electrospray is a competitive ionization process whereby 
compounds in the droplet compete for a limited number of charged sites at the surface. As 
such, it is capacity-limited, and LC-MS based techniques must be carefully evaluated to 
ensure that matrix effects or coeluting drugs do not impact quantitative assay performance. 
In this report, we describe efforts to ameliorate such effects in the absence of an isotopically 
labeled internal standard. Matrix effects are highly variable and heavily dependent on the 
physico-chemical properties of the substance. Although there is no universal solution to 
their resolution, conditions at the electrospray interface can mitigate these issues. Using 
this approach, the LC-MS/MS assay was fully validated and limits of detection and 
quantitation of 0.1 and 0.5 ng/mL suvorexant were achieved in blood.   
Keywords:   Suvorexant, Matrix effects, Ion suppression, LC-MS/MS, LC-Q/TOF-MS
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IDENTIFICATION OF SUVOREXANT IN BLOOD USING LC-MS/MS: 
IMPORTANT CONSIDERATIONS FOR MATRIX EFFECTS AND 
QUANTITATIVE INTERFERENCES IN TARGETED ASSAYS 
Introduction  
Suvorexant (MK-4305) is among a novel class of medications called Dual Orexin 
Receptor Antagonists (DORAs) that are used for the treatment of insomnia (1). According 
to the National Institutes of Health, insomnia affects approximately one-third of the 
American population and ten percent of these individuals experience next-day impairment 
associated with insomnia (2).  Suvorexant is marketed under the tradename Belsomra® by 
Merck and Co., Inc. and it is thought to have a lower abuse potential than other traditional 
sedative hypnotics, which could make it a popular option for newly-prescribed insomnia 
patients (3,4). The Food and Drug Administration (FDA) approved suvorexant in August 
2014 and it was placed under Schedule IV of the Controlled Substances Act before 
becoming commercially available in 2015 (3,5). Unlike conventional sedative hypnotics, 
suvorexant has no effect on gamma-aminobutyric acid (GABA) receptors, and instead 
inhibits orexin A and B in the lateral hypothalamus to control the transition from 
wakefulness to sleep (6). Suvorexant has a half-life of approximately 12 hours and peak 
plasma concentrations are typically reached within two hours of administration of a 10-mg 
oral dose, with bioavailability (~82%) decreasing as the dose increases (7,8). The volume 
of distribution (Vd) of suvorexant is 0.5-0.9 L/kg (9). Blood/plasma ratios have not been 
fully investigated and limited literature is available concerning the distribution of 
suvorexant in biological specimens of forensic interest (10). However, due to its relatively 
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long half-life and the prominence of sedative hypnotic medications in driving impairment 
and drug-facilitated sexual assault investigations, suvorexant is a drug of forensic interest. 
Relatively few reports have described the analysis of suvorexant in biological 
samples, therefore little is known of its role in human performance toxicology 
investigations. The physicochemical properties of the drug may pose a challenge in terms 
of detection using traditional screening methods, and few labs routinely target the 
compound. Suvorexant is a neutral drug with a high boiling point (669°C). As a 
consequence, it is a late-eluting compound using common gas chromatography-mass 
spectrometry (GC-MS) stationary phases (11).   Carson et al. published a GC-MS method 
for the detection of suvorexant in urine using a DB-5MS column (30 m x 0.25 mm) with a 
reduced (0.1 µm) film thickness, which resulted in an elution time of 11.7 minutes. The 
more commonly used DB-5 column with a 0.25 µm film thickness resulted in an elution 
time of nearly thirty minutes. This could be problematic in terms of detection in routine 
screening, because the drug may elute after data acquisition has ended.  The GC-MS 
method described above was successfully validated in accordance with published 
guidelines, but in the absence of a commercially-available deuterated suvorexant analog, 
estazolam-D5 was as the internal standard (Figure 3.1) (11,12). Although isotopically 
labeled internal standards are generally preferred, these compounds share the 7-membered 
azepane/azepine ring, a heterocyclic triazole, and a chlorine. Waters et al. also published a 
fast GC-MS screening method for suvorexant that resulted in a retention time of 5.25 
minutes, which was achieved using tandem GC columns. However, the authors also 
analyzed suvorexant standard under commonly used conditions for GC-MS screening and 
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reported a retention time of 23.7 minutes, also acknowledging that the compound could be 
easily missed by traditional GC-MS identification (10). 
 
Figure 3.1. Chemical structures of suvorexant (a) and the internal standard, estazolam-D5 (b). 
 
Liquid chromatography-mass spectrometry (LC-MS) techniques are some of the 
most versatile and increasingly-used analytical methods in forensic toxicology 
laboratories. LC-MS approaches have many advantages over traditional gas 
chromatography-mass spectrometry techniques, including the ability to analyze 
compounds with increased polarity, thermal lability and poor volatility.  LC-MS can also 
allow for the detection of analytes that would otherwise require derivatization using GC-
MS. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is commonly used 
to detect and quantify analytes of interest due to its high selectivity and sensitivity.  
Due to its recent introduction to the market, there have been relatively few 
published reports that describe the analysis of suvorexant in biological samples using LC-
MS-based methods. The drug manufacturer (Merck & Co.) described a method for the 
detection of suvorexant in plasma during a clinical study using LC-MS/MS. An 
isotopically-labeled suvorexant standard (suvorexant-13C2H3) synthesized in-house was 
used for method development (13). Although the method demonstrated sensitivity over a 
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range of 1-1000 ng/mL, only one m/z transition was utilized for identification which is 
insufficient for forensic purposes (14).  
Methods for the detection of suvorexant in plasma were also published by Iqbal et 
al. using LC-MS/MS (15,16). In a related study, they described the use of dispersive liquid-
liquid micro-extraction and LC-MS/MS analysis to identify suvorexant in human and rat 
urine (17). Although the method resulted in an LOD of 0.1 ng/mL and an LOQ of 0.3 
ng/mL, carbamazepine was used as the internal standard (IS) in the latter two reports. Not 
only does carbamazepine not bear any structural similarity to suvorexant, but it is also a 
commonly encountered anticonvulsant, making it a poor candidate for use as an internal 
standard. We previously reported methods to detect suvorexant in urine and blood using 
acidic/neutral liquid-liquid extraction (LLE) and liquid chromatography-quadrupole/time 
of flight-mass spectrometry (LC-Q/TOF-MS) (18,19). Both methods utilized estazolam-
D5 as the internal standard and were fully validated for forensic use.  Limits of detection 
and quantitation in blood were 0.5 ng/mL (19), with a corresponding LOD and LOQ of 0.5 
and 5 ng/mL in urine (18).  
The only other published report for suvorexant in blood used LC-MS/MS. Waters 
et al. identified suvorexant in three case specimens using fast-GC-MS screening and LC-
MS/MS quantitation. The LC-MS/MS method was validated for blood and urine using 
diazepam-D5 as the internal standard. The LOD and LOQ for both blood and urine were 
0.5 ng/mL and 1 ng/mL, respectively. The method was then applied to authentic blood, 
urine and homogenized tissues that had been subjected to protein precipitation followed by 
phospholipid removal using Agilent Captiva ND Lipid cartridges (10).  
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When using LC-MS based techniques, ion suppression and enhancement are 
important considerations, particularly when analyzing complex matrices (20). These can 
be assessed qualitatively using post-column infusion techniques, or quantitatively using 
post-extraction addition. Both approaches have merit. Post-extraction addition is a static 
technique that allows the matrix effect (ME) to be numerically estimated at the retention 
time of the analyte. In contrast, post-column infusion is a dynamic technique because it 
identifies chromatographic regions where an analyte could be susceptible to ME. Ideally, 
ion suppression or enhancement should not exceed 25% and should be reproducible 
between matrices (CV <15%) (12). Although both ion suppression and enhancement can 
occur, ion suppression is more common than enhancement, and electrospray ionization 
(ESI) is more susceptible to matrix effects than atmospheric pressure chemical ionization 
(APCI) (21,22). Of the published LC-MS methods for suvorexant, only the method 
developed by Merck used APCI (13). Although tandem (QQQ) and high resolution mass 
spectrometry (HRMS) techniques are considered to be highly selective, mass filtering 
occurs after separation has been achieved. Sources of ion suppression may include co-
eluting compounds, metabolites, degradation products, endogenous compounds within the 
matrix itself, and exogenous compounds introduced during sample preparation (21,22). 
Matrix effects are also heavily dependent on the biological sample (i.e. urine, blood, 
plasma) and preparation techniques (extraction type). During quantitative analysis, matrix 
effects can lead to both positive and negative bias, depending on whether they coelute with 
the analyte or the internal standard. Removal of every potential matrix interferent is no 
more feasible than absolute chromatographic resolution of every possible compound. This 
demonstrates the importance of using stable isotope labeled internal standards (SIL-IS) 
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when available (20,22). These demonstrate near identical behavior to the analyte during 
sample preparation, separation and ionization, which can compensate for matrix effects 
(21). Standard addition techniques can also compensate for ion suppression. However, this 
method requires a much larger quantity of specimen due to multiple sampling, making it 
an unpopular choice for routine forensic analyses where specimen quantity may be limited.  
Particularly for new or novel substances, a SIL-IS may not be commercially 
available. This further highlights the need to critically evaluate ion suppression and 
enhancement both qualitatively and quantitatively during method development. Any 
substance that coelutes with the compound of interest will compete with the analyte during 
ionization in the source.  This can effectively decrease ionization for an analyte, 
particularly if there is a large excess of coeluting substance. The potential for reduced 
ionization efficiency due to matrix effects and other co-eluting drugs of interest may not 
be evident if interferences are evaluated only qualitatively.  Although published standards 
only require interferences from other drugs to be evaluated qualitatively (12), the practice 
in our laboratory has been to evaluate quantitatively, as well as qualitatively. A large excess 
of a coeluting drug can suppress ionization in much the same way as matrix components. 
However, the decreased overall efficiency will not impact retention time or cause ion ratios 
to be out of range. As a consequence, ion suppression of the analyte in an “unknown” 
sample will not be discernable during analysis, potentially contributing to a negative bias 
in the quantitative result. Conversely, if the internal standard is suppressed, a positive bias 
during quantitative analysis is possible. Although careful monitoring of the absolute 
internal standard intensity between samples (calibrator, controls, samples) can help identify 
the latter, no such resolution is possible for compounds that coelute with the analyte in 
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unknown case specimens. In a previously validated method to identify suvorexant in blood 
using LC-Q/TOF-MS, no matrix effects were identified. However, a significant bias from 
sertraline (which coeluted with the internal standard) was identified quantitatively, but not 
qualitatively (19). In this report, we discus differences in assay performance in terms of 
ion suppression caused by matrix and other drugs, using both LC-Q/TOF-MS and LC-
MS/MS. 
Methods 
Chemicals and Reagents 
Suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-
yl][5-methyl-2-(2H-1,2,3,-triazol-2-yl)phenyl]methanone) was purchased from Cayman 
Chemical as a powder (Ann Arbor, MI). Estazolam-D5 internal standard (100 µg/mL) was 
purchased as a methanolic standard from Cerilliant Corp. (Round Rock, TX). Fifty-two 
common drugs were received as methanolic standards (1 mg/mL) from Cerilliant Corp. 
(Round Rock, TX), which included benzodiazepines, barbiturates, and sedative hypnotic 











Table 3.1. Common drugs evaluated in the interference study.  
Common Drugs  Z-Drugs 
11-nor-9-carboxy-delta-9-THC methaqualone  zaleplon 
acetaminophen morphine  zolpidem 
amitriptyline oxycodone  zopiclone 
amphetamine oxymorphone   
bupropion phencyclidine  Barbiturates 
caffeine phenytoin  amobarbital 
carbamazepine propoxyphene  butalbital 
carisoprodol pseudoephedrine  pentobarbital 
cocaine salicylic acid  phenobarbital 
codeine sertraline  secobarbital 
cyclobenzaprine THC   
dextromethorphan tramadol  Benzodiazepines 
fluoxetine trazodone  7-aminoclonazepam 
gabapentin valproic acid  7-aminoflunitrazepam 
hydrocodone   alprazolam 
hydromorphone   clonazepam 
ketamine   diazepam 
MDMA   flurazepam 
meperidine   nordiazepam 
meprobamate   oxazepam 
methadone   temazepam 
MDMA, methylenedioxymethamphetamine; THC, tetrahydrocannabinol. 
Acetic acid (glacial), toluene (ACS grade) and sodium acetate (ACS grade) were 
obtained from Mallinckrodt Chemicals (St. Louis, MO). LC/MS grade methanol, LC/MS 
grade acetonitrile and ACS grade diethyl ether were obtained from J.T. Baker (Center 
Valley, MA). N-butyl chloride (99+%, pure), hexane (OptimaR), and ethyl acetate (HPLC 
grade) were purchased from Fisher Scientific (Pittsburgh, PA). Formic acid (>95%) was 
obtained from Sigma-Aldrich (St. Louis, MO). An in-house Millipore Direct-Q ® UV 
Water Purification System (Billerica, MA) was used for the purification of deionized water.  
Drug-free bovine blood containing 1% (w/v) sodium fluoride and 0.2% (w/v) 
potassium oxalate was purchased from Quad Five (Ryegate, MT). Sodium acetate buffer 
(0.4 M) at pH 3.6 was prepared for routine use in liquid-liquid extractions. Mobile phase 
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A consisted of 0.1% formic acid in deionized water and mobile phase B consisted of 0.1% 
formic acid in acetonitrile. Suvorexant stock solution was prepared at a concentration of 
0.1 mg/mL in methanol. Working standards of suvorexant and estazolam-D5 were 
routinely prepared in methanol at a concentration of 1 µg/mL and 2 µg/mL, respectively. 
LC Separation 
LC conditions were identical for both LC-Q/TOF-MS and LC-MS/MS assays. A 
Poroshell EC-C18 column (2.1 x 100 mm, 2.7 µm particle size) and matching Poroshell 
120 EC-C18 guard column (2.1 x 5 mm, 2.7 µm particle size) were maintained at 35°C. A 
flow rate of 0.4 mL/min was used with the following gradient elution profile: 40% B (0); 
40-80% B (0-3 mins); hold 80% B (3-4 min); 80-40% B (4-5 mins). A post-equilibration 
time of 2 minutes was utilized before injection of the next sample, with a 6-second needle 
wash in between injections to prevent carryover. 
Q/TOF-MS Analysis 
LC-Q/TOF-MS analysis was performed using an Agilent Technologies 1290 
Infinity Binary LC System coupled to a 6530 Accurate-Mass Quadrupole Time-of-Flight 
LC/MS system (Santa Clara, CA). Positive electrospray ionization (ESI) mode was used 
with the following manually optimized ionization conditions: 300°C gas temperature, 13 
L/min gas flow, 45 psi (310 kPa) nebulizer pressure, 350°C sheath gas temperature, and 12 
L/min sheath gas flow. The mass spectrometer was operated with a capillary voltage of 
3000 V, nozzle voltage of 2000 V, and fragmentor voltage of 150 V. A collision energy of 
50 eV was used for suvorexant with targeted MS/MS data acquisition. Two product ion 
transitions were used (m/z 451.1644 > 186.0664 and m/z 451.1633 > 104.0493). 
Quantitation ions are underlined. A collision energy of 30 eV for estazolam-D5 was used 
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with two ion transitions (m/z 300.1059 > 272.0875 and m/z 300.1059 > 210.1076) in 
targeted MS/MS mode. The MS scan rate was 5 spectra/second (100-1600 amu), isolation 
widths were 1.3 amu, mass tolerance was ± 5 ppm, and acquisition time was 200 (ms/spec) 
(19). Whole blood extracts were routinely reconstituted in a 1:1 mixture of mobile phase 
A/B (30 µL) and 2 µL was injected onto the LC-Q/TOF-MS for analysis. 
MS/MS Analysis 
LC-MS/MS analysis was performed using an Agilent 1290 Infinity Liquid 
Chromatograph System coupled to an Agilent 6470 Triple Quadrupole Mass Spectrometer 
(Santa Clara, CA). Positive ESI mode was used and initial ionization conditions were 
optimized using Agilent MassHunter Source Optimizer software as follows: 300°C gas 
temperature, 8 L/min gas flow, 20 psi (138 kPa) nebulizer pressure, 400°C sheath gas 
temperature, 10 L/min sheath gas flow, nozzle voltage of 0 V and a capillary voltage of 
4000 V. For suvorexant and estazolam-D5, fragmentor voltages of 127 V and 140 V were 
used, respectively. Data was acquired in dynamic multiple reaction monitoring (dMRM) 
mode with two transitions for each species. The transitions monitored for suvorexant were 
m/z 451.2 > 186.0 (21 eV) and m/z 451.2 > 104.0 (73 eV). The transitions for estazolam-
D5 were m/z 300.0> 272.1 at (24 eV) and m/z 300.0 > 210.1 at (48 eV). Dwell times for 
all transitions were 200 ms. Following observation of ion suppression using the software-
optimized source conditions, the source conditions from the LC-Q/TOF-MS assay 
(described above) were evaluated on the LC-MS/MS. Whole blood extracts were routinely 
reconstituted in a 1:1 mixture of mobile phase A/B (30 µL) and 2 µL was injected onto the 




An Agilent 7890A Gas Chromatograph equipped with a 5975C Mass Selective 
Detector was used to identify suvorexant and potential matrix interferences that were 
observed during initial method development. Suvorexant was determined using the 
previously validated procedure (11). Chromatographic separation was achieved using a 
DB-5MS column (30 m x 0.25 mm) with a 0.1 µm film thickness. The inlet temperature 
was 280°C and the temperature gradient was as follows: 260°C for 0.1 min, ramp to 290°C 
at 30°C/min followed by 16 min hold (17.1 min total run time). A 10:1 split ratio was 
employed with a 2 µL sample injection volume. Six pre-injection and six post-injection 
methanol washes were performed between each sample injection. Electron impact (EI) 
ionization of 70 eV was used, and data was acquired using selected ion monitoring (SIM) 
acquisition following a 2.4 min solvent delay. Dwell times for estazolam-D5 (m/z 210.1, 
264.1 and 299.1) and suvorexant (m/z 104.1, 186.1, and 450.2) were 50 ms and 75 ms, 
respectively.   
Endogenous phospholipid screening was also performed using a generic full scan 
GC-MS method (40-550 Da) using a DB-5MS column (30 m x 0.25 mm) with a 0.1 µm 
film thickness. The inlet temperature was 250°C with the following temperature gradient: 
160°C for 5 min with a ramp to 290°C at 30°C/min (for 9.167 min) for 18.5 min total run 
time. A 10:1 split ratio was employed with a 2 µL sample injection volume and twelve pre- 
and post- injection methanol washes. 
Extraction 
Suvorexant was isolated from whole blood using liquid-liquid extraction (LLE) as 
described earlier (19). Briefly, whole blood (0.5 mL) was fortified with IS to achieve a 
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final concentration of 100 ng/mL.  Following the addition of 1 mL sodium acetate buffer 
(0.4 M pH 3.6) and N-butyl chloride (2.5 mL), samples were mixed on a rotary mixer (5 
mins) and centrifuged (3000 rpm/ 1734 x g, 5 mins). Following removal of the supernatant, 
organic extracts were evaporated to dryness under nitrogen at 50°C and reconstituted in 30 
µL methanol (for GC-MS) or 30 µL 1:1 mobile phase A/B (for LC-Q/TOF-MS and LC-
MS/MS).  
Unlike the previously validated LC-Q/TOF-MS method, significant ion 
suppression was observed using the LC-MS/MS assay.  Due to the methods being identical 
(with the exception of source conditions and data acquisition) endogenous interferences 
were further explored. Initially, alternative extraction solvents were evaluated. Direct 
comparisons were made between N-butyl chloride, ether/toluene (1:1) and hexane/ethyl 
acetate (9:1) extraction solvents. Analyte recovery and endogenous matrix interferences 
were investigated. Additional phospholipid removal was assessed using three proprietary 
clean-up cartridges (1 mL) as follows: Agilent Captiva EMR- Lipid (Santa Clara, CA), 
Phenomenex Phree™ Phospholipid Removal Solutions (Torrance, CA), and Supelco 
Analytical HybridSPE™-Precipitation Technology (Sigma-Aldrich, St. Louis, MO).  
Lipid removal was performed in accordance with the manufacturers’ 
recommendations, using acetonitrile containing 1% formic acid as the precipitation agent. 
Since whole blood was used, samples were prepared for cartridge filtration by first 
performing offline protein precipitation. To 0.5 mL of blood, 1 mL cold acetonitrile (with 
and without 1% formic acid) was added with vortex mixing (n=2). Cold acetonitrile was 
used to enhance protein precipitation, and the performance of the extraction was evaluated 
with and without the addition of 1% formic acid. The samples were centrifuged at 3500 
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rpm (2360 x g) for 5 minutes and the supernatant (~1 mL) was decanted into commercial 
lipid removal cartridges. Samples were eluted under vacuum and the eluent was collected 
into glass conical tubes. Acetonitrile was evaporated under nitrogen (60°C) until near 
dryness and 1 mL of sodium acetate buffer (0.4 M, pH 3.6) was added, followed by LLE 
as described above. 
Evaluation of Matrix Effects 
Both post-column infusion and post-extraction addition are routinely used in our 
laboratory to investigate matrix effects during method development and validation.  Elution 
of endogenous interferences during the chromatographic run was evaluated using ten drug-
free blood extracts from independent sources. Suvorexant and internal standard were 
infused into the MS using a T-connector and a KDS 100 Legacy Single Syringe Pump (KD 
Scientific, Holliston, MA). Matrix effects were then evaluated quantitatively using post-
extraction addition in which ten drug-free matrices were extracted in duplicate and fortified 
with low and high concentrations (20 and 100 ng/mL) of suvorexant and IS. Neat standards 
were prepared concurrently by fortifying mobile phase with equivalent amounts of drug. 
Matrix effects were determined by direct comparison of the ion abundance in the presence 
and absence of matrix. Average matrix effects should not exceed ±25% and the CV of the 
suppression or enhancement should not exceed 15%. Although no quantitative 
interferences were identified for the LC-Q/TOF-MS method, ion suppression exceeding 
25% was identified at both concentrations using the initial LC-MS/MS assay. Source 
optimization for this assay was performed using MassHunter Source Optimizer software 
based on analytical response (intensity). Notably, these conditions differed slightly from 
the manually-optimized LC-Q/TOF-MS conditions developed previously.   
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In an effort to mitigate matrix effects, three extraction solvents and commercial 
lipid removal cartridges were evaluated as described above. Qualitative and quantitative 
matrix effects were directly compared using LC-MS/MS and LC-Q/TOF-MS assays, with 
and without additional lipid removal. Finally, the validated LC-Q/TOF-MS source 
parameters were applied to the LC-MS/MS method. Utilizing both sets of source 
conditions, matrix effects were directly compared using post-column infusion and post-
extraction addition techniques. 
Validation of LC-MS/MS and LC-Q/TOF-MS Assays 
The LC-MS/MS method was validated in accordance with published 
recommendations (12) and performance was compared to the previously validated LC-
Q/TOF-MS method (19). Parameters that were assessed included limit of detection, limit 
of quantification, precision, bias, calibration model, carryover, matrix effects and 
interferences.  
The limit of detection (LOD) and limit of quantitation (LOQ) were determined 
empirically by fortifying three independent sources of blood with suvorexant (0.1, 0.25, 
0.5, 1, 2, 5, 10 ng/mL) and internal standard (100 ng/mL) in duplicate over three days. The 
LOD was defined as the lowest concentration of drug that produced a signal-to-noise (S/N) 
ratio greater than 3:1, ion ratios within 20% of the expected value, and a retention time 
within 2% of the known standard. The LOQ was defined as the lowest concentration of 
suvorexant to produce a S/N ratio greater than 10:1, ion ratios within 20% of the expected 
value, a retention time within 2% of the verified standard, and bias within 20%.  
Precision and bias were evaluated using fortified pooled blood samples at identical 
concentrations as the previously validated LC-Q/TOF-MS method (5, 50, and 160 ng/mL 
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suvorexant and 100 ng/mL IS) in triplicate over five days. The precision and bias for each 
instrument were compared to evaluate performance of the assay at each concentration.  
Calibration model was assessed using eight fortified whole blood calibrators (2, 5, 
10, 25, 50, 100, 150, and 200 ng/mL suvorexant) over five days. Linear and quadratic 
models (with and without weighting) were evaluated using residual plot analysis and 
coefficients of determination. Carryover was studied by analyzing a drug-free extract 
immediately following the injection of the highest calibrator. The assay was determined to 
be carryover-free if no drug was detected (i.e. did not meet reporting criteria) when 
performed in triplicate.  
Interferences from other commonly encountered drugs were analyzed by 
fortification of blood with more than 50 common drugs (Table 3.1). Positive and negative 
controls were evaluated using a 100-fold excess of interferent to analyte (i.e. 10 ng/mL 
suvorexant; 1000 ng/mL other drug). Interferences were assessed qualitatively (i.e. peak 
shape, retention time, chromatographic quality) and quantitatively (% bias). Upon isolation 
of potential drug interferences, controls were again analyzed using concentration ratios of 
1:10, 1:1, and 10:1 interferent:analyte to determine the magnitude of quantitative biases 
resulting from any drug interference. 
Results 
Matrix Effects Using LC-Q/TOF-MS and LC-MS/MS 
Matrix effects were evaluated qualitatively and quantitatively using the same drug-
free matrices (n=10), all of which were obtained from independent sources of bovine blood. 
Table 3.2 highlights the differences observed.  Although matrix effects were well within 
acceptable criteria using the LC-Q/TOF-MS assay, the LC-MS/MS method exceeded 
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acceptability criteria at both low and high concentrations (20 and 100 ng/mL) for 
suvorexant (Table 3.2). Performance criteria were exceeded in terms of the magnitude of 
the suppression (>25%), and the variability between matrices (CV>15%). The LC-Q/TOF-
MS assay performance was superior in this respect.  
Table 3.2. Comparison of matrix effects using LC-MS/MS and LC-Q/TOF Assays. Parameters 
outside of acceptable limits are shown in bold. 
 
Assessment of matrix effects using post-column infusion further illustrates the issue 
in the LC-MS/MS assay. Figure 3.2 depicts the change in absolute signal for both 
suvorexant and the internal standard during the five minute chromatographic run. No 
suppression or enhancement was observed for estazolam-D5 (1.4 min), but ion intensities 
for suvorexant (3.1 min) were clearly influenced by matrix components. Changes in signal 
intensity are expected when small, polar molecules (that are poorly retained) elute from the 
column. However, the suppression observed in the latter part of the chromatogram may be 
attributed to nonpolar or lipophilic compounds (e.g. phospholipids, cholesterol, fatty acids, 
fatty acid esters). 
 Average Matrix Effect (%CV, n=10) 
 LC-Q/TOF-MS LC-MS/MS (Initial) LC-MS/MS (Final) 
 Suvorexant IS Suvorexant IS Suvorexant IS 
Low (20 ng/mL) 16 (9%) 19 (7%) -35 (23 %) 12 (5 %) -8 (15%) -5 (13%) 





Figure 3.2. Initial LC-MS/MS matrix effects using post-column infusion (100 ng/mL). Overlaid extracted ion chromatograms for suvorexant and 






This was further investigated using the previously validated GC-MS assay in 
combination with full-scan data acquisition (11). The persistence of cholesterol, fatty acids 
and fatty acid esters in the optimized LLE using N-butyl chloride is shown in Figure 3.3. 
These endogenous co-extractive species were identified only tentatively using MS library 
searching (NIST MS library).  
Three solvent systems (N-butyl chloride, ether/toluene (1:1) and hexane/ethyl 
acetate (9:1)) were evaluated during the original LLE method development using LC-
Q/TOF-MS. No significant differences were observed in terms of the analytical recovery 
of suvorexant between the solvents (19). These were re-evaluated using the LC-MS/MS 
assay from the standpoint of matrix effect. No qualitative or quantitative differences were 
observed between the solvents, and the same lipids persisted. Various commercial lipid 
clean-up devices were then investigated in an attempt to mitigate suppression. The devices 
were used as a pre-extraction clean-up technique by first performing protein precipitation 
on the fortified whole blood and subjecting the resulting supernatant to treatment in 
accordance with the manufacturers’ recommendations. The presence of formic acid in the 
acetonitrile precipitation solvent resulted in negligible differences in extraction efficiency 
following the lipid clean-up, therefore cold acetonitrile without formic acid was used as 
the optimal protein precipitation reagent. The GC-MS screening method described above 
was used to evaluate the effectiveness of the lipid removal devices.  Although several of 
the fatty acids and fatty acid esters remained, cholesterol was completely eliminated using 
the Agilent Captiva-EMR and Phenomenex Phree™ devices. Cholesterol still remained 
following the Supelco Phospholipid-Ultra cartridges (Figure 3.4).  Due to the higher oven 
temperature used in the validated suvorexant assay, only cholesterol was present in the 
121 
 
targeted SIM method. However, its presence was not problematic because it was clearly 
resolved from suvorexant and the internal standard. Figure 3.5 depicts the total ion 
chromatogram using the targeted SIM method following LLE, with and without additional 
phospholipid removal. Many of the proprietary lipid removal devices trap lipids based upon 
a combination of size exclusion and hydrophobic interactions. The latter may explain the 























Figure 3.5. Total ion chromatogram following LLE, with and without additional phospholipid 
removal using the targeted GC-MS assay. 
 
 Based on their earlier performance, Agilent Captiva EMR-Lipid cartridges were 
further investigated. Mitigation of ion suppression was evaluated using post-column 
infusion. The same ten drug-free matrices with and without pre-extraction clean-up prior 
to LLE were injected while suvorexant and estazolam-D5 were constantly infused to the 
source. These samples were also analyzed by LC-Q/TOF-MS in parallel to determine if the 
additional lipid removal had any effect on the previously published results. The absence of 
matrix effects was confirmed using the LC-Q/TOF-MS assay (Figure 3.6 A).  No 
suppression was present in LLE extracts and pre-extraction lipid removal was not 
necessary. In contrast however, significant suppression was present in the LC-MS/MS 
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assay and the pre-extraction lipid removal prior to LLE did not significantly improve 
matrix effects (Figure 3.6 B).   
Although identical LC separation profiles were used, and both instruments were 
operated using positive ESI, the LC-Q/TOF-MS source parameters were manually 
optimized during method development.  In contrast, the LC-MS/MS source parameters 
were optimized using Agilent MassHunter Source Optimization software in which the gas 
flows, voltages, and temperatures were selected to maximize the absolute response of the 
analyte. Unexpectedly, this resulted in unacceptable matrix effects using the LC-MS/MS 
assay.  
Since the observed ion suppression was not resolved with solvent selection or 
additional pre-extraction phospholipid removal, source conditions were re-evaluated. 
When the source conditions for the published LC-Q/TOF-MS method were employed 
using the LC-MS/MS method, matrix effects were completely eliminated (Figure 3.6 C). 
Using this approach, the lipid removal step was not necessary. Modification of the source 
conditions reduced matrix effects for suvorexant to -8% and -9%, from -35% and -26% for 
low and high concentrations, respectively (Table 3.2). Although the signal intensity for 
suvorexant was slightly reduced, matrix interferences were completely mitigated. The 
manually optimized source parameters (Table 3.3) were used for the final validation of the 










Figure 3.6. Comparison of LC-Q/TOF-MS and LC-MS/MS matrix effects using post-column 
infusion, with and without lipid removal.  
127 
 
Table 3.3. Initial and finalized source conditions used for the LC-MS/MS method validation. 
Parameter Initial Final 
Gas Temperature (°C) 300 300 
Gas Flow (L/min) 8 13 
Nebulizer (psi) 20 45 
Sheath Gas Temp (°C) 400 350 
Sheath Gas Flow (L/min) 10 12 
Capillary (V) 4000 3000 
Nozzle (V) 0 2000 
 
Interferences from Other Drugs 
Potential interferences from other drugs were investigated using the fifty-two 
common drugs listed previously (Table 3.1). Positive controls (10 ng/mL suvorexant, 100 
ng/mL IS) and negative controls with internal standard only (100 ng/mL) were prepared 
with the addition of potential interferents at 100-fold excess concentrations (1000 ng/mL). 
No qualitative interferences were present for either suvorexant or the IS. Retention times, 
peak areas, chromatographic quality and ion ratios were all within acceptable limits. 
However, a quantitative interference was detected, which produced a % bias of more than 
±20% for the 10 ng/mL suvorexant control. Extracts were evaluated using the MS2 scan 
mode in order to identify which coeluting drug was responsible for the interference. These 
were attributed to sertraline (RT 1.4 min) and propoxyphene (RT 1.3 min). Although 
coelution of these drugs with the IS (1.4 min) did not impact the quality of the MRM 
transitions or chromatographic peak, they were responsible for a significant positive 
quantitative bias, likely due to the reduced ionization efficiency of the internal standard. 
This quantitative interference was explored further using positive drug controls (100 ng/mL 
suvorexant and IS) in the presence of ten-fold lower, equivalent, and ten-fold higher 
concentrations of propoxyphene and sertraline in triplicate.  
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The magnitude of the quantitative interference at a 1:10, 1:1 and 10:1 ratio of 
interferent to internal standard is shown in Figure 3.7.  Unacceptable positive bias (24% 
and 22%) was observed for sertraline at equivalent and ten-fold higher concentrations, 
relative to the IS. Quantitative bias due to propoxyphene was even more pronounced, 
exceeding acceptable thresholds under all conditions tested (32 to 95%). Notably, the 
magnitude of the positive bias increased with increasing concentration of the interferent. 
This can be attributed to the reduced ionization efficiency of the IS due to the presence of 
the coeluting species, the competition for charge within the droplet, and the capacity-
limited ionization within the ESI source itself. 
 
Figure 3.7. Systematic bias caused by coelution drugs. Bias was evaluated using interferent: 
internal standard (IS) concentration ratios of 1:10, 1:1 and 10:1 for sertraline and propoxyphene 
(n=3). 
Overall Assay Performance 
Validation parameters for the LC-Q/TOF-MS assay were previously described 






















0.5 ng/mL, respectively. Extracted ion chromatograms for suvorexant at the LOD are 
depicted in Figure 3.8.  Precision and bias at the LOQ were 8.2% (n=18) and -7%. The 
calibration model was selected using various weighting options, residual plot analysis, and 
coefficients of determination. Although the LOQ was 0.5 ng/mL, a calibration range of 2 
– 200 ng/mL was selected for routine analysis using a weighted (1/X) quadratic model. 
Coefficients of determination (R2) ranged from 0.991-0.999 with an average R2 value of 
0.997 over five days. Intra- and inter-assay precision ranged from 4-7% (n=5) and 7-9% 
(n=15), respectively, using one-way ANOVA (Table 3.4). No carryover was observed.  
 
Figure 3.8. Representative extracted ion chromatograms of IS (100 ng/mL) and suvorexant in a 
blood extract at the limit of detection (0.1 ng/mL). 
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Differences in LC-MS/MS and LC-Q/TOF-MS assay performance are summarized 
in Table 3.5. Although the LC-MS/MS method had increased sensitivity with a LOD of 
0.1 ng/mL, LOQs using both methods were 0.5 ng/mL in whole blood. No appreciable 
differences were observed in terms of precision and bias, and following adjustment of the 
source conditions, matrix effects using the LC-MS/MS were completely mitigated. The 
side-by-side comparison of assay performance using both instruments confirms the 
experience in our laboratory, that quantitative targeted assays using LC-Q/TOF-MS are 
indeed comparable to LC-MS/MS. 
Table 3.5. Summary of assay performance for the LC-MS/MS method and the previously validated 
LC-Q/TOF-MS method (19). 
Validation Parameter LC-Q/TOF-MS LC-MS/MS 
LOD 0.5 ng/mL 0.1 ng/mL 
LOQ 0.5 ng/mL 0.5 ng/mL 










Bias -5-2% -2-2% 
Matrix Effects Low (20 ng/mL) 





Carryover None None 
 
Discussion 
During the validation of a quantitative assay for suvorexant in blood, significant 
differences in matrix effects were observed between LC-MS/MS and LC-Q/TOF-MS 
assays.  Notably, software optimized source conditions that maximize absolute signal 
intensity for precursor and product ions did not produce optimum overall assay 
performance. Matrix effects have been described as the “Achilles heel” of quantitative LC-
MS based assays (23). Despite the fact that LC-MS/MS is often considered to be the 
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preferred technique for quantitative analyses in biological matrices, important 
considerations and limitations exist. LC-MS based techniques are often preferred for 
bioanalysis due to their sensitivity and selectivity. However, the impact of matrix effects 
on accuracy, precision and robustness of bioanalytical methods is an area of concern in 
quantitative analyses (23-25).  
Matrix effects are observed when a coeluting species affects the ionization 
efficiency of the analyte. Kebarle and Tang were the first to describe matrix effects using 
electrospray ionization in 1993 (26). Although the exact mechanism is unknown, it is 
believed to originate from the competition between the analyte and the coeluting substance 
at the electrospray interface. Although these effects may not be evident from 
chromatographic responses, they can have a deleterious effect on both accuracy and 
sensitivity in quantitative analyses (23). Post-column infusion and post-extraction addition 
techniques can be used to visualize matrix effects and quantify their influence, respectively. 
Amelioration of these effects may involve changes to the sample extraction methodology, 
additional sample preparation steps, re-optimization of chromatographic separation, 
alteration of mobile phase additives, or use of a coeluting or stable isotope labeled internal 
standard. At the time of this study, a deuterated internal standard for suvorexant was not 
commercially available. Although standard addition techniques can also compensate for 
matrix effects, they are not widely used for forensic toxicology purposes due to multiple 
sampling and increased sample volumes.  
At the electrospray interface a fine spray of highly charged droplets produce single 
or multiply charged species from an aqueous/organic liquid mixture. In the presence of 
heat and a strong electric field, gas phase ions are produced.  Changes in ionization 
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efficiency related to matrix effects can occur in either the liquid phase or the gas phase: In 
the liquid phase, saturation of the ESI droplets with analyte at their surface can inhibit the 
ejection of ions trapped inside the droplet. Physico-chemical properties including surface 
activity and polarity influence the competition for limited charge or space within the 
droplet. Biological matrices with endogenous compounds with high basicity and surface 
activity can quickly saturate ionization, resulting in suppression. High concentrations of 
analyte can also increase viscosity and surface tension of the droplet, changing efficiency 
of their formation, evaporation, and the number of gas phase ions that reach the detector. 
Various gas phase mechanisms have also been proposed. Once in the gas phase, charge can 
be lost through neutralization reactions or charge transfer. In addition, ESI can be 
influenced by the type of instrumentation and ion suppression can vary significantly 
between different source geometries (i.e. Z-spray ion source, orthogonal spray ion source). 
Therefore, source design must be considered as variations in capillary diameter, distance 
from capillary tip to counter electrode, electrolyte formation, and the resulting droplet 
radius can greatly impact ion suppression between different instruments that employ ESI 
(27). APCI is less susceptible to ME than ESI techniques. During ESI, ionization takes 
place in the liquid phase and the ion is transferred to the gas phase in a charged state. 
During APCI the molecule is transferred to the gas phase in the neutral state and is 
subsequently ionized. As a result, APCI is not susceptible to any of the mechanisms that 
can influence liquid phase ionization suppression. Although enhancement of ionization is 
also possible, it is described with less frequency.  
Decreases in ionization efficiency can be caused by endogenous or exogenous 
suppressors. Endogenous suppressors can include salts, surfactants, carbohydrates, lipids, 
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polar organic molecules, and other co-extractive compounds found in biological matrices 
(25).  Exogenous suppressors are interfering substances that come from a source other than 
the biological matrix. They can include artifacts from sample preparation or 
chromatography, including plasticizers, phthalates, organic acids, buffers, other 
compounds or coeluting drugs. Residual matrix components and phospholipids in 
particular can be a significant source of bias and imprecision in quantitative analysis (24). 
This is highly relevant in forensic toxicology, particularly during multi-analyte or 
systematic toxicological analyses using complex biological matrices (28). Rapid LC-based 
methods where multiple drugs are simultaneously quantified without a coeluting or SIL-IS 
are most vulnerable, due to the capacity-limited nature of electrospray ionization.   
At the time of development there was no commercially available deuterated analog 
for suvorexant which could have mitigated the ion suppression caused by matrix 
components and coeluting drugs. The study highlights the need to critically evaluate the 
potential for quantitative bias during drug interference studies, particularly if a SIL-IS is 
not available. The study also demonstrates that although additional sample preparation and 
chromatographic changes can be undertaken, these can be labor intensive and meet with 
limited success. In this study, unacceptable endogenous matrix effects were completely 
eliminated by modification of the source conditions. Source optimization is highly 
compound dependent, as well as instrument dependent. Differences in sheath gas 
temperature, flow, nebulizer pressure, and capillary and nozzle voltage can greatly 
influence ionization. This compound dependence can be exploited for the purpose of 
endogenous matrix interferences. Although this amounts to a detuning of the source, the 
assay may be more robust as a result (29,30). While this approach slightly decreased overall 
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intensity of the instrument response, the assay still demonstrated excellent limits of 
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MOLECULAR LIPOPHILICITY OF SUVOREXANT USING EXPERIMENTAL 






















Suvorexant is a dual orexin receptor antagonist (DORA) that promotes sleep by 
reducing wakefulness and arousal. Relatively few published analytical methods describe 
the analysis of suvorexant in forensic casework. Information regarding its distribution or 
occurrence in specimens of forensic interest is lacking, and some of the physicochemical 
properties of the drug have not been fully investigated. The aim of this study was to 
investigate the molecular lipophilicity of suvorexant, identify the drug in a series of thirteen 
toxicological investigations, and discuss its potential for postmortem redistribution. 
Partition coefficients of suvorexant were determined using octanol/water and other 
aqueous systems using liquid chromatography-quadrupole/time of flight-mass 
spectrometry (LC-Q/TOF-MS). Experimentally determined Log P values were compared 
with those obtained using predictive computational software. Suvorexant was 
quantitatively determined in a series of thirteen forensic toxicology investigations. 
Toxicological specimens included antemortem and postmortem blood, plasma/serum and 
vitreous fluid. The experimentally determined Log P value for suvorexant was in close 
agreement with theoretical Log P values. Suvorexant was identified in antemortem and 
postmortem blood at concentrations of 3-42 ng/mL. Paired central (C) and peripheral (P) 
blood was obtained in two cases, yielding C/P ratios of 2.0 and 2.2, consistent with 
previously published reports (0.9-1.4). Furthermore, all concentrations were within the 
therapeutic or sub-therapeutic range. Despite its lipophilic nature, this neutral and heavily 
protein bound drug may not exhibit significant postmortem redistribution. Other drugs 
were present in all of the cases reported, most frequently with opioids (85%) and 
benzodiazepines (54%).  
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MOLECULAR LIPOPHILICITY OF SUVOREXANT USING EXPERIMENTAL 
AND THEORETICAL ESTIMATES: IMPLICATIONS FOR FORENSIC 
TOXICOLOGY 
Introduction 
Suvorexant (Belsomra®) is among a novel class of dual orexin receptor antagonists 
that are prescribed to treat insomnia. The drug inhibits the neuropeptides orexin A and B 
that are produced by neurons in the hypothalamus. These neuropeptides (also known as 
hypocretin 1 and 2) control the wake-promoting centers of the brain. Suvorexant decreases 
arousal and wakefulness, therefore producing an indirect sleep-promoting effect. It’s 
mechanism of action and pharmacodynamics are distinct from other classical hypnotic 
drugs. As the first drug in its class, it was approved by the Food and Drug Administration 
(FDA) in 2014 and became commercially available in 2015 (1). It is approved for use in 
Japan, the United States, Canada and Australia. In the US it is listed under Schedule IV of 
the Controlled Substances Act (2). As a sedative hypnotic, it is a drug of interest to the 
forensic toxicology community. However, there have been relatively few case reports 
involving the drug to date, perhaps due to the scope of testing that is performed during 
toxicological screening. Due to its relatively recent introduction, its role in forensic 
toxicology investigations is still unknown. Limited literature has been published regarding 
the distribution of suvorexant in toxicological specimens and there is a gap in the literature 
detailing the physicochemical properties of suvorexant that could help predict its behavior 
in biological specimens after death. As a sedative hypnotic, it is a drug of interest to the 
forensic toxicology community. However, there have been relatively few case reports 
involving the drug to date, perhaps due to the scope of testing that is performed during 
toxicological screening. Due to its relatively recent introduction, its role in forensic 
toxicology investigations is still unknown. Limited literature has been published regarding 
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the distribution of suvorexant in toxicological specimens and there is a gap in the literature 
detailing the physicochemical properties of suvorexant that could help predict its behavior 
in biological specimens after death. 
The structure of suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-
1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone, MK-4305) is shown in 
Figure 4.1. Its molecular formula is C23H23ClN6O2 (450.9 g/mol) and it has a high boiling 
point (670°C). Chemically, it is an organochlorine compound that contains a 1,3-
benzoxazole, diazepane, aromatic amide and triazole functionality. 
 
Figure 4.1. Chemical structure of suvorexant.  
Peak plasma suvorexant concentrations are observed within two hours of oral 
administration (3). Following a 10-mg dose in healthy men (n=5), peak plasma 
concentrations (Cmax) were 0.44 µM (198 ng/mL) (4). The FDA reports accumulations of 
1- to 2-fold with once-daily dosing. Steady-state is achieved within 3 days and the mean 
half-life was approximately 12h (95% CI: 12 to 13) (1). The drug is extensively bound 
(>99%) to plasma proteins (serum albumin and α-1-acid glycoprotein) and oral 
bioavailability is reported to be ~82% (3).  
The volume of distribution (Vd) for suvorexant has been reported to be 0.5-0.9 L/kg, 
and the FDA reported values between 49-105.9 L depending on the route of administration 
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(1, 5). The different units used to report Vd have caused inconsistencies among published 
reports for suvorexant (1, 6). The Vd is essentially a proportionality constant that relates 
the amount of drug in the body to the concentration of the drug in the plasma at equilibrium. 
Drugs that are highly bound to plasma proteins but not to tissue components tend to have 
low volumes of distribution. Conversely, those that accumulate in organs due to active 
transport or by specific binding to tissue molecules have high volumes of distribution, 
which can exceed the anatomical body volume. In clinical studies the Vd can be used to 
estimate the dose required to achieve a given plasma concentration. This is particularly 
important when peak plasma thresholds are necessary to achieve the therapeutic effect (as 
is often the case for hypnotic drugs). Drug dosage may be adapted accordingly and may 
need to consider changes in Vd due to individual height, weight, body mass and age. 
Distribution of drugs throughout the body is dependent on many factors including the 
lipophilicity of the drug, acid/base character, protein binding and transport mechanisms. In 
the postmortem period, distribution is further complicated by site and time-dependent 
variables.  
While lipophilicity and the Vd can influence the tendency of a drug to exhibit PMR, 
many other factors are important. While antemortem samples can be among the most useful 
specimens for this purpose, they are not always available. Drug lipophilicity plays a key 
role in the interaction between compounds and receptors as well as other macromolecules, 
some of which may constitute biological membranes (7). Food and drugs are highly 
dependent on permeability and solubility to reach their target site in the body, both of which 
are influenced by the lipophilicity of a compound. In addition, metabolism or 
biotransformation of a compound can alter its properties such as size, mass, charge, and 
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lipophilicity (8). Measuring lipophilicity can provide information on a drug’s affinity for 
lipid environments and can be measured in a number of ways (9).  
Molecular lipophilicity is perhaps one of the most important physicochemical 
properties of a drug. It influences solubility, absorption, distribution, central nervous 
system (CNS) penetration, plasma protein binding, and partitioning into tissues and organs. 
The lipophilicity of a species may be determined experimentally by measuring the 
differential solubility of a compound between two immiscible layers. The resulting ratio of 
concentrations of the compound in each phase is referred to as the partition coefficient (P), 
most often expressed as Log P. The most commonly used solvent systems are n-octanol 
and water. For ionizable substances, the drug may exist in a variety of species (charged and 
uncharged) at any given pH. In those instances, the distribution coefficient (D) is the most 
appropriate measurement, since it represents the differential solubility of all species 
(charged and uncharged) in the system. For ionizable species, Log P can be estimated from 
the calculated Log D value, as long as the pKa for the drug is known. Although both Log 
P and Log D describe the lipophilicity of a compound, Log D is a useful descriptor for 
ionizable species. Nevertheless, the parameter is useful in forensic toxicology when 
comparing molecular lipophilicity between species. Due to the logarithmic scale, a Log P 
value of 1 indicates a 10-fold preference for the organic phase, opposed to the aqueous 
phase. Even within a particular drug class, Log P values vary considerably. Among the 
opioids, Log P values range from <1 (e.g., oxymorphone) to 5 (e.g., methadone). 
Experimental measurement of Log P values can be determined using shake-flask, 
electrochemical, pH-metric and chromatographic-based methods. Alternatively, Log P can 
be predicted computationally, using a variety of software approaches.  
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 There are many ways to experimentally determine Log P values for a compound 
either directly, or indirectly. The shake-flask method, filter probe, chromatographic, pH-
metric and electroanalytical (potentiometric titration, cyclic voltammetry) techniques are 
widely used (8-14). The shake-flask method is a direct measurement that is considered to 
be among the most accurate (11). Using this approach, an organic/aqueous mixture (e.g., 
octanol/water) is shaken with analyte until equilibrium is achieved. The phases are 
subsequently separated, and the concentration of the analyte is then measured in each 
phase. Disadvantages of using this method are the special consideration of solvent volumes 
to ensure accurate determination of analyte concentration in each phase, the need for high 
purity of solutes and solvents, solubility of the analyte itself, and the formation of micro-
emulsions (8, 9). Other drawbacks include its labor intensiveness, inaccuracy due to 
potential impurities, adsorption to glass walls, and for highly lipophilic compounds, very 
low concentrations in the aqueous phase (in the parts per billion range). However, the 
shake-flask method is considered the most reliable technique to measure the lipophilicity 
of compounds with Log P values ranging from -3 to 4, and is a recommended procedure 
due to its simplicity. Additionally, in order to model biological partitioning, different 
aqueous systems can be used, with different ionic strengths and pH values.  
Computational methods based upon atom, fragment, electrotopological, and 
knowledge-based systems are also available. This theoretical approach can be extremely 
useful during the drug discovery process, or when very little is known about a substance 
(i.e., new psychoactive substances). In some computational models, the Log P value is 
calculated by determining the summation of hydrophobic contributions from each 
constitutive fragment of a molecule to equal the hydrophobicity of that molecule. As the 
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length of constituent groups increase or as branching increases, the Log P may also be 
reduced from the expected value. These factors as well as the addition of polar groups (such 
as H- or S-) are considered to compensate for the effects of hydrogen bonding and 
hydrophobic shielding. These additional considerations are included in a “correction 
factor” that can be incorporated into Log P estimations. Molecule structure, perception of 
features (number of each atom, number of each bond type, number of hydrogens attached 
to non-hydrogens, connections characteristics, functional groups, polar fragments, and ring 
information), and correction factors may be considered (7). ALogPS 2.1, ACD Labs/LogP 
and KowWin 1.67 are common computational methods for Log P prediction and these are 
explored in more detail in this study.   
ALogPS 2.1 predicts theoretical lipophilicity of a compound in addition to its 
aqueous solubility. Lipophilicity values are predicted by evaluating electronic and 
topological characteristics of the molecule. Electrotopological-state (E-state) indices are 
assigned to each atom type and its neighboring atoms, and with associative neural network 
modeling that was developed by Tetko et al, log P values can be estimated (13-16). The 
KowWin software estimates Log P values through the use of the atom/fragment 
contribution method. Each atom or fragment contribution value is summed and then 
multiplied by the frequency each of those occurs in the molecule. A reported advantage of 
the KowWin estimation is that it incorporates a correction factor that takes into account the 
linear equation constant and steric interactions (13, 15). ACD Labs/LogP octanol-water 
partition coefficient values are estimated through the use of experimentally or statistically 
determined fragment contribution summations (17). ACD Labs/LogP also uses three 
different algorithms (Classic, GALAS, or consensus model) to help predict LogP based on 
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molecular fragmentation and structural factors (17,18). ACD/LogP uses the “additive-
constitutive” algorithm which sums contribution from individual atoms, as well as 
fragments and their intramolecular interactions. This algorithm also takes into special 
consideration carbon atoms not within functional groups based on their hybridization and 
hydrogen bonds, and checks for the possibility of tautomerization (19). Although each 
computational approach has proven useful for predicting Log P values, some studies have 
shown that programs that using topological data combined with E-state indices may 
provide more consistent Log P value estimations (15). 
Relatively few studies have described the analysis of suvorexant in biological 
matrices. Analytical methods for the quantitation of suvorexant in a variety of fortified 
matrices have been published using multiple platforms. Quantitation of suvorexant in urine 
has been reported using gas chromatography-mass spectrometry (GC-MS), LC-Q/TOF-
MS and liquid chromatography-tandem mass spectrometry (LC-MS/MS) (20-22). Methods 
have also been described for plasma using LC-MS/MS with atmospheric pressure chemical 
ionization (APCI) and electrospray ionization (ESI) (23-25). Only three published methods 
describe the quantitation of suvorexant in whole blood (one of the most frequently 
encountered forensic matrices) using LC-Q/TOF-MS and LC-MS/MS (26-28). In a series 
of case reports from Japan, Waters described the analysis of suvorexant in postmortem 
specimens from three autopsy cases, including tissues (27). As the only published case 
report to date involving suvorexant, relatively little is known regarding the distribution of 
suvorexant postmortem, or its role in forensic toxicology investigations.  
This study further explores the physicochemical properties of the drug and presents 
twelve additional medicolegal death investigations (MDIs) and one antemortem 
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investigation where suvorexant was identified. Molecular lipophilicity was studied using 
both experimental and computational methods. A previously published and validated 
method was used to detect suvorexant in antemortem and postmortem toxicology 
specimens using LC-Q/TOF-MS (26). Toxicological findings were compared to those 
described by Waters et al, and the potential for postmortem redistribution is discussed (27).  
Materials and Methods 
Chemicals and Reagents 
Suvorexant was obtained as a powder from Cayman Chemical (Ann Arbor, MI) 
and estazolam-D5 (0.1 mg/mL) was obtained from Cerilliant (Round Rock, TX).  N-butyl 
chloride (99+% pure, 1-chlorobutane, Acros Organics) and Optima LC/MS grade 
acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). Formic acid (>95%) was 
obtained from Sigma-Aldrich (St. Louis, MO). LCMS grade methanol, concentrated 
hydrochloric acid (36.5-38.0%), sodium borate, and dibasic sodium phosphate were 
purchased from J.T. Baker (Center Valley, MA). Monobasic sodium phosphate, acetic acid 
(glacial), boric acid (granular), sodium acetate, and sodium chloride were obtained from 
Mallinckrodt Chemicals (St. Louis, MO). Potassium chloride, monobasic potassium 
phosphate, and n-octanol (>99.5%, TCI America) were obtained from VWR (Radnor, PA). 
All deionized water was produced in-house using a Millipore Direct-Q® UV Water 
Purification System (Billerica, MA). Drug-free bovine blood treated with 0.2% potassium 
oxalate (w/v) and 1% (w/v) sodium fluoride was received from QuadFive (Ryegate, MT). 
Adjudicated case specimens including antemortem blood, postmortem heart blood, 





An Agilent 1290 Infinity Binary LC coupled to an Agilent 6530 Accurate Mass 
Quadrupole Time-of-Flight LC/MS (Santa Clara, CA) was used for the identification of 
suvorexant in toxicology specimens and for the determination of suvorexant partition 
coefficients. The targeted LC-Q/TOF-MS assay utilized positive electrospray ionization 
(ESI) and targeted acquisition (26). The MS scan range was 100-1600 amu, at a MS scan 
rate of 5 spectra/second, acquisition time of 200 ms/spec and mass tolerance of ± 5 ppm. 
Two product ions transitions were used for suvorexant (m/z 451.1664 > 186.0664 and 
451.1664 > 104.0493) and the internal standard (IS) estazolam-D5 (m/z 300.1059 > 
272.0875 and m/z 300.1059 > 210.1076). Quantitation ions are underlined. Collision 
energies of 50 and 30 eV were used for suvorexant and the IS, respectively. Ionization 
conditions were as follows: 150 eV fragmentor voltage, 2000 V nozzle voltage, 3000 V 
capillary voltage, 45 psi nebulizer pressure, 300°C drying gas temperature, 13 L/min 
drying gas flow, 350°C sheath gas temperature, and 12 L/min sheath gas flow. The mobile 
phase consisted of 0.1% formic acid in deionized water (A) and 0.1% formic acid in 
acetonitrile (B). Separation was achieved with gradient elution using a Poroshell 120 EC-
C18 column (2.1 x 100 mm, 2.7 µm particle size) and Poroshell 120 EC-C18 guard column 
(2.1 x 5 mm, 2.7 µm particle size) at 35°C. Using a flow rate of 0.4 mL/min, gradient 
elution was as follows: 40-80% B (0-3 mins); hold 1 min; decrease to 40% (5 mins), 
followed by post-equilibration (2 minutes).  
Determination of Partition Coefficients 
Theoretical partition coefficients (Log P) were calculated for suvorexant using 
three predictive software packages: ALogPS version 2.1, ACD Labs/LogP, and KowWin 
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1.67. Experimental partition coefficients were determined using the classical shake-flask 
method with n-octanol and water, in addition to other aqueous buffer/octanol systems with 
varying ionic strengths and pHs (Table 4.1). The aqueous systems that were used for Log 
P determinations included 10 mM hydrochloric acid (pH 2), 10 mM acetate buffer (pH 5), 
10 mM phosphate buffer (pH 7.4), 100 mM phosphate buffer (pH 7.4), 10 mM phosphate 
buffered saline (pH 7.4), 200 mM phosphate buffered saline (pH 7.4) and 10 mM borate 
buffer (pH 8 and 9). Aqueous suvorexant stock solutions were prepared at concentrations 
of 10 and 100 µg/mL. To measure partitioning of suvorexant between aqueous and organic 
phases, 900 µL of deionized water (or buffer), 100 µL suvorexant stock solution (100 
µg/mL), and 1000 µL of n-octanol were added to 10-mL screw-top, round-bottom glass 
centrifuge tubes (n=3). The proportion of drug in the octanol layer was measured indirectly 
using aqueous controls (no octanol). Aqueous controls (n=3) were prepared by adding 900 
µL of deionized water (or buffer) and 100 µL suvorexant stock solution (10 µg/mL) in 
glass centrifuge tubes.  Samples were rotary mixed for 5 minutes at 45 rpm, followed by 
centrifugation for 5 minutes at 4000 rpm. The n-octanol layer was then discarded and 250 
µL of the aqueous fraction was transferred to a new tube. The aqueous fraction was then 
diluted 1:1 with 250 µL mobile phase, and 250 µL of this dilution was subsequently 
transferred to vials for LC-Q/TOF-MS analysis. The aqueous controls were prepared 
similarly by performing 1:1 dilution of control (250 µL) with mobile phase before 
transferring 250 µL of this solution to LC vials. Log P was determined by comparing the 
abundance of suvorexant in the octanol and aqueous layers (accounting for the ten-fold 
dilution factor) using the following equation: 






Statistical analyses using one-way analysis of variance (ANOVA) and t-tests were 
performed to identify any significant differences in partitioning using the various aqueous 
systems. Results were compared to determine the effect of pH and ionic strength on the 
distribution of suvorexant between aqueous and organic phases. 
Identification of Suvorexant in Authentic Case Samples 
Suvorexant working solutions were prepared at concentrations of 0.02, 0.2, and 2 
µg/mL in methanol. Drug-free whole blood was fortified with suvorexant over a calibration 
range of 2-200 ng/mL. Estazolam-D5 was prepared at a concentration of 2 µg/mL in 
methanol. Specimens from adjudicated casework were extracted using a previously 
validated extraction method for suvorexant in blood (26). For blood and vitreous 
specimens, 0.5 ml of sample was fortified with IS to achieve a final concentration of 100 
ng/mL. Sodium acetate buffer, 1 mL (0.4M, pH 3.6) and N-butyl chloride (2.5 mL) were 
added before rotary mixing for 5 min and centrifuging at 3000 rpm (5 min).  The organic 
layer was removed and evaporated to dryness under nitrogen at 50°C. Samples were 
reconstituted in 30 µL mobile phase A/B (50:50), transferred to LC vials and 2 µL was 
injected onto the LC-Q/TOF-MS for analysis. Using a weighted (1/x) calibration model, 
the limit of detection (LOD) and limit of quantitation (LOQ) in whole blood was 0.5 ng/mL 
(26).  
Results and Discussion 
Partition Coefficient Determination 
Experimental partition coefficients were determined using a variety of 
octanol/aqueous systems in triplicate. These are depicted in Figure 4.2 and Table 4.1. The 
octanol/water partition coefficient (Log P) was 3.45 ± 0.28, demonstrating the strong 
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tendency for suvorexant to favor organic solvent. Log P values at pH 2-10 ranged from 
3.23- 4.04. One-way ANOVA (α= 0.01) indicated that there were no significant differences 
between any of the experimentally determined Log P values (F(8,18)=3.54, p=0.01). Log 
P values were not influenced by pH (2-10 at 10mM) (F(5,12)=3.47, p=0.04) at α= 0.01)) 
or ionic strength. Two-tailed t-tests revealed no significant differences between 10 and 100 
mM phosphate buffer at pH 7.4 (α= 0.01) and phosphate buffer containing 10 or 200 mM 
saline (α= 0.01). This is consistent with its behavior as a neutral drug, despite its 
nitrogenous nature (20, 21).  
Partition coefficients were also estimated using predictive software. The Log P 
values for ALogPS, ACD Labs/LogP and KowWin were 3.86, 3.62 ± 0.86, and 4.65, 
respectively (Table 4.2). The KowWin software uses atom/fragment contribution methods 
to estimate a theoretical octanol-water partition coefficient (13, 15). ACD Labs/Log P 
software uses a combination of algorithms to predict partition coefficients. These 
algorithms combined are based on thousands of experimental Log P values, isolation of 
carbons, and adjustment for data for similar compounds, while a consensus algorithm will 
weigh the calculated value to the best suited structure model. ACD/LogP values are 
determined based on molecular fragmentation and structural factors (17, 18). ALogPS 
software will predict the octanol/water partition coefficient through a combination of 
neural networks which will work in parallel to calculate a theoretical value and was trained 
on a database of thousands of molecules. These estimations are based on electronic and 
topological characteristics of a molecule, which may provide more consistency in 
theoretical Log P calculations (13, 15). ACD/LogP and ALogPS provided Log P values 
that were closest to the experimentally determined value. Theoretically determined values 
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using the shake-flask method were within 0.2 and 0.4 of the experimentally determined 
value (Table 4.2). This suggests that the summation of atom/fragment contribution and 
correction factors utilized by KowWin were not as effective compared with ACD/LogP 
and ALogPS. 
Figure 4.2. Partition coefficient (Log P) values for suvorexant in various aqueous systems (mean 
± 1SD). 
Table 4.1. Mean partition coefficients (n=3) for suvorexant using various aqueous systems. 
Aqueous System pH Ionic Strength (mM) Mean ± SD %CV 
Deionized water - - 3.45 ± 0.28 8.0% 
10 mM HCl 2 10 3.41 ± 0.27 7.8% 
10 mM Acetate buffer 4 10 3.23 ± 0.18 5.6% 
10 mM Phosphate buffer 7.4 10 4.04 ± 0.21 5.3% 
100 mM Phosphate buffer 7.4 100 3.97 ± 0.09 2.3% 
10 mM PBS 7.4 200 3.97 ± 0.51 12.8% 
200 mM PBS 7.4 3.72 3.72 ± 0.01 0.4% 
10 mM Borate buffer 8 10 3.68 ± 0.28 7.7% 
10 mM Borate buffer 9 10 3.84 ± 0.20 5.3% 
 
 
pH 2 pH 5
pH 7.4 pH 7.4
pH 7.4




















Table 4.2. Comparison of experimental and theoretical Log P values for suvorexant. 







3.45 NA 100% 
ALogPS 3.86 0.41 112% 
ACD Labs/LogP  3.62 0.17 105% 
KowWin 4.65 0.79 135% 
 
Suvorexant in Toxicology Investigations 
Specimens from adjudicated casework were analyzed to determine the presence of 
suvorexant. These included twelve medicolegal investigations and one antemortem 
investigation involving a suspected impaired driver. Among the MDI cases, a total of four 
antemortem and thirteen postmortem specimens were evaluated, including both central and 
peripheral blood. Table 4.3 summarizes the case information, including the source of the 
blood (when known). Concentrations in whole blood ranged from 3 to 42 ng/mL. 
Concentrations in postmortem specimens were well within the therapeutic range and the 
calibration range of the assay (2-200 ng/mL) (Figure 4.3). Peak plasma concentrations 
have been described for healthy men following 10, 50, and 100-mg oral doses of 
suvorexant by Sun et al, which resulted in Cmax values of 198, 392, and 955 ng/mL, 
respectively (4). Suvorexant is currently available in doses of 5, 10, 15, and 20 mg, 
suggesting that peak plasma concentrations would typically be <200 ng/mL for patients 
prescribed the recommended 10-mg dosage (4). All postmortem samples tested 
demonstrated good chromatographic quality, acceptable ion ratios, and signal to noise 
ratios. Extracted ion chromatograms for a representative extract (Case# 6) are shown in 







Table 4.3. Concentrations of suvorexant in forensic investigations.  









AM Blood Gray 3.2 
Amphetamine < 50 ng/mL; Methamphetamine 145 ng/mL; Alprazolam 
37 ng/mL; Morphine 11 ng/mL1; Trazodone present 
2 45 
MDI 
Peripheral blood Gray 3.5 
Ethanol 0.018 g/dL; Morphine 427 ng/mL1; Diazepam 106 ng/mL; 
Nordiazepam 254 ng/mL; 7-Aminoclonazepam 30 ng/mL; Mirtazapine 
present; Sertraline present 
  Heart blood Gray 7 
Ethanol 0.071 g/dL; Morphine 942 ng/mL1; 6-MAM present; Diazepam 
113 ng/mL; Nordiazepam 194 ng/mL; 7-Aminoclonazepam 16 ng/mL; 
Mirtazapine present; Sertraline present 
  Vitreous Gray ND Ethanol not detected2; Morphine 48 ng/mL1; 6-MAM present 
3 78 
MDI 
Peripheral Blood Gray 16.8 
Oxycodone 32 ng/mL1; Diphenhydramine 200 ng/mL; Fentanyl 5.4 
ng/mL; Norfentanyl 0.68 ng/mL 
  Heart Blood Gray 36.5 - 
4 51 
MDI 
AM Blood Gray 21 
Alprazolam 84 ng/mL; Hydrocodone 11 ng/mL; Bupropion 370 ng/mL;   
Hydroxybupropion 880 ng/mL; Ketamine 130 ng/mL; Norketamine 93 
ng/mL; Metoprolol 1500 ng/mL; Ramelteon 15 ng/mL; Ramelteon M-II 
21 ng/mL 
  AM Plasma/Serum Gold 3.6 - 
5 50 
MDI 
Femoral Blood  Gray 36.8 
Lamotrigine 10 mcg/mL; Levetiracetam 29 µ/mL; 10-
Hydroxycarbazepine 92 µg/mL; Fluoxetine 100 ng/mL; Norfluoxetine 
270 ng/mL; Mirtazapine 140 ng/mL; mCPP 150 ng/mL; 
Diphenhydramine 7700 ng/mL; Cyclobenzaprine 87 ng/mL 
6 44 
MDI 
Cardiac Blood Gray 13.2 
Caffeine Positive; Cotinine Positive; Oxymorphone 400 ng/mL1; 
Paroxetine 240 ng/mL; Tramadol 43 ng/mL; O-Desmethyltramadol 22 
ng/mL; Diphenhydramine 2500 ng/mL 
7 62 
MDI 
Peripheral Blood  Gray 40.5 
Caffeine Positive; Cotinine Positive; 7-Amino Clonazepam 38 ng/mL; 
Benzoylecgonine 330 ng/mL; Mirtazapine 6 ng/mL; Fentanyl 14 ng/mL; 









Femoral Blood Gray 27.7 
Caffeine Positive; Morphine 21 ng/mL1; Oxymorphone 5.1 ng/mL1; 
Levetiracetam 2.1 µg/mL; Venlafaxine 260 ng/mL; O-




Femoral Blood Gray 15.6 
Caffeine Positive; Naloxone Positive; Diazepam 420 ng/mL;  
Nordiazepam 460 ng/mL; Temazepam 29 ng/mL; Clonazepam 9.9 
ng/mL; 7-Amino Clonazepam 110 ng/mL; Morphine 87 ng/mL1; 
Hydrocodone 34 ng/mL1; Oxycodone 430 ng/mL1;  
Oxymorphone 6.7 ng/mL1; Carisoprodol 5.7 µg/mL; Meprobamate 17 
µg/mL; Sertraline 58 ng/mL; Desmethylsertraline 180 ng/mL; THCA 11 
ng/mL; THC 2.1 ng/mL; Cyclobenzaprine 26 ng/mL; Fentanyl 1.6 
ng/mL; Norfentanyl 0.45 ng/mL 
10 51 
MDI 
Peripheral Blood Gray 26.5 
Caffeine Positive; Naloxone Positive; Amitriptyline 350 ng/mL; 
Nortriptyline 630 ng/mL; Hydroxyzine 200 ng/mL 
11 33 
MDI 
AM Blood Lavender 29.6 
Caffeine Positive; Cotinine Positive; Duloxetine 93 ng/mL; 
Eszopiclone/Zopiclone 11 ng/mL 
  AM Plasma/Serum Green 12.9  
12 36 
MDI 
Peripheral Blood Gray 17.2 
Caffeine Positive; Naloxone Positive; Alprazolam 48 ng/mL; 
Benzoylecgonine 220 ng/mL; THCA 5.3 ng/mL; THC 0.79 ng/mL;  
Fentanyl 16 ng/mL; Norfentanyl 4.2 ng/mL 
13 NK 
MDI 
Iliac Blood Gray 41.5 
Caffeine Positive; Lamotrigine 3.4 µg/mL; Quetiapine 17000 ng/mL;  
Yohimbine Positive 
 
AM, antemortem; MDI, medicolegal death investigation; m-CPP, meta-chlorophenylpiperazine; THC, Δ-9-tetrahydrocannabinol; THCA, carboxy-THC; 6-









Figure 4.3. Representative calibration curve (2-200 ng/mL) in whole blood using the previously 
validated method (26).  
 
Figure 4.4. Representative extracted ion chromatogram (EIC) for suvorexant (13.2 ng/mL) and 
the IS (Case # 6). 
160 
 
Vitreous fluid was available in only one case. Although suvorexant was identified 
in both peripheral and heart blood, it was not identified in the vitreous, likely due to the 
very low drug concentration and poor partitioning due to its lipophilic character (Table 
4.2).  Suvorexant was identified in a total of seventeen specimens, including postmortem 
and antemortem blood, as well as serum/plasma. Blood/plasma ratios could not be 
determined due to hemolysis, and because the time of the antemortem blood and plasma 
collection was not known.  
Suvorexant was identified in combination wide variety of other drugs, including 
amphetamines, cannabinoids, opioids, benzodiazepines and other therapeutics. None of the 
cases involved suvorexant alone. Opioids (11) and benzodiazepines (7) were the most 
commonly co-occurring substances, representing 85% and 54% of the suvorexant-positive 
cases. Other hypnotics or sedatives that are sometimes used as sleep aids (zopiclone, 
diphenhydramine, hydroxyzine) were identified in five cases. The mean age of the subjects 
was 46 (range 25-78). Suvorexant concentrations reported in Table 4.3 represent the values 
obtained using the LC-Q/TOF-MS method described here. Suvorexant had been previously 
quantified in nine of the thirteen cases. The mean concentration upon reanalysis was in 
close agreement with original results (74%), despite refrigerated storage times of twenty 
months in some cases, and the absence of chemical preservative.  
Paired central/peripheral blood samples were available in only two cases, yielding 
unremarkable C/P ratios of 2.0 and 2.2. This was consistent with the previous study by 
Waters et al, which reported C/P ratios of 0.9-1.4 (27). Waters described the distribution 
of drug in liver, kidney, spleen, pancreas, lung, muscle and fat. Also tested were right and 
left heart blood, left femoral blood, and urine. In all three cases, decedents had been 
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prescribed 20-mg tablets of suvorexant to be taken once nightly. The cause of death in the 
first case was determined to be drowning, but the decedent had levels of suvorexant in the 
blood samples ranging from 421-491 ng/mL. Drug concentrations in the fat were lower 
than blood (359 ng/g). The second case was determined to be a polydrug intoxication with 
blood levels ranging from 11-17 ng/mL, and highest tissue concentration of 40 ng/g was 
identified in the lung. The third case involved a suicide by hanging, with blood 
concentrations ranging from 138-155 ng/mL, and highest tissue concentration of 278 ng/g 
reported in fat (27). Notably, concentrations of suvorexant in urine were negligible or non-
detectable. This might be attributed to the reported hydroxylation and extensive 
glucuronidation of the drug, which results in fecal elimination (66%) (3).  
During clinical trials, gender and body mass index (BMI) were assessed in the 
pharmacokinetic models. In females, the area under the curve (AUC) and Cmax were 
increased by 17% and 9% respectively following the 40 mg dose. Average concentrations 
of suvorexant approximately 9 hours after dosing were 5% higher among females. 
Although dose adjustments were not necessary based on gender alone, significant 
differences were observed in obese patients. Oral clearance is inversely related to BMI. In 
obese patients, the FDA reported AUC and Cmax were increased by 31% and 17%, 
respectively. Mean concentrations 9 hours post-dose were 15% higher in patients with a 
BMI>30kg/m2, compared to those within the normal BMI range (25 kg/m2 or below) (1). 
As might be predicted, AUC and Cmax in obese females were increased 46% and 25%, 
compared to non-obese females. Based upon the increased exposure among this group, the 
FDA recommends caution when considering increases in dose. No differences were 
observed between race and age (1).    
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Although suvorexant is a lipophilic drug, there is no evidence as yet to support 
significant postmortem redistribution. Many factors contribute to PMR including plasma 
protein binding, basicity, and lipophilicity. The study herein describes the analysis of 
suvorexant in 13 forensic toxicology investigations. The samples analyzed included 
antemortem and postmortem blood, serum/plasma and vitreous humor. The drug is 
reported to undergo metabolism to hydroxylated and glucuronidated species. However, 
there are no commercially available metabolites for suvorexant at this time, precluding 
their analysis in this study. 
Only one case involved a living subject. The case involved a single-vehicle crash 
where the operator failed to maintain control of the vehicle and left their lane of travel. The 
driver’s speech was slow, slurred, and at times incoherent. He was unsteady on his feet, 
appeared confused, had difficulty staying awake, and engaged in conversations with 
himself. His hand movements were shaky and eyelid tremors were present. The subject’s 
30 second time estimation was 50 seconds. Methamphetamine, alprazolam, morphine, 
trazodone and suvorexant were present in the blood (Table 4.3). Although the 
concentration of suvorexant was extremely low, its presence in a methamphetamine user 
is of note, possibly to offset the stimulant effects of the drug to prepare for sleep. 
Conclusion 
Suvorexant has not been widely reported in forensic investigations. Dose-related 
somnolence and CNS depression are the most common adverse effects associated with its 
use.  It has also been shown to impair driving skills and may increase the risk of falling 
asleep while driving (6). Next-day impairments are found to be highest if suvorexant is 
taken with less than a full night of sleep remaining, with higher doses, or if co-administered 
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with other CNS depressants or CYP3A inhibitors. Although rare, parasomnias including 
sleep driving, preparing and eating food, making phone calls and other complex behaviors 
have been associated with hypnotics, including suvorexant (29). A dose-dependent 
increase in suicidal ideation has been observed, especially in patients with a previous 
diagnosis of depression (30). In this report, partition coefficients for suvorexant using 
experimental and computational methods were in good agreement. Of the thirteen cases 
presented, suvorexant concentrations were well within the therapeutic range. The vast 
majority of cases involved mixed drug intoxications, particularly involving opioids, 
benzodiazepines, or both. Despite its lipophilicity (Log P, 3.5), the Vd of suvorexant is low 
to moderate, and postmortem redistribution may not be a significant concern based on 
limited published reports to date. 
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Liquid-chromatography mass spectrometry (LC-MS) is a powerful bioanalytical tool that 
is gaining widespread use in operational forensic toxicology laboratories. However, 
changes in ionization efficiency caused by endogenous or exogenous species must be 
carefully considered. While different modes of ionization can be used, electrospray 
ionization (ESI) can be especially prone to this phenomenon due to capacity-limited 
ionization. Decreased ionization efficiency of the target analyte or internal standard are 
possible in the presence of a competing coeluting compound during droplet desolvation in 
the source. This decreased ionization efficiency can influence the accuracy and sensitivity 
of analytical methods. While quantitative matrix effects are evaluated routinely during 
method development and validation, ion suppression arising from other drugs is not always 
assessed quantitatively, or in sufficient depth. In this study, the hypnotic drug suvorexant 
was used as a model compound for the investigation of such interferences. The potential 
for significant bias in quantitative analysis was demonstrated using this previously 
validated assay. Although stable isotope labeled internal standards can mitigate this issue, 
they are not always commercially available for new or emerging substances. In this study, 
quantitative biases due to ionization suppression are discussed, and techniques to overcome 
this challenge are presented.  




DRUG-MEDIATED ION SUPPRESSION OF SUVOREXANT AND 
MITIGATION OF INTERFERENCES USING LIQUID CHROMATOGRAPHY-
QUADRUPOLE/TIME OF FLIGHT MASS SPECTROMETRY (LC-Q/TOF-MS) 
AND LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC-
MS/MS) 
Introduction 
LC-MS techniques are increasingly used for a wide variety of applications, 
including forensic toxicology. LC-based methods facilitate the identification of thermally 
labile, polar, or nonvolatile analytes, without the need for derivatization (1, 2). Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) techniques have become the 
benchmark for bioanalytical assays due to their improved sensitivity and selectivity (3-5). 
High resolution mass spectrometry (HRMS), such as liquid chromatography-
quadrupole/time of flight-mass spectrometry (LC-Q/TOF-MS), is also increasingly used. 
Despite their many advantages, performance of LC-MS based techniques can be negatively 
impacted by changes in ionization efficiency, including ion enhancement, or more 
frequently, ion suppression. 
It was once commonly believed that LC-MS techniques would provide “unrivaled 
selectivity” using electrospray ionization (ESI) (1, 4). Electrospray is a technique that 
allows a wide variety of ion types to be transferred from the solution to the gas phase, 
enjoying widespread utility for biomolecules that sometimes exceed 100,000 Da (6). ESI 
is convenient in the sense that it uses conventional ionic solutions to transfer ions from the 
liquid to the gas phase, and the ionization of compounds can be altered by manipulating 
the solution chemistry (6). The ESI source contains a highly charged capillary which is 
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responsible for pneumatic manipulation of the solvent into a finely charged spray (7). The 
intensity of the spray is ultimately affected by source parameters such as the temperatures 
and gas flow rates used (7). Charged droplets are formed from electrolyte dissolved in a 
solvent which are subsequently evaporated, resulting in a smaller volume for the charges 
to disperse until fission occurs. The droplet fission process repeats until small, highly 
charged droplets are produced that are capable of transforming gas phase ions. Transfer to 
the gas phase occurs and ions are subsequently routed to the ion sampling region of the 
spectrometer (6). 
Ion suppression is more likely to occur when multiple species are in the droplet in 
the absence of chromatographic resolution. The phenomenon becomes more problematic 
when minimal sample clean-up is performed, when the target analyte is only present in 
trace amounts, or when short run-times are used (i.e., fast LC) (1). Factors that increase the 
likelihood of ion suppression include high concentration, mass and basicity, as well as 
coelution with the analyte of interest (1). The total number of ions that can be formed 
during ESI is directly dependent upon the total surface area of all the droplets. Basicity and 
surface activity of coeluting compounds can determine their ionization efficiency. If the 
basicity or surface activity is higher for an interference than the analyte, and if it is present 
at sufficiently high concentration, the capacity to ionize all of the species in the droplet 
may be exceeded and the analyte signal is suppressed (1). Suppression is not only 
compound-dependent but can be caused by several mechanisms. One of the mechanisms 
by which ion suppression can occur is by competition between coeluting interfering ions 
and the target analyte for gas phase emission in the ESI source (1, 8, 9). In ESI, the analytes 
are introduced in the liquid phase. As the eluent is vaporized, the electrical density at the 
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surface of the droplet increases until it reaches its Rayleigh stability limit, which will then 
cause the droplet to divide into smaller droplets by electrostatic repulsion. This process 
will continue until the solvent has evaporated and the analyte ions enter the gas phase. 
However, when interferences are present in high concentrations this will increase the 
surface tension of the solvent droplet and result in reduced ability of the analytes to meet 
the droplet surface for ionization (1). Any analyte that is left within these droplets at the 
end of the fission process does not transfer to the gas phase and consequently does not 
make it through the detector. As such, the nature of ESI is capacity limited, and an excess 
of competing ions can result in ion suppression of the target analyte. As such, ion 
suppression can negatively influence the reliability of analytical results. In cases where 
internal standards are suppressed, an overestimation (positive bias) of the analyte 
concentration can result. Conversely, suppression of the analyte itself can produce a 
negative bias. Neither scenario is acceptable in forensic toxicology, where quantitative 
measurements may be relied upon. While it has been suggested that when an interference 
or matrix effect is detected, chromatography should be re-optimized to provide resolution 
between the interference and analyte, it is simply not always possible to achieve resolution 
from all known (and unknown) compounds or interferences. Such an approach may result 
in excessive run times, band broadening and decreased sensitivity. Therefore, a 
compromise is required. 
Ion suppression is often highly dependent on the ionization source that is used. 
Atmospheric pressure chemical ionization (APCI) is less susceptible to some of the 
mechanistic ion suppressing events, as analytes are already in the gas phase prior to 
ionization (1, 10). However, APCI techniques are less commonly used than ESI, sometimes 
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due to their decreased analytical sensitivity. Source design and geometry can also affect 
ion suppression (1, 9, 11). Stable isotope labeled internal standards (SIL-ISs) are preferred 
for MS-based methods because they compensate for variations in extraction efficiency, 
chromatographic separation and detector sensitivity. More importantly, they are 
particularly useful for mitigating matrix effects and other interferences caused by capacity-
limited ionization (12, 13). In theory, any coeluting internal standard should help 
compensate for ion suppression, this can be difficult to achieve without extensively 
shortening run times (13). With SIL-ISs, atoms in the analyte are replaced with stable 
isotopes such as 2H and 13C to give similar properties as the analyte and result in 
comparable retention times. Frequently, three or more atoms are replaced with its stable 
isotope, but unwanted resolution may occur with an increasing number of 2H substitutes 
due to the mass difference between 1H and 2H being greater than the difference between 
12C and 13C substitutions (14). Other factors to consider when choosing a labeled internal 
standard are the location of the substitutions on the analyte, the retention time, the 
molecular structure and weight, and the mobile phase that is used (14). 
Matrix effects are the most commonly described cause of ion suppression or 
enhancement, but less frequently described matrix effects such as coeluting drugs can also 
be problematic when using ESI-based techniques. The mechanism for ion suppression in 
the presence of interfering compounds is much the same as with other endogenous matrix 
effects (lipids, extraction artifacts, additives), in that ions compete for transfer to the gas 
phase in the source, and such ionization is capacity limited. Possible sources of ion 
suppression (matrix or drug) must be thoroughly evaluated during method development, 
optimization and validation. 
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Interferences from coeluting species were previously explored for a suvorexant 
assay in whole blood using LC-Q/TOF and LC-MS/MS (15, 16). Suvorexant ([(7R)-4-(5-
chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3,-triazol-
2-yl)phenyl]methanone) (Figure 5.1A) is a sedative hypnotic drug that was recently 
introduced to the market in 2015, and resides under Schedule IV of the federal Controlled 
Substances Act (17, 18). Sensitive analytical methods are needed for its detection in 
forensic toxicology casework, particularly in impaired driving or drug-facilitated sexual 
assault (DFSA) investigations. We previously reported quantitative methods to identify 
suvorexant in whole blood using an acidic/neutral liquid-liquid extraction, followed by LC-
Q/TOF and LC-MS/MS detection (15, 16). Both methods were validated in accordance 
with guidelines for forensic toxicology laboratories (19). The methods were both robust 
with LOQs of 0.5 ng/mL in whole blood, however quantitative interferences were observed 
in the presence of sertraline, a common drug that coeluted with the internal standard 
(estazolam-D5 (Figure 5.1B)). When assessing ion suppression or enhancement in LC-
based quantitative methods, current guidelines state that potential interferences be analyzed 
in fortified samples, neat reference materials, or in previously analyzed case samples (19). 
While there are recommendations for assessing matrix effects (post-column infusion or 
post-extraction addition), there are no defined guidelines for assessing interferences from 
commonly encountered drugs or other exogenous compounds (3, 10). Drug interferences 
can be evaluated qualitatively or quantitatively, but there is no current requirement to 
assess the latter in forensic toxicology. Nevertheless, this is good laboratory practice to 
ensure the reliability of quantitative measurements. Although reports regarding signal 
suppression and enhancement have focused more on matrix effects than drug interferences, 
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the mechanism by which they influence the ionization is the same. These effects have been 
described as the “Achilles heel” of LC-MS based methods and although they can be 













Figure 5.1. Structures of suvorexant (A), estazolam-D5 (IS) (B), and suvorexant-D6 (IS) (C).  
 
The purpose of this study was to highlight these concerns and investigate possible ways to 
mitigate these issues. Interferences that arise as a product of capacity limited ionization in 
ESI methodologies can go undetected qualitatively (because retention time and ion ratios 
are unaffected), but still result in quantitative bias (4, 6, 20). This was the case for two 
previously reported suvorexant assays, for which there was no SIL-IS at the time of the 
development (15, 16). In this study, the mechanism of ion suppression was investigated 
using a statistical approach, and strategies for mitigating the effects of coeluting drug 
C) Suvorexant-D6 
B) Estazolam-D5 A) Suvorexant 
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interferences in the absence of isotope labeled internal standards are discussed. 
Subsequently, the use of deuterated suvorexant (suvorexant-D6 (Figure 5.1C)) was 
investigated, and comparisons are made with and without the use of a SIL-IS. 
Materials and Methods 
Chemical and Reagents 
Suvorexant was purchased from Cayman Chemical (Ann Arbor, MI) as a powder. 
Estazolam-D5 and suvorexant-D6 internal standards were obtained from Cerilliant Corp. 
(Round Rock, TX) as methanolic standards (100 µg/mL). Fifty-two additional drugs (for 
the interference testing) were purchased from Cerilliant Corp. as listed in Table 5.1. Stock 
and working standards for all compounds were routinely prepared in methanol. The internal 
standard (IS) solution consisted of estazolam-D5 and suvorexant-D5 solutions (2 µg/mL) 
in methanol. 
Table 5.1. Fifty-two common drugs used to evaluate qualitative and quantitative interferences in 
the detection of suvorexant from whole blood using LC-Q/TOF and LC-MS/MS. 
Interference Study Drug Panel  
Barbiturates 
Amobarbital, butalbital, pentobarbital, phenobarbital, secobarbital 
 
Benzodiazepines 
7-aminoclonazepam, 7-aminoflunitrazepam, alprazolam, clonazepam, diazepam, flurazepam, 
nordiazepam, oxazepam, temazepam 
 
Z-Drugs 
Zaleplon, zolpidem, zopiclone 
 
Common Drugs 
11-nor-9-carboxy-delta-9-THC, acetaminophen, amitriptyline, amphetamine, bupropion, 
caffeine, carbamazepine, carisoprodol, cocaine, codeine, cyclobenzaprine, dextromethorphan, 
fluoxetine, gabapentin, hydrocodone, hydromorphone, ketamine, MDMA, meperidine, 
meprobamate, methadone, methaqualone, morphine, oxycodone, oxymorphone, phencyclidine, 
phenytoin, propoxyphene, pseudoephedrine, salicylic acid, sertraline, THC, tramadol, 
trazadone, valproic acid 
 
MDMA, methylenedioxymethamphetamine; THC, tetrahydrocannabinol. 
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Sodium acetate (ACS grade) and glacial acetic acid (ACS grade) were obtained 
from Mallinckrodt Chemicals (St. Louis, MO). N-butyl chloride (Acros Organics, 99+% 
pure), Optima LC-MS grade formic acid, and Optima LC-MS grade acetonitrile were 
obtained from Fisher Scientific (Pittsburg, PA). LC-MS grade methanol was acquired from 
J.T. Baker (Center Valley, MA). All deionized water was purified in-house using a 
Millipore Direct-Q® UV Water Purification System (Billerica, MA). Whole drug-free 
bovine blood containing 1% sodium fluoride (w/v) and 0.2% potassium oxalate (w/v) was 
purchased from QuadFive (Ryegate, MT). 
Instrumentation 
Separation of analytes was achieved using two Agilent 1290 Infinity Binary LC 
systems (Santa Clara, CA) with identical LC conditions. For both platforms, matching 
Poroshell EC-C18 columns (2.1 x 100 mm, 2.7 µm particle size) and guard columns (2.1 
x 5 mm, 2.7 µm particle size) were used. Mobile phases A and B were comprised of 0.1% 
formic acid in deionized water and 0.1% formic acid in acetonitrile, respectively. Gradient 
elution at 35°C was performed at a 0.4 mL/min flow rate as follows: 40% B (0 min), 40-
80% B (0-3 min), hold 80% B (1 min), decrease 80-40% B (until 5 min), followed by re-
equilibration (15, 16). 
HRMS acquisition was performed on an Agilent 6530 Accurate Mass Quadrupole 
Time-of-Flight LC/MS (Santa Clara, CA) with positive mode electrospray ionization (ESI) 
using a previously published method (15). Detection of analytes was performed in parallel 
by LC-MS/MS on an Agilent 6470 Triple Quadrupole Mass Spectrometer (Santa Clara, 
CA) in positive ESI mode as previously described (16). ESI conditions for both ionization 
sources were identical: 300°C drying gas (13 L/min), 350°C sheath gas (12 L/min), 45 psi 
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nebulizer pressure, 3000 V capillary voltage, and 2000 V nozzle voltage. LC-Q/TOF 
analysis was performed using targeted MS/MS data acquisition (100-1600 amu) with 
narrow isolation widths (1.3 amu). A mass tolerance of ± 5 ppm was used, with a MS scan 
rate of 5 spectra/sec and a 200 ms/spec acquisition time (15). LC-MS/MS data was acquired 
using dynamic multiple reaction monitoring (dMRM) mode, with 200 ms dwell time for 
all ion transitions, as previously described (16). Compound-specific parameters such as 
fragmentor voltage, ion transitions, and collision energies for collision induced dissociation 
(CID) for suvorexant and IS can be found in Table 5.2. 
Table 5.2. LC-Q/TOF-MS and LC-MS/MS instrument-specific parameters for data acquisition in 










LC-Q/TOF-MS Suvorexant 150 451.1644 186.0664 50 
    104.0493 50 
 Estazolam-D5 150 300.1059 272.0875 30 
    210.1076 30 
 Suvorexant-D6 150 457.2020 192.1032 50 
    110.0865 50 
LC-MS/MS Suvorexant 127 451.2 186.0 21 
    104.0 73 
 Estazolam-D5 140 300.0 272.1 24 
    210.1 48 
 
Identification of exogenous drug-mediated interferences was performed using the 
LC and source conditions described. The LC-Q/TOF method was adapted for auto MS/MS 
data acquisition with the following stipulations: 40-1000 amu MS scan range (absolute 
thresholds of 200 counts for MS and 5 counts for MS/MS), 10 spec/sec MS scan rate, 5 
spec/sec MS/MS scan rate, MS/MS medium isolation width (4 amu), and fixed collision 
energies of 30, 40, and 50 eV. An absolute precursor threshold of 6000 counts was used 
(0.01% relative) with 2 max precursors per cycle. LC-MS/MS data acquisition was 
180 
 
performed using MS2 scan mode at 135V fragmentor voltage, 100-500 amu scan range, 
and 500 ms scan time. The step size was 0.1 amu and a time filter width of 0.07 min was 
used. 
Extraction 
Suvorexant and IS were isolated from whole blood using and acidic/neutral liquid-
liquid extraction. Drug-free blood was fortified with internal standard (100 ng/mL) and 
suvorexant over the calibration range (2-200 ng/mL). Sodium acetate buffer (0.4 M, pH 
3.6) (1mL) and N¬-butyl chloride (2.5 mL) were added, followed by rotation (5 min) and 
centrifugation (3000 rpm, 5 min). The supernatant was removed to conical tubes and 
evaporated to dryness under nitrogen stream (50°C). Reconstitution of sample was 
performed with 1:1 mobile phase A/B (30 µL). The injection volumes for LC-Q/TOF-MS 
and LC-MS/MS analysis were 2 µL.  
Identification of Interferences 
Interferences were evaluated both qualitatively and quantitatively during validation 
of the LC-Q/TOF-MS and LC-MS/MS methods (15, 16). In the absence of a stable isotope 
internal standard for suvorexant at the time of validation, estazolam-D5 was used as the 
internal standard during initial interference studies. Interferences were evaluated by 
fortifying negative (0 ng/mL), low (10 ng/mL), and high (100 ng/mL) suvorexant-positive 
samples with 52 common drugs (1000 ng/mL). Qualitative interferences were evaluated 
using peak shape, retention time and ion ratios for suvorexant and internal standard in the 
presence (and absence) of other drugs. Retention time acceptance was ±2% and ion ratios 
acceptance was ±20% of the verified standard. Quantitative interferences were evaluated 
by comparing calculated concentrations of suvorexant to the true value and assessing bias. 
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If a quantitative bias exceeding ±20% was observed, the source of the drug interference 
was identified using auto MS/MS acquisition (LC-Q/TOF) or MS2 scan mode (LC-
MS/MS). Once identified, suspected sources of drug interference with retention times close 
to suvorexant or estazolam-D5 were further investigated.  Isolated interferences were then 
analyzed at different concentration ratios (1:10, 1:1, and 10:1 interferent to analyte) to 
determine the magnitude of the quantitative bias. 
Mitigation of Interferences 
Following isolation of drugs responsible for quantitative interferences (sertraline 
and propoxyphene), different strategies for mitigating interferences were assessed. The 
sample blood volume was assessed at 0.25 mL, 0.5 mL, and 1 mL in the presence of 
sertraline (1:10, 1:1, and 10:1 to that of the IS) to determine the effect sample volume can 
have on quantitative bias. Additionally, LC injection volumes (at the same concentration 
ratios) were assessed at 0.5, 1, and 2 µL in an attempt to mitigate drug-mediated 
interferences. Neat and extracted samples containing suvorexant, IS, and sertraline were 
compared to determine differences in response in the absence of matrix and to further 
demonstrate capacity limitations in ESI. The internal standard response for extracted 
samples containing sertraline was also compared to IS response in calibration samples to 
determine significant differences in the presence of sertraline. The newly available 
suvorexant-D6 standard was added to the LC-Q/TOF-MS acquisition method and 
qualitative and quantitative drug interferences were evaluated again to determine 





Using LC-Q/TOF targeted MS/MS, dilution integrity was investigated for various 
dilutions without and without the use of suvorexant-D6. Suvorexant-positive blood stock 
was prepared at 160 ng/mL. Positive QCs were prepared using 0.5 mL whole positive blood 
and were fortified with either estazolam-D5 (n=4) or suvorexant-D6 (n=4) internal 
standard (100 ng/mL). Dilution integrity was investigated using 2-fold and ten-fold 
dilutions of blood. The appropriate volume of blood (0.25 mL or 0.05 mL) was diluted in 
either sodium acetate buffer (pH 3.6, 0.4M), or drug-free blood (0.25 mL or 0.45mL) to 
achieve a total diluted specimen volume of 0.5 mL. Dilutions were performed in two 
identical sets, and each set was fortified with respective internal standard (n=4). Results 
were compared with quantitative values in undiluted blood (n=4). Following fortification 
of internal standard, samples were subjected to LLE as described and quantitated using a 
weighted 1/x quadratic calibration model (2-200 ng/mL).  
Results and Discussion 
Identification of Interferences 
During the initial method validation, both LC-Q/TOF-MS and LC-MS/MS methods 
were evaluated for qualitative interferences from 52 common drugs. No qualitative 
interferences were identified in either assay using negative and positive controls: peak 
shape, retention time and ion ratios for estazolam-D5 and suvorexant were all within 
acceptable criteria (Figure 5.2). However, other drugs were present at 10-fold and 100-
fold higher concentration (relative to the analyte or IS) quantitative biases were observed 
using low (10 ng/mL) and high (100 ng/mL) suvorexant positive controls. Sources of drug 
interference were identified from precursor ions using full scan acquisition on the LC-
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Q/TOF-MS. Extracted ion chromatograms for two drugs that coeluted with estazolam-D5 
are shown in Figure 5.3. Although no interferences were identified for suvorexant, 
propoxyphene and sertraline elute very close to the internal standard. These were further 
investigated using whole blood fortified with an excess of drug relative to the IS. Sertraline, 
which coeluted with the internal standard, was identified as the quantitative interference 
using LC-Q/TOF-MS and was further investigated at 1:10, 1:1, and 10:1 
sertraline:estazolam-D5 concentrations (n=3). It was determined that as the drug 
concentration increased, the magnitude of the positive bias also increased (83% at 10:1), 
exceeding acceptability limits in forensic toxicology (Figure 4) (15, 19). This positive bias 
in the quantitative result was attributed to the decrease in ionization efficiency of the IS. 
The same experiment was repeated during the cross-validation of the LC-MS/MS method. 
MS2 scan mode acquisition was used to identify the potential interferences. Again, no 
qualitative interferences were identified, however a quantitative interference was attributed 
to sertraline and propoxyphene, with the added interferent resulting from very slight 
retention time differences between the two EC-C18 columns used on each platform. The 
bias associated for sertraline was 24% at equivalent concentrations and 22% at 10-fold 
higher concentrations, whereas propoxyphene bias ranged from 32-95% for all 
concentrations used (Figure 5.4) (16). This further demonstrates the difficulty eliminating 
all interferences simply by altering chromatographic conditions, as one interference can 
easily be replaced by another due to small shifts in retention time. Although every effort is 
made to establish chromatographic methods that a fit for purpose, resolution of analyte or 
IS form every possible other drug or metabolite is not an achievable goal. Although this 
issue may be rare, it may be under-recognized if laboratories do not assess drug 
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interferences quantitatively. Moreover, the problem will be exacerbated if rapid-LC 
methods are utilized for quantitative determination.   
 
Figure 5.2. Extracted ion chromatograms (EICs) for suvorexant (100 ng/mL), estazolam-D5, and 





Figure 5.3. Extracted ion chromatogram (EIC) for interferences (1000 ng/mL) identified near the 
retention time of the IS (100 ng/mL).   
 
Figure 5.4. Systematic bias using ESI due to coelution of IS and interfering drugs at 




























Using the LC-Q/TOF-MS assay, the absolute response of IS in the presence of 
sertraline at differing ratios (1:10, 1:1, and 10:1 sertraline:estazolam-D5) was statistically 
evaluated using one-way analysis of variation (ANOVA). Results were found to be 
significantly different (F(3,15)= 22.9,  p<0.001, α=0.05). Two-tailed t-tests showed no 
differences in response at 1:10 or 1:1 sertraline:estazolam-D5. However, a significant 
difference was observed between calibrator response and controls containing 10:1 
sertraline:estazolam-D5 (α= 0.05). The same was true for LC-MS/MS when responses 
were compared using ANOVA (F(3,15)= 119.2, p<0.0001, α= 0.05). Two-tailed t-tests 
showed significant differences between calibrators and sertraline controls at 10:1 
(p<0.0001, α=0.05). While the overall decreased ionization efficiency of the internal 
standard in the source was clearly evident from the decreased response for estazolam-D5 
in the presence of an excess of coeluting drug, this type of interference could go undetected 
for an analyte in a case sample where the expected response is unknown.  
The effects of capacity limited ionization are only exaggerated in the presence of 
matrix as more species compete for access to the droplet surface during the ionization and 
gas-phase emission process in ESI. These endogenous species can increase viscosity of the 
solvent droplets and can also reduce efficiency with the presence of unionized precipitating 
species which can decrease desolvation. This phenomenon was shown when the absolute 
response of estazolam-D5 in the presence of sertraline was also compared between 
extracted samples and neat preparations (100 ng/mL IS and 1:10, 1:1, and 10:1 sertraline). 
Using two-tailed student t-tests, at 1:10 sertraline: estazolam-D5 there were no significant 
differences in LC-Q/TOF-MS response, however the internal standard response was 
significantly different between extracts and non-extracted samples at 1:1 (p= 0.01) and 
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10:1 (p= 8.0 x 10-3) at α= 0.01. LC-MS/MS response was significantly different between 
extracted and neat samples at 10:1 (p= 2.2 x 10-3, α= 0.05). While equivalent concentrations 
of sertraline and estzolam-D5 resulted in no analytical response differences between 
extracted controls and calibrators, as described, the estazolam-D5 response is significantly 
affected in the presence of matrix at this concentration when compared to a neat 
preparation. The matrix effect contributions to decreased ionization efficiency must also 
be considered when determining strategies for eliminating interferences.  
Mitigation of Interferences 
Once sertraline and propoxyphene were identified as the interferences responsible 
for unacceptable quantitative bias, several strategies for mitigation were explored. 
Sertraline was chosen as the model interferent due to its presence in both analytical 
methods (LC-Q/TOF-MS and LC-MS/MS) and subsequent experiments were performed 
in parallel on each instrument. The effect of sertraline on the quantitation of suvorexant 
was studied using varying sample volumes (0.25, 0.5, or 1 mL of whole blood) and LC 
injection volumes (0.5, 1, and 2 µL) in triplicate. 
Using LC-Q/TOF-MS analysis, quantitative bias was within ±20% for samples that 
contained 10-fold lower (10 ng/mL) or equivalent (100 ng/mL) concentrations of sertraline 
to that of estzolam-D5 (100 ng/mL) using all sample volumes and injection volumes. 
However, as the concentration of sertraline was increased to 10-fold that of the IS, 
quantitative bias exceeding acceptability was observed at all sample volumes using the 2 
µL injection volume (in the validated method). Using 0.5 mL whole blood (as required by 
the original extraction protocol), bias was mitigated by decreasing the LC injection volume 
to 0.5 µL. Bias could also be mitigated by using half the sample volume (0.25 mL blood) 
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in combination with injection volumes of 0.5 and 1 µL, but still exceeded ±20% at a 2 µL 
injection (Figure 5.5A). The same pattern was evident for the quantitative bias observed 
using LC-MS/MS at varying sample and injection volumes. Due to the overall increased 
sensitivity of the LC-MS/MS, bias could not be reduced to <20%, but consistent increases 
in bias were observed as the sample and injection volumes were increased. The magnitude 
of quantitative bias using 1 mL of sample (across all injection volumes) was large enough 
that it produced a relative suvorexant response that exceeded the upper limit of quantitation 
(ULOQ) (200 ng/mL) (i.e., >100% bias (Figure 5.5B). The same was true for the validated 
method protocol (0.5 mL blood, 2 µL injection) where bias exceeded 100% and the relative 
response for suvorexant was beyond that of the ULOQ (Figure 5.5B). These observations 
support the phenomenon of capacity limited ionization and its downstream effects on 
















Figure 5.5. Quantitative bias observed in the LC-Q/TOF method (A) and the LC-MS/MS method 
(B) using various sample and injection volumes when sertraline was present at a 10-fold excess 













































Although a stable isotope labeled internal standard for suvorexant was not 
commercially available during the time of the initial LC-Q/TOF-MS and LC-MS/MS 
method development and validation (15, 16), one recently became available. Suvorexant-
D6 was added to the LC-Q/TOF targeted data acquisition method, and product ions (Table 
5.2) were selected for quantitation with a weighted (1/x) quadratic model (2-200 ng/mL) 
as described earlier (15). Interferences from the same 52 drugs were evaluated once more. 
As expected, no qualitative or quantitative interferences were identified even at 10-fold 
and 100-fold excess concentrations relative to the drug (suvorexant). Additionally, the 
sertraline and propoxyphene interference experiments were repeated at concentration ratios 
1:10, 1:1, and 10:1 relative suvorexant-D6 (100 ng/mL), and quantitative bias was <20% 
at all concentrations (Figure 5.6). 
 
Figure 5.6. Quantitative bias (>20%) observed for suvorexant in the presence of interfering drugs 




















Dilution integrity studies are required if the quantity (i.e., volume) of specimen 
used is subject to modification.  When performing such studies, the reduced volume of 
specimen may remain undiluted, or may be diluted with aqueous media or buffer prior to 
the extraction. In this study, we compared dilution integrity at 1:1 and 1:10 using 
estazolam-D5 and suvorexant-D6 as in the internal standard. Statistical significance was 
assessed using a two-tailed student t-test (α= 0.05). When dilutions were performed at 1:1 
with estazolam-D5 as the IS, no significant differences in concentration were observed 
between the diluted and undiluted positive control when the dilution was performed using 
drug-free blood. However, significant differences were observed between the positive 
controls when the specimen was diluted with buffer, and when the sample volume was 
halved with no dilution (Figure 5.7A). When a 1:10 dilution was performed using 
estazolam-D5 as the internal standard, concentrations were significantly different using 
each dilution method (Figure 5.7B). The experiment was repeated using suvorexant-D6 as 
the internal standard, and measured concentrations and bias were not statistically 
significant for 1:1 dilution using one-way ANOVA (F (3,12)= 0.30, p= 0.83, α= 0.05)) or 
10:1 (F (3,12)= 2.0, p= 0.17, α= 0.05) regardless of how the dilution was performed 









Figure 5.7. Comparison of dilution integrity at 1:1 (A) and 1:10 (B) using blood, buffer or 
decreased sample volume alone (160 ng/mL suvorexant & 100 ng/mL IS) (n=4, mean ± 1SD). 
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These observed differences due to the composition of the dilution medium (i.e., 
none, buffer or drug-free blood) were attributed to the influence of viscosity on extraction 
efficiency. Despite some structural similarity (diazepine/azepane, triazole and 
halogenation), extraction efficiencies for estazolam-D5 and suvorexant are not identical. 
Liquid-liquid extraction efficiencies rely upon the physical mixing and interaction of 
analyte between the biological matrix and the solvent layer. As such, they are influenced 
by viscosity. The observed differences between the dilution medium once again highlights 
the value of isotope labeled internal standards to compensate for analytical factors during 
extraction. 
Conclusion 
ESI based LC-MS techniques are undoubtedly one of the most valuable tools in 
forensic toxicology today. However, additional care is needed during method validation to 
ensure that analytical methods are free from quantitative bias caused by coeluting 
substances (matrix, or drug). While much attention is placed on quantitative matrix effects, 
ion suppression caused by other drugs that may also coelute is often overlooked or not 
thoroughly investigated. These should be investigated qualitatively and quantitatively 
during method development so that potential limitations can be identified. Matrix effects 
and other interferences can have a detrimental impact on the precision and bias of 
quantitative LC-ESI-MS methods and can ultimately results in decreased sensitivity (4, 5, 
10, 21). While endogenous interferences are often discussed in LC-based methods, 
exogenous interferences can also be present which can include extraction artifacts, buffers, 
and coeluting drugs (3, 10). There has been a common misconception that high resolution 
mass spectrometry and tandem mass spectrometry techniques are less susceptible to the 
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effects of interferences due to their mass selectivity, namely the filtering capabilities in 
tandem MS and mass accuracy in HRMS (4, 21); but the suppression caused by capacity 
limited ionization occurs before ions enter the mass spectrometer, making these methods 
just as susceptible to interferences due to coelution. As demonstrated here, both high 
resolution and tandem mass spectrometry techniques can suffer from this limitation. If not 
thoroughly investigated, quantitative analyses might be subject to considerable positive or 
negative bias. These effects can be mitigated, however.  
Stable isotope labeled internal standards can be used to overcome these issues in 
LC-MS assays (1, 2). Alternative measures are also possible in instances where an SIL-IS 
in not available, particularly new or emerging drugs. Reducing the number of species 
present in solvent droplets by decreasing sample (matrix) volume, LC injection volume, or 
source conditions can help. However, these solutions are compound-dependent and must 
be investigated on an individual basis.  Regardless, sources of ion suppression beyond just 
those attributed to matrix effects should be thoroughly evaluated qualitatively and 
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Suvorexant (Belsomra®) is a sedative hypnotic that was approved for use in 2015. It has a 
novel mechanism of action and was the first dual orexin receptor antagonist (DORA) to be 
approved for the treatment of sleep disorders. Sedative hypnotics often feature prominently 
in forensic investigations such as impaired driving and drug-facilitated sexual assault 
(DFSA) cases. As such, suvorexant is a drug of interest and its identification in forensic 
toxicology investigations is of significance. However, limited studies have been published 
to date and the disposition or importance of its metabolites has been largely uninvestigated. 
Only one study to date has described the metabolism of suvorexant. In this report, we 
investigate the enzymes responsible for metabolism and explore the prevalence of 
metabolites in blood from a series of thirteen forensic investigations. Recombinant 
cytochrome P450 enzymes (rCYPs) were used to generate phase I metabolites for 
suvorexant in vitro and metabolites were identified using liquid chromatography-
quadrupole/time-of-flight-mass spectrometry (LC-Q/TOF-MS). Four rCYP isoenzymes 
(3A4, 2C19, 2D6, and 2C9) were found to contribute to suvorexant metabolism. The only 
metabolite identified in blood or plasma arose from hydroxylation of the benzyl triazole 
moiety (M9). This metabolite was identified in seventeen blood and plasma specimens 
from twelve medicolegal death investigations and one impaired driving investigation. In 
the absence of a commercially available reference material, the metabolite was confirmed 
using rCYP-generated in vitro controls using high resolution mass spectrometry.  
Keywords:       Suvorexant, Metabolism, CYP450, Blood, Plasma, LC-Q/TOF-MS
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CYP450-MEDIATED METABOLISM OF SUVOREXANT AND 
INVESTIGATION OF METABOLITES IN AUTHENTIC CASE SPECIMENS 
Introduction 
Suvorexant is novel dual orexin receptor antagonist (DORA) that is marketed under 
the tradename Belsomra® and is used for the treatment of insomnia. Orexin antagonism is 
a novel approach for treating insomnia. Orexin neurons were only discovered in the late 
1990s by two independent research groups and have been implicated in the sleep to wake 
cycle, as production of orexin results in decreased activity in the sleep-promoting parts of 
the brain (1-3). In postmortem studies of individuals that suffered from narcolepsy it has 
been discovered that there was a lack of orexin-producing neurons in the lateral 
hypothalamus, further suggesting that the orexin signaling plays a large role in regulating 
wakefulness (3-6). With this discovery, dual orexin receptor antagonists have been 
developed to mimic these effects and to provide alternative therapeutic options for 
insomnia treatment. Suvorexant acts by inhibiting orexin A and B in the lateral 
hypothalamus to produce suppression of the wake cycle, thereby inducing sleep in its users. 
Unlike other traditional sedative hypnotics prescribed for insomnia, suvorexant has no 
effect on γ-aminobutryic acid (GABA) activity and is thought to have a lower abuse 
potential. Moreover, DORAs are a promising approach due to the pharmacokinetics of 
these compounds, which aim to restrict their effects to the duration of sleep with minimal 
carryover or “hangover” effects into the following day after bedtime use (2). 
Suvorexant became commercially available in 2015 and is currently placed under 
Schedule IV of the Controlled Substances Act (CSA) (7). Suvorexant is currently available 
in the United States, Japan, and Canada (8-10). Following a 10 mg oral dose, peak plasma 
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concentrations are ~198 ng/mL which are reached within 2 hours, and steady state plasma 
concentrations can be reached within three days of daily suvorexant administration (11, 
12). Suvorexant is recommended to be administered within 30 minutes of going to sleep 
and at least 7 hours before the anticipated time of wakening (13, 14). The mean oral 
bioavailability of suvorexant is ~82% and it is extensively protein bound (99.5%) to human 
serum albumin and α-1-acid glycoprotein (14, 15). The drug has a relatively long half-life, 
is highly lipophilic, and has volume of distribution of 0.5-0.9 L/kg (9, 16, 17). 
Suvorexant is a drug of forensic interest due to its relatively long half-life (~12 
hours on average) and its classification as a sedative hypnotic. In the prescribing 
information, administration of the high dose (20 mg) is discouraged prior to driving and 
other next-day activities that require alertness (15). Suvorexant has the potential to appear 
in impaired driving investigations due to its adverse side effects, or even in cases of drug-
facilitated sexual assault (DFSA). However, few methods have been developed for its 
analysis in biofluids of forensic interest. Methods for the detection of suvorexant in urine, 
blood, plasma, and tissues have been developed for use with gas chromatography-mass 
spectrometry (GC-MS), liquid chromatography tandem mass spectrometry (LC-MS/MS), 
and liquid chromatography-quadrupole/time-of-flight-mass spectrometry (LC-Q/TOF-
MS) (18-26). Only one of these methods has examined suvorexant in case specimens from 
three forensic autopsy cases (24). Therefore, little is known about its role in human 
performance toxicology or in forensic investigations, and its potential for postmortem 
redistribution should be evaluated with more cases studies. Moreover, only one study has 
evaluated the in vivo and in vitro metabolism of suvorexant, and no studies have been 
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published to date describing the analysis of suvorexant metabolites in forensic casework 
(11). 
Ciu et al. is the only research group to date that has studied the in vivo and in vitro 
metabolism of suvorexant (11). The metabolism of suvorexant was investigated in a 
clinical dosing study with the use of healthy volunteers. A radiolabeled dose (50 mg) of 
suvorexant ([14C]-suvorexant) was orally administered to individuals, and elimination was 
monitored over 14 days. Suvorexant was excreted principally via the feces (66%), with 
only 23% of the drug eliminated in the urine. Identification of potential metabolites was 
performed using high resolution mass spectrometry (HRMS) and nuclear magnetic 
resonance (NMR). In plasma, suvorexant (30%) and a hydroxylated metabolite, M9 (37%) 
were the principal compounds detected. The chemical structures for these two species can 
be found in Figure 6.1. Further oxidation of M9 produced the carboxylic acid derivative 
(M4), which was the principal metabolite in urine, together with its glucuronide. M4 was 
also the major metabolite in feces, accounting for approximately 17% of a dose. In addition 
to hydroxylation of the benzyl alcohol (M9), hydroxylation also occurred at the 
chlorobenzoxazole (M8) and methyldiazapane ring (M10a), followed by glucuronidation. 
Dechlorinated species were also reported and mechanisms for their formation were 














The in vitro characterization of suvorexant metabolism was performed using human 
liver microsomes (HLMs) and selected recombinant CYP450 enzyme systems (3A4, 3A5 
and 2C19). Immunoinhibition studies were performed using specific anti-CYP monoclonal 
antibodies (anti-CYP 1A2, 3A4/5, 2C8/9/19 and 2D6). It was concluded that CYP 3A4 
was the principal enzyme involved in metabolism, with only minor contributions from CYP 
2C19. No CYP 1A2, 2C8 or 2D6 activity was observed. Data showed that suvorexant was 
well absorbed (>90%) and extensively metabolized. As a result, suvorexant metabolites 
account for a large fraction of circulating species present following oral administration of 
the drug (11). Although none of the metabolites are believed to be pharmacologically 
active, none are commercially available. This presents a challenge for forensic analysis and 
would preclude quantitative analysis if parent/metabolite ratios were of interest. 
HRMS techniques are a powerful bioanalytical tool and have gained popularity in 
identifying metabolites using in vivo and in vitro approaches. Traditionally, NMR analysis 
was used for structural elucidation of metabolite in metabolomic studies, but HRMS has 
become increasingly used due to high sensitivity and structural elucidation capabilities 
using accurate mass and MS/MS fragmentation patterns (27, 28). In this study, metabolism 
of suvorexant was investigated in vitro for the purpose of identifying suvorexant 
metabolites in specimens from thirteen forensic investigations. To produce metabolite 
controls for the purpose of identifying these compounds in human blood, serum/plasma, 
and vitreous humor, recombinant CYP isoenzyme incubations were performed in vitro 
using eight isoenzymes. Following confirmation of enzyme activity and metabolite 
production, these isoenzyme incubations were used as positive controls to qualitatively 
206 
 
evaluate metabolites in these specimens. The potential utility of suvorexant metabolite 
identification in forensic investigations is discussed. 
Materials and Methods 
Chemicals and Reagents 
Suvorexant was obtained from Cayman Chemical (Ann Arbor, MI, USA) in 
powdered form and was prepared in methanol at 1 mg/mL. Suvorexant-D6 (100 µg/mL), 
estazolam-D5 (100 µg/mL), ketoconazole (2 mg/mL) and fluvoxamine (1 mg/mL) were 
obtained from Cerilliant Corp. (Round Rock, TX, USA) in methanol. Acetonitrile (Optima, 
LC/MS grade) and formic acid (Optima, LC/MS grade) were obtained from Fisher 
Scientific (Pittsburg, PA, USA). Methanol (LC/MS grade) was purchased from J.T. Baker 
(Center Valley, MA, USA). A Millipore Direct-Q® UV Water Purification System 
(Billerica, MA) was used for the in-house purification of deionized water. Sodium acetate 
and glacial acetic acid (used to prepare sodium acetate buffer (pH 3.6, 0.4 M)), were 
obtained from Mallinckrodt Chemicals (St. Louis, MO, USA). N-butyl chloride (1-
chlorobutane, 99+% pure) was purchased from Fisher Scientific (Pittsburg, PA, USA) and 
potassium phosphate (mono and dibasic) were obtained from VWR (Radnor, PA, USA). 
Whole bovine blood for controls and calibrators was obtained from QuadFive (Ryegate, 
MT, USA). Sodium fluoride (1% w/v) and potassium oxalate (0.2% w/v) were used as 
preservative and anticoagulant. Recombinant human cytochrome P450 (rCYP) isoenzymes 
expressed in Escherichia coli (bactosomes) and control bactosomes were purchased from 
Sekisui Xenotech, LLC (Kansas City, KS, USA). Reduced nicotinamide adenosine di-
phosphate (NADPH) regenerating systems were obtained from Corning® Gentest™ 
(Glendale, AZ, USA). NADPH system solution A consisted of 40 U/mL glucose-6-
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phosphate dehydrogenase in 5 mM sodium citrate and NADPH solution B consisted of 26 
mM NADP+, 66 mM glucose-6-phospate, and 66 mM magnesium chloride in aqueous 
solution.  
Instrumentation 
An Agilent 1290 Infinity Binary LC system coupled to an Agilent 6530 Accurate 
Mass Quadrupole Time-of-Flight LC/MS (Santa Clara, CA) was used for identification 
and analysis of metabolites. Mobile phases A and B were 0.1% formic acid in water and 
acetonitrile, respectively. The LC was equipped with an Agilent InfinityLab Poroshell 120 
EC-C18 column (2.1 x 100 mm x 2.7 µm) and Poroshell EC-C18 guard column (2.1 x 5 
mm x 2.7 µm) that were maintained at 35°C. Separation was achieved using the following 
gradient: Begin 40% B, hold 40% B (3 min), increase 40-80% B (1 min), hold 80% B (2 
min), decrease 80-40% B (1 min), followed by post-equilibration (2 min). A 6-second 
needle wash was employed to prevent carryover. Electrospray ionization was used in 
positive mode under the following conditions: 300°C drying gas temperature (13 L/min), 
350°C sheath gas temperature (12 L/min), 45 psi nebulizer pressure, 150 V fragmentor 
voltage, 2000 V nozzle voltage, and 3000 V capillary voltage. Collision induced 
dissociation was evaluated at 10, 30, and 50 eV. Auto MS/MS (full scan) data acquisition 
was used for a mass range of 40-1000 amu using medium isolation widths (~4 amu). The 
MS scan rate was 3 spectra/sec while the MS/MS scan rate was 8 spectra/sec. Previous 
literature-reported metabolite exact masses were calculated using MassHunter mass 
calculator and masses were added to a preferred list in the auto MS/MS method. 
MassHunter Qualitative Analysis software was used for data analysis. Phase I metabolites 
were identified using mass accuracy (± 5 ppm) and MS/MS fragmentation patterns. 
208 
 
Recombinant CYP Incubations 
Eight rCYP isoenzymes were evaluated for the production of suvorexant 
metabolites in vitro as follows: CYPs 3A4, 2C19, 2D6, 2C9, 2C8, 2C18, 2B6, and 1A2. 
Each isoenzyme was incubated individually to evaluate its contribution to suvorexant 
metabolism. In accordance with manufacturer recommendations and previously published 
studies, 50 µM of suvorexant and 50 pmol/mL rCYP isoenzyme was used for incubations 
at 37°C (29). The total reaction volume was 0.5 mL which also included 100 mM potassium 
phosphate buffer (pH 7.4), 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM 
magnesium citrate, and 0.4 U/mL glucose-6-phosphate dehydrogenase. Time points of 0, 
30, 60, 120, 180, and 240 minutes were evaluated for metabolite formation. Reactions were 
quenched by taking an incubation mixture aliquot of 25 µL and adding to an equal volume 
of stop solution consisting of 5 µM internal standard (suvorexant-D6) and 0.1% formic 
acid in acetonitrile. The solution was centrifuged at 4°C for 3 minutes at 10,000 x g and 
12.5 µL of the resulting supernatant was diluted (1:1) with mobile phases A/B (50/50). 
Control incubations which contained control bactosomes (no CYP insertion) were prepared 
similarly to rCYP incubations and blanks (no drug) for each rCYP were prepared by 
replacing suvorexant solution with phosphate buffer. An LC injection volume of 2 µL was 
used for sample introduction and analysis. 
Inhibition 
Inhibition was studied using known chemical inhibitors for rCYPs 3A4, 2C19, 2D6, 
and 2C9. For rCYP 3A4, 2C19, and 2C9 inhibition ketoconazole (40 µM) was used, and 
for rCYP 2D6 inhibition fluvoxamine (40 µM) was used. Incubations were performed for 
each of the four isoenzymes with and without the presence of inhibitor in triplicate. The 
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previously described incubation procedure was utilized with the addition of ketoconazole 
or fluvoxamine to the set of inhibited samples. Inhibition was studied following a 60-
minute incubation, in which aliquots were removed, quenched, centrifuged, and diluted for 
LC-Q/TOF-MS analysis. 
Identification of Metabolites  
Metabolite formation was identified by monitoring changes in relative suvorexant 
response (normalized to the response of suvorexant-D6) over time (0-240 min). A preferred 
list of suspected metabolites was used to improve the quality of MS/MS spectra. CID 
energies of 10, 30 and 50 eV were used, and structural assignments were made where 
possible based upon mass accuracy. 
Qualitative Identification in Authentic Specimens 
Suvorexant was previously quantitated in authentic blood and serum/plasma 
specimens from thirteen forensic investigations using a published, validated analytical 
method (25). Briefly, 0.5 mL of specimen was extracted using a simple acidic/neutral 
liquid-liquid extraction (LLE) with 1 mL sodium acetate buffer (pH 3.6, 0.4 M) and 2.5 
mL N-butyl chloride, and estazolam-D5 (100 ng/mL) was used as the internal standard. 
Samples were rotated for 5 min and centrifuged for 5 min at 1734 x g (3000 rpm). Organic 
solvent was transferred to conical tubes and dried under nitrogen stream (50°C). Samples 
were reconstituted in 50:50 mobile phase A/B, transferred to LC vials, and 2 µL were 
injected into the instrument. The previous quantitative method resulted in an LOD and 
LOQ of 0.5 ng/mL and calibration range of 2-200 ng/mL using a weighted (1/x) quadratic 
calibration model. In this study metabolites were qualitatively identified in the same 
antemortem and postmortem authentic specimens following fortification with estazolam-
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D5 and suvorexant-D6 internal standards (100 ng/mL) and extraction with the described 
LLE. Whole bovine blood was used for negative (100 ng/mL ISs) and positive (100 ng/mL 
ISs, 100 ng/mL suvorexant) controls. In the absence of commercially available suvorexant 
metabolite reference materials or standards, positive metabolite controls were produced in 
vitro with rCYP incubations. Metabolite data was acquired for samples using auto MS/MS 
as described, and metabolites were confirmed using retention time matching to positive 
rCYP incubations, mass accuracy (±5 ppm), and mass spectral fragmentation patterns. 
Results and Discussion 
Identification of Phase I Metabolites 
A total of three suvorexant metabolites were identified which were all produced by 
hydroxylation of the parent compound (m/z 467) and eluted at 3.03, 3.18, and 4.37 minutes. 
The chromatographic separation of suvorexant, suvorexant-D6, and the hydroxysuvorexant 
isomers is depicted in Figure 6.2. and MS/MS spectra are shown in Figure 6.3. Chemical 
formula, exact mass, accurate mass, and mass errors are summarized in Table 6.1. All mass 
errors for metabolite precursor ions were within ± 5 ppm. Suvorexant produces a prominent 
m/z 186 ion, consistent with the benzyltriazole fragment (C10H8N3
+). Hydroxysuvorexant 
isomer 2 was readily identified as the M9 metabolite due to the m/z 202 ion, consistent 
with the benzyl alcohol fragment. Two other minor metabolites (isomers 1 and 3) were 
identified. The prominence of the m/z 186 ion indicated that hydroxylation occurred 
elsewhere on the molecule, such as the chlorobenzoxazole group (M8) or methyldiazepane 
ring (M10a) as suggested by Ciu et al. (11). Structural assignments for suvorexant and 
metabolites product ions with their respective mass errors at each collection energy used 
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(10, 30, 50 eV) are shown in Table 6.2. Due to the absence of diagnostic fragment ions 
(even at elevated CID voltages), further differentiation was not possible.  
 
Figure 6.2. Extracted ion chromatograms for suvorexant (4.838 min; m/z 451), suvorexant-D6 















Table 6.1. Retention time, chemical formulas, exact mass, accurate mass, and mass error for 














Suvorexant 4.84 C23H23ClN6O2 451.1644 451.1637 -1.55 
Hydroxysuvorexant 
isomer 1 
3.03 C23H23ClN6O3 467.1593 467.1603 +2.14 
Hydroxysuvorexant 
isomer 2 (M9) 
3.18 C23H23ClN6O3 467.1593 467.1605 +2.57 
Hydroxysuvorexant 
isomer 3 
4.37 C23H23ClN6O3 467.1593 467.1596 +0.64 
 
Table 6.2. Chemical formulas, exact mass, accurate mass, and mass error for product ions of 















Suvorexant 10 [C10H8N3O+] 186.0662 186.0657 -2.69 
 30 [C10H8N3O+] 186.0662 186.0660 -1.07 
 50 [C10H8N3O+] 186.0662 186.0658 -2.15 
Hydroxysuvorexant isomer 1 10 [C10H8N3O+] 186.0662 186.0663 +0.54 
 30 [C10H8N3O+] 186.0662 186.0658 -2.15 
 50 [C10H8N3O+] 186.0662 186.0665 +1.61 
Hydroxysuvorexant isomer 2 
(M9) 
10 [C10H8N3O2+] 202.0611 202.0612 +0.49 
 30 [C10H8N3O2+] 202.0611 202.0607 -1.98 
 50 [C10H8N3O2+] 202.0611 202.0613 +0.99 
Hydroxysuvorexant isomer 3 10 [C10H8N3O+] 186.0662 186.0656 -3.22 
 30 [C10H8N3O+] 186.0662 186.0654 -4.30 
 50 [C10H8N3O+] 186.0662 186.0669 +3.76 
 
rCYP Activity 
Using eight different rCYP isoenzymes evaluated, suvorexant metabolites were 
identified using rCYP 3A4, 2C19, 2D6 and 2C9. The abundance of each metabolite was 
measured relative to the internal standard (suvorexand-D6). Hydroxysuvorexant isomer 1 
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was attributed to rCYPs 3A4 and 2C19, while isomer 3 was produced in the presence of 
rCYPs 3A4 and 2C9. The M9 metabolite, was produced by four isoforms: rCYP 2D6, 3A4, 
2C9 and 2C19. Metabolism was not observed for these species in the control isoenzyme 
incubations or in the blank samples (free from suvorexant).  
Inhibition studies were performed to confirm the results using 60-minute 
incubations. Inhibited and uninhibited reactions were performed in parallel, each in 
triplicate. The RPAs of suspected metabolites and suvorexant-D6 internal standard were 
compared for inhibited and uninhibited samples (Figure 6.4). Significant inhibition was 
observed for all isoforms (42-100%) (Table 6.3). While the involvement of rCYP 3A4 for 
the production of hydroxylated isomers 1 and 3 was consistent with Cui et al., activity was 
also observed using rCYPs 2C9 and 2C19. Notably, Cui et al. did not evaluate rCYP 2C9 
in their study. Interestingly they concluded that CYP 2D6 was not involved in the 
metabolism of suvorexant. In contrast, the M9 metabolite was produced in the greatest 
abundance by rCYP 2D6 in our study (Figure 6.4) and its activity was confirmed in the 
inhibition study. While this study cannot attest to the in vivo formation rates or enzyme 
kinetics of these metabolites, it does confirm the activity of isoenzymes that were not 




Figure 6.4. Inhibition of hydroxysuvorexant isomer production using rCYPs 3A4, 2C19, 2D6, 
and 2C9 at 60 min, which is expressed as relative response to the internal standard (suvorexant-



















































Table 6.3. Percent inhibition for hydroxylated suvorexant metabolites (n=3). 
 
Identification of Metabolites in Authentic Case Specimens 
Suvorexant quantitation was previously performed for authentic blood, 
serum/plasma, and vitreous fluid specimens using a previously validated method and the 
presence of suvorexant was confirmed. The parent analyte was present in concentrations 
ranging from 3-42 ng/mL and only vitreous fluid (n=1) could not be reliably quantitated 
due to extremely low suvorexant concentrations below detection capabilities (LOD=0.5 
ng/mL). A total of eighteen specimens were analyzed involving twelve medicolegal death 
investigations and one impaired driving investigation. The presence of other drugs in the 
specimens, or the role of suvorexant in the investigation was not known. Since suvorexant 
metabolite reference materials are not commercially available, positive metabolite controls 
were produced in vitro with rCYP incubations to identify potential suvorexant metabolites 
in these case specimens. Data was acquired using the auto MS/MS (full scan) method 
described in this study following LLE of forensic specimens. Negative and positive blood 
controls were analyzed to ensure precursor ions were not a result of endogenous interfering 
species. Metabolites were confirmed using retention time matching to positive rCYP 
incubations, mass accuracy (±5 ppm), and mass spectral fragmentation patterns. Of the 
thirteen forensic investigations, hydroxysuvorexant (M9) was identified in all case samples 
with the exception of vitreous humor (Table 6.4). The inability to detect metabolites for 
Metabolite rCYP % Inhibition (Mean ± SD) 
Hydroxysuvorexant isomer 1 
3A4 
2C19 
100 ± 0 
48 ± 3 





92 ± 2 
42 ± 9 
63 ± 7 
62 ± 2 
Hydroxysuvorexant isomer 3 
3A4 
2C9 
92 ± 1 
60 ± 2 
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suvorexant in this sample is not surprising given the absence of parent drug in this matrix 
and the low concentration in blood. No other metabolites were detected in the case 
specimens. A representative extract containing 13.2 ng/mL of suvorexant and M9 
metabolite is shown in Figure 6.5. All M9 identifications were within ± 5 ppm for mass 





Table 6.4. Concentrations of suvorexant in forensic investigations and subsequent identification 

















1 DUID AM Blood 3.2 3.16 1.93 -3.96 
2 MDI Blood (P) 3.5 3.16 3.00 0.00 
  Blood (C) 7 3.16 2.35 -1.98 
  Vitreous humor  ND -- -- -- 
3 MDI Blood (P) 16.8 3.17 4.07 -3.96 
  Blood (C) 36.5 3.15 -0.43 -4.95 
4 MDI AM Blood 21 3.15 4.50 -4.95 
  AM Serum/Plasma 3.6 3.15 0.86 -3.46 
5 MDI Blood (P) 36.8 3.15 -1.93 -1.48 
6 MDI Blood (C) 13.2 3.17 -0.64 -2.97 
7 MDI Blood (P) 40.5 3.17 -3.00 -2.97 
8 MDI Blood (P) 27.7 3.16 -0.21 -1.48 
9 MDI Blood (P) 15.6 3.16 2.14 -1.48 
10 MDI Blood (P) 26.5 3.16 -2.35 -2.97 
11 MDI AM Blood 29.6 3.16 2.35 -0.99 
  AM Serum/Plasma 12.9 3.14 -0.64 -4.45 
12 MDI Blood (P) 17.2 3.14 -3.64 4.95 
13 MDI Blood (P) 41.5 3.15 -1.93 -1.48 
DUID, driving under the influence of drugs; MDI, medicolegal death investigation; ND, Not 














The hydroxylated species M9 was confirmed as the primary phase I metabolite in 
unhydrolyzed blood samples. Although the metabolite is not believed to be 
pharmacologically active, drug/metabolite ratios can be of interpretive value in forensic 
toxicology, particularly medicolegal death investigation. However, quantitative analyses 
cannot be performed in the absence of a commercially available reference material.  
Studies using rCYPs confirmed earlier reports regarding the involvement of CYP 
3A4 and minor contributions of 2C19 (11). However, additional activity was identified for 
2C9 and 2D6. The latter has implications in terms of genetic polymorphisms and the large 
interindividual differences observed in terms of enzyme activity. In-situ generated rCYP 
controls were used to confirm the presence of M9 in a series of thirteen suvorexant 
investigations. The metabolite was readily identified in 17 of the 18 specimens analyzed. 
This confirms earlier reports by Cui et al. that showed that suvorexant and the M9 
metabolite accounted for 37% and 30% of the radiolabeled dose in plasma. As a first-in-
class dual orexin receptor antagonist, suvorexant is a drug of forensic interest that should 
be considered during toxicological analyses.  
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Suvorexant is a novel insomnia medication with a unique mechanism of action. As 
a first-in-class dual orexin receptor antagonist, it is a drug of forensic interest. While few 
methods have been published regarding its detection in biological matrices, only one report 
to date described its distribution in postmortem fluids and tissues. As such, suvorexant’s 
role in forensic investigations is relatively unknown and little information is available 
regarding its role in human performance toxicology. There are no reports detailing the 
analysis of suvorexant metabolites in casework, and some physicochemical properties of 
the drug are unstudied.  
A method for the detection of suvorexant in whole blood was developed and 
validated using LC-Q/TOF-MS. Suvorexant was extracted from blood using a simple 
acidic/neutral LLE with N-butyl chloride. The LOD and LOQ were 0.5 ng/mL and a 
weighted (1/x) quadratic calibration model (R2=0.995) over a concentration range of 2-200 
ng/mL was used. Bias ranged from -5-2%, inter-assay precision (n=15) was 13%, 5%, and 
8% for low, medium, and high concentrations, while intra-assay precision (n=5) was 10%, 
4%, and 5%. Accuracy ranged from 95-102% over these concentrations. No carryover was 
observed, and mean matrix effects were 16% and 15% at low and high concentrations of 
suvorexant, respectively. Although no qualitative interferences from common drugs were 
observed, significant bias as a result of ion suppression was observed when sertraline was 
present at concentrations in excess of the internal standard, estazolam-D5. The interference 
was attributed to decreased ionization efficiency in the electrospray interface of the source 
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due to capacity limited ionization. These results further highlight the importance of stable 
isotope labeled internal standards, but these are not always commercially available.  
The LC-Q/TOF-MS suvorexant method in blood was translated to, and cross-
validated with LC-MS/MS. However, significant differences in matrix effects were 
observed for the two platforms, with LC-MS/MS matrix effects falling outside of validation 
guideline acceptability limits. The LC-MS/MS source parameters had been optimized 
using software, unlike the LC-Q/TOF-MS method which had been optimized manually 
prior to validation. Notably, this caused unacceptable values for matrix effects by LC-
MS/MS, despite having an increased analytical response for suvorexant. Matrix effects 
were re-evaluated using various extraction solvents and commercial lipid clean-up devices 
which resulted in no observable differences. Applying the manually optimized LC-Q/TOF-
MS parameters (i.e., de-tuning the source) in the LC-MS/MS assay eliminated the matrix 
effect, demonstrating how conditions at the electrospray interface can be manipulated to 
mitigate interferences. The LC-MS/MS method was subsequently validated and resulted in 
an LOD of 0.1 ng/mL and LOQ of 0.5 ng/mL in blood, respectively. The same calibration 
range was using (2-200 ng/mL) with a weighted (1/x) quadratic calibration model. Bias 
ranged from -2-2% and at low, medium, and high concentrations, intra-assay precision 
ranged from 4-7% and inter-assay precision ranged from 7-9%. Matrix effects were -8% 
and –9% at low and high concentrations of suvorexant using the new source conditions, 
and no carryover was observed. While no qualitative interferences were identified, there 
was a significant quantitative bias when sertraline and propoxyphene were present in 
concentrations exceeding that of the internal standard (estazolam-D5). The LC-MS/MS 
validation showed that both analytical platforms had comparable performance and were 
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sensitive for suvorexant at forensically relevant concentrations. Again, the utility of SIL-
ISs was emphasized for the mitigation of potential quantitative interferences in targeted 
assays.  
Given the limited literature describing the physicochemical properties of 
suvorexant and its unknown potential to undergo postmortem redistribution, partition 
coefficients of suvorexant were theoretically and experimentally determined to help 
characterize its lipophilicity. Theoretical partition coefficients were determined for 
suvorexant using ALogPS, ACD Labs/LogP, and KowWin predictive software which 
resulted in Log P values of 3.86, 3.62 ± 0.86, and 4.65, respectively. Experimental Log P 
values were determined using the shake-flask method using octanol/water and various 
aqueous buffer systems. The octanol/water partition coefficient was 3.45 ± 0.28 (n=3). 
Partitioning between octanol and various aqueous buffers with pH 2-9 and ionic strength 
from 10-200 mM resulted in Log P values of 3.23-4.04. Values were not significantly 
different (α= 0.01) using one-way ANOVA, consistent with its observed behavior as a 
neutral drug. Experimentally determined Log P values were in good agreement with those 
derived theoretically. Computational methods that made use of electrotopological 
estimations (ACD Labs/Log P, ALogPS) provided the closest values. Suvorexant was 
highly lipophilic, which could influence its behavior and disposition in the body before and 
after death.  
Using the LC-Q/TOF-MS validated method, suvorexant was quantitated in 
specimens from a series of thirteen forensic investigations. The case specimens included 
antemortem and postmortem blood as well as serum/plasma and vitreous humor. 
Suvorexant was detected at concentrations ranging from 3-42 ng/mL, which are well within 
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the therapeutic range for suvorexant. C/P ratios were 2.0 and 2.2 for paired central and 
peripheral blood samples (n=2) which was in good agreement with the only published case 
report to date. Although inferences regarding PMR should be drawn from large 
populations, preliminary data on this new drug did not suggest significant postmortem 
redistribution.   
An isotopically labeled internal standard was not commercially available at the time 
LC-Q/TOF-MS and LC-MS/MS methods were being validated. Using estazolam-D5 as the 
internal standard, significant quantitative biases were identified when certain other drugs 
were present in high concentrations. These drugs (sertraline and propoxyphene) coeluted 
with the internal standard and decreased ionization efficiency in the electrospray ionization 
source. Various strategies to mitigate this interference were explored which included 
decreasing the sample volume and the LC injection volume. It was determined that 
quantitative interferences could be improved when smaller sample and injection volumes 
were used. This indicating that as the number of ionizable species in the solvent droplet 
were decreased, there is less competition between the interfering species and the analyte of 
interest for desolvation in the source. Since the time of the original validation, a suvorexant 
SIL-IS (suvorexant-D6), became available and was evaluated in this interference study. It 
was determined that no interferences were observed using the original 52 common drugs, 
and quantitative interferences that resulted in unacceptable bias were completely mitigated. 
In addition, issues with dilution integrity experiments due to changes in the viscosity of the 
aqueous fraction were also ameliorated. This study highlighted the importance of 
evaluating method performance, particularly regarding matrix effects and drug-mediated 
interferences, qualitatively and quantitatively as well as using SIL-IS when available.  
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To date, only one published study has described the in vivo and in vitro metabolism 
of suvorexant. Despite the identification of oxidative metabolites in plasma, urine and 
principally feces, no commercially available reference standards are available, precluding 
metabolite quantification in forensic specimens. Recombinant CYPs (rCYP 3A4, 2C19, 
2D6, 2C9, 2C8, 2C18, 2B6 and 1A2) were used to further investigate the metabolism of 
this new drug. Three phase I metabolites of suvorexant were identified using LC-Q/TOF-
MS. Activity was demonstrated for a total of four rCYPs (3A4, 2C19, 2D6 and 2C9), all 
of which were confirmed using inhibitors. The involvement of 2C9, and in particular 2D6 
(neither of which were identified previously), highlights the importance of additional 
studies.  
The oxidative metabolite, M9, was identified using mass accuracy and MS/MS 
spectra. In-situ generated controls using rCYPs were used to confirm its presence in a series 
of thirteen forensic investigations. M9 was readily confirmed in seventeen of the eighteen 
specimens tested. Should a metabolite standard become available for this compound, 
parent-to-metabolite concentration ratios could be evaluated. These can be of use in 
medicolegal death investigations, particularly if a large bolus of drug is suspected, as may 
be the case following a suicide.  
As suvorexant continues to be prescribed to patients diagnosed with insomnia, 
sensitive methods for its detection are needed. As a drug class, sedative hypnotics feature 
prominently in human performance toxicology (i.e., impaired driving, drug-facilitated 
sexual assault) and postmortem toxicology (i.e., medicolegal death investigations).  
Despite challenges associated with its detection, particularly using routine immunoassay-
based or gas chromatographic-based screening, it should be considered. This research 
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provides forensic toxicology laboratories with sensitive and robust analytical methods for 
the quantitation of suvorexant using two different LC-MS platforms, and is the first to 
describe its analysis in blood using high resolution mass spectrometry. Moreover, 
physicochemical properties of suvorexant were explored which can help with interpretation 
of concentrations that are measured in various forensic specimens. This study adds to the 
limited literature regarding the analysis of suvorexant in authentic samples and is the first 
to describe the analysis of suvorexant metabolites in a forensic setting. The identification 
of new isoforms that might be responsible for metabolism is also a significant finding, 
particularly for CYP 2D6, which is known to be polymorphic. In addition to this new body 
of knowledge regarding suvorexant, important observations and limitations related to 
electrospray ionization were documented. Differences in assay performance between 
MS/MS and Q/TOF-MS platforms were identified, particularly as they related to matrix 
effects from endogenous species. Drug-mediated ion suppression was also explored and 
experimental approaches to mitigate these effects were investigated in order to improve the 
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